The Myelodysplastic Syndromes
Judit Várkonyi Editor
The Myelodysplastic Syndromes
1 3
Editor Prof. Judit Várkonyi 3rd Department of Internal Medicine Semmelweis University Kútvölgyi út 4, 1125 Budapest Hungary
[email protected]
ISBN 978-94-007-0439-8â•…â•…â•… e-ISBN 978-94-007-0440-4 DOI 10.1007/978-94-007-0440-4 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2011921323 © Springer Science+Business Media B.V. 2011 No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Cover design: deblik, Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
“In memory of my late father Zoltán Várkonyi and with love and gratitude to my dear husband Janos Quittner and son Zoltán Quittner”
Preface
Myelodysplastic syndromes (MDS) are the most common hematological malignancies involving mainly the elderly. They are defined as clonal stem cell disorders and characterized by ineffective hematopoiesis involving one to all bone marrow cell lineages [1]. The dominant morbidity of MDS relates to symptomatic cytopenias. According to various reports the annual incidence of MDS ranges widely from 2 to 12 per 100,000, increasing to 30–50 cases per 100,000 among persons aged 70 or older. It is believed that the true incidence of MDS has been underestimated and appears to be comparable to that of multiple myeloma and chronic lymphocytic leukemia [2, 3]. MDS may arise de novo, or as a result of previous environmental damage, or chemo-or radiotherapy with a peak incidence at 2–4 years following the initial exposure [4]. It might therefore be hypothesized that MDS arises due to cumulative environmental exposure in genetically predisposed individuals [5]. MDS may be regarded as a progression model in which the acquisition of genetic events occur by gain or loss of genetic material. MDS was previously named “preleukemia” or “smoldering leukemia” with a lack of terminal cells due to high apoptosis rate and the subsequent failure of differentiation. In about 25% of all cases when MDS progresses to AML—stem cell apoptosis stops and the cells fail to differentiate, a process that has been widely studied. In the past decade much progress had been achieved. We know more about disease pathophysiology resulting in increased emphasis on patient care and the evolution of targeted therapy. The chapters of this book offer updated knowledge on all clinically important aspects of the disease. Topics of great current interest are discussed by leading authors on MDS from different parts of the world. We would like to recommend this book to all those interested in this exciting and rapidly expanding field of hematology, including. medical students and postgraduates. Although MDS is a clonal disease it is not yet recognized as a malignant disease by the majority of health care systems. Consequently, access of MDS patients to novel, expensive and targeted therapeutic modalities is generally unsatisfactory. It is hoped that the present volume will increase awareness of the necessity of opti-
vii
viii
Preface
mal treatment beyond simple supportive measures and facilitate the introduction of optimal treatment adequately sponsored by decision makers in health care systems.
References 1.╇Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JCY, Schimmer AD (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7:118–129 2.╇Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008 112(1):45–52 3.╇Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 87:691–699 4.╇Raposa T, Várkonyi J (1987) The relationship between sister chromatid exchange induction and leukemogenicity of different cytostatics. Cancer Detect Prev 10(1–2):141–151 5.╇Willman C (2001) MDS/AML: models of genetic progression and clues to etiology. Leukemia Res 25(1):1 (Abstr. Or3)
Budapest, Hungary
Prof. Judit Várkonyi
Contents
1 ╇ The History of the Myelodysplastic Syndromes ����������������������������������尓� ╅╇ 1 Ray M. Lowenthal 2 ╇Susceptibility to MDS: DNA Repair and Detoxification Genes ���������� ╅╇ 5 Claire Seedhouse and Nigel Russell 3 ╇Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation ����������������� 25 H.-P. Horny and P. Valent 4 ╇Diagnostic Criteria and Classification of Myelodysplastic Syndromes ����������������������������������尓������������������������������������尓������������������������� 43 Peter Valent, Friedrich Wimazal, Wolfgang R. Sperr and Hans-Peter Horny 5 ╇ Cytogenetics of MDS ����������������������������������尓������������������������������������尓�������� 55 Detlef Haase, Christina Ganster, Christian Steidl, Katayoon Shirneshan, Friederike Braulke and Julie Schanz 6 ╇ Molecular Changes in Myelodysplastic Syndrome ����������������������������� â•… 87 Florian Nolte and Wolf-K. Hofmann 7 ╇ Prognostic Scoring in MDS ����������������������������������尓���������������������������������� ╇ 103 Michael Pfeilstöcker 8 ╇Flow Cytometry in Myelodysplastic Syndromes ����������������������������������尓 ╇ 121 C. Alhan, T. M. Westers, G. J. Ossenkoppele and Arjan A. van de Loosdrecht 9 ╇MDS as an Autoimmune Process ����������������������������������尓������������������������� ╇ 145 W. Ingram, Y. Kordasti and G. J. Mufti he Myelodysplastic Overlap Syndromes ����������������������������������尓���������� ╇ 159 10 T W. Ingram and G. J. Mufti ix
x
Contents
11 I ron and Copper Metabolism in the Myelodysplastic Syndromes ����� ╇ 175 Judit Várkonyi, Gabriella Bekő, Zoltán Prohászka and István Karádi 12 P athogenesis and Management of Iron Overload in MDS ������������������ ╇ 187 Chaim Hershko 13 C ytokines in MDS: Abnormalities and Treatment ������������������������������ ╇ 205 Howard S. Oster, Drorit Neumann and Moshe Mittelman 14 T herapeutic Modalities and New Molecular Targets in MDS ������������ ╇ 219 Guillermo Garcia-Manero 15 H aematopoietic Stem Cell Transplantation in MDS for Adults ��������� ╇ 239 Tamás Masszi 16 J MML and Myelodysplastic Syndrome in Children ��������������������������� ╇ 253 Henrik Hasle Appendix ����������������������������������尓������������������������������������尓������������������������������������尓 ╇ 279 Index ����������������������������������尓������������������������������������尓������������������������������������尓������� ╇ 285
Contributors
C. Alhan╇ Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands Gabriella Bekő╇ 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary Friederike Braulke╇ Abteilung Hämatologie/Onkologie, Georg-AugustUniversität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany e-mail:
[email protected] Christina Ganster╇ Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany e-mail:
[email protected] Prof. Chief Guillermo Garcia-Manero MD╇ Section of Myelodysplastic Syndromes, Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, PO Box 428, Houston, TX 77025, USA e-mail:
[email protected] Detlef Haase╇ Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany e-mail:
[email protected] Dr. Henrik Hasle╇ Department of Pediatrics, Skejby Hospital, Aarhus University, 8200 Aarhus N, Denmark e-mail:
[email protected] Chaim Hershko MD╇ Department of Hematology, Shaare Zedek Medical Center, P. O. Box 3235, Jerusalem, Israel e-mail:
[email protected] Wolf-K. Hofmann╇ Department of Hematology and Oncology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
xi
xii
Contributors
H.-P. Horny╇ Institute of Pathology, Escherichstrasse 6, 91522 Ansbach, Germany e-mail:
[email protected] Dr. W. Ingram╇ Department of Haematology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK e-mail:
[email protected] István Karádi╇ 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary Y. Kordasti╇ Department of Haematological Medicine, King’s College London, London, UK Arjan A. van de Loosdrecht, MD, PhD╇ Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands e-mail:
[email protected] Ray M. Lowenthal AO, MBBS, MD, FRCP, FRACP, FAChPM╇ Department of Clinical Haematology and Medical Oncology and Menzies Research Institute Tasmania, Royal Hobart Hospital, Hobart, TAS, Australia Department of Medicine, University of Tasmania, 7000 Hobart, Australia e-mail:
[email protected] Tamás Masszi╇ Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital of Budapest, St. László Campus, Gyáli út 5-7, 1097 Budapest, Hungary e-mail:
[email protected] Moshe Mittelman╇ Department of Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 64239 Tel Aviv, Israel e-mail:
[email protected] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel G. J. Mufti╇ Department of Haematological Medicine, King’s College London, London, UK Drorit Neumann╇ Department of Cell and Developmental Biology, Tel Aviv University, Sackler School of Medicine building, Ramat Aviv, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Florian Nolte╇ Department of Hematology and Oncology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany e-mail:
[email protected] G. J. Ossenkoppele╇ Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands Howard S. Oster╇ Department of Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 64239 Tel Aviv, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv
Contributors
xiii
Michael Pfeilstöcker╇ 3rd Medical Department and L. Boltzmann Institute for Leukemia Research & Hematology, Hanusch Hospital, H. Collinstr 30, 1140 Vienna, Austria e-mail:
[email protected] Zoltán Prohászka╇ 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary Prof. Nigel Russell╇ Department of Academic Haematology, University of Nottingham, Clinical Sciences Building, Nottingham University Hospitals—City Campus, NG5 1PB Nottingham, UK Julie Schanz╇ Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany e-mail:
[email protected] Dr. Claire Seedhouse╇ Department of Academic Haematology, University of Nottingham, Clinical Sciences Building, Nottingham University Hospitals—City Campus, NG5 1PB Nottingham, UK e-mail:
[email protected] Katayoon Shirneshan╇ Abteilung Hämatologie/Onkologie, Georg-AugustUniversität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany e-mail:
[email protected] Wolfgang R. Sperr╇ Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria Christian Steidl╇ Department of Pathology, British Columbia Cancer Agency, 600 W 10th Avenue, V5Z 4E6 Vancouver BC, Canada e-mail:
[email protected] P. Valent MD╇ Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria e-mail:
[email protected] Judit Várkonyi╇ 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary e-mail:
[email protected] T. M. Westers╇ Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands Friedrich Wimazal╇ Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna Waehringer Guertel 18-20, 1090 Vienna, Austria Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria
Chapter 1
The History of the Myelodysplastic Syndromes Ray M. Lowenthal
The conditions that now come under the rubric of the myelodysplastic syndromes (MDS) have been recognised for over a century under a variety of names. Indeed, few haematological conditions seem to have excited as much interest in their history. Every review of MDS, it seems, is accompanied by a historical overview. So, how to provide information that is different? Where to begin? Perhaps we should look earlier than the first possible description of the disorder. The portrayal of MDS as an entity has relied on many preceding breakthroughs in the development of the speciality of haematology. One of the first was the recognition of the bone marrow as being the site of blood formation, a discovery attributed to Ernst Neumann (1834–1918) [1, 2]. The first comprehensive description of the various blood cells and their morphology was given by the German scientist/ physician Paul Ehrlich (1854–1915) in 1879 [3]. Ehrlich as a young man developed staining techniques which allowed the ‘colourless’ corpuscles (the leucocytes) to be visualised. This he achieved by utilising aniline dyes which contemporaneously were being developed by the German chemical industry for textile manufacturers [4]. Amongst other things he was the first to describe aplastic anaemia and distinguish it from other forms of anaemia. Ehrlich himself relied on developments in microscopy which took place over several centuries [5], and include particularly the name of Antonj van Leeuwenhoek (1632–1723). Another early discovery that has relevance to the MDS story was made in 1898. It was in that year that Marie and Pierre Curie described the element radium and its radioactivity, a discovery which in turn led to the development of radiotherapy. In the early part of the twentieth century radiotherapy was commonly used to treat the splenomegaly of some types of leukaemia and presumably also MDS; an irony, given that we now know that ionising radiation itself can cause leukaemia and MDS [6]. Indeed both Marie Curie and her elder daughter Irène, who carried on her R. M. Lowenthal () Department of Clinical Haematology and Medical Oncology and Menzies Research Institute Tasmania, Royal Hobart Hospital, Hobart, TAS, Australia Tel.: +61-3-6222-8157 Fax: +61-3-6226-4894 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_1, ©Â€Springer Science+Business Media B.V. 2011
1
2
R. M. Lowenthal
mother’s work on radioactivity after her mother’s death, are said to have died of ‘leukaemia’. Even more ironically Marie’s final illness, as reported in the biography written by her younger daughter Eve, could well be interpreted as MDS, particularly as she is said to have been anaemic for years beforehand. According to Eve, quoting the physician who cared for her, Marie died of ‘aplastic pernicious anaemia of rapid, feverish development. The bone marrow did not react’ [7]. Layton and Mufti (1986) provide a comprehensive bibliography of the important advances in the history of MDS up to that time [8]. They claim that the first account of MDS can be attributed to von Leube in 1900 who described a case of megaloblastic anaemia which preceded the onset of leukaemia [9]. Early appellations for the conditions which now come under the heading of MDS included pseudo-aplastic anaemia [10], a term that was based on the presence of peripheral blood cytopenias with a cellular rather than aplastic marrow; and refractory anaemia [11] on the grounds of the patient having a form of anaemia that did not respond (was ‘refractory’) to the known haematinics, iron, folic acid and vitamin B12 [12]. The first winner of the Harvey Cushing prize for the best essay on a topic in medical history was Jean Captain Sabine, who in 1938, wrote “A History of the Classification of Human Blood Corpuscles.” In it he summarised all the work up to that point [13]. In 1942 Chevallier and colleagues described a case they called odo-leukemia, odo allegedly being Greek for ‘threshold’ (indicating the condition being on the threshold of—or almost—leukaemia [14]. Interestingly they attributed their case to excessive exposure to benzene. In the late 1940s it was recognised that some cases of peripheral blood cytopenias ultimately transformed into acute leukaemia (usually of the myeloid type), thus leading to the terms preleukaemia or preleukaemic anaemia [15]. Then in the 1950s came the appreciation that cases of ‘refractory’ leucopenia or thrombocytopenia had a similar significance to refractory anaemia; this led to broadening of the terminology to include refractory cytopenia [16]. Further study of the natural history of the refractory cytopenias showed that they by no means all transformed to leukaemia, indeed only a minority did so, leading to the appreciation that the term ‘preleukaemia’ was prognostically misleading and that an alternative term was needed. Other early terms used (before 1976) included sideroblastic anaemia [17], smouldering leukaemia [18, 19] and dysmyelopoietic anaemia—this latter term continues to have currency [20]. The term subacute myeloid leukaemia probably refers to a subset of MDS [21]. The first FAB classification of the leukaemias, which included MDS, was proposed in 1976 [22] and a revision which expanded the system as it applied to MDS was introduced in 1982 [23]. The initial WHO classification was developed in 2000 [24] and revised in 2008 [25, 26]. Highlights in the scientific understanding of MDS include the first verification of the clonality of the condition, by G6PD isoenzyme studies [27] and the discovery of cytogenetic abnormalities including 5q- [28, 29]. In 1997 Greenberg et€al. introduced an international prognostic scoring system (IPSS) [30] that has become widely used; it was created in an attempt to synthesise information from several previously used scoring systems including those devised in Bournemouth, UK [31], Valencia, Spain [32], and Dusseldorf, Germany [33].
1â•… The History of the Myelodysplastic Syndromes
3
The history of the treatment of MDS is unfortunately much shorter and less satisfactory than the history of its discovery and biology. Highlights include the use of bone marrow transplantation [34], the first report of use of growth factors, with GM-CSF [35]; the introduction of azacytidine, the first demethylating agent brought into clinical practice [36]; and the use of lenalidomide [37]. Hopefully when the history of the myelodysplastic syndromes is re-written in decades hence, much more will be said about the success of treatments.
References ╇ 1. Neumann E (1869) Über die Bedeutung des Knochenmarkes für die Blutbildung. ein Beitrag zue Entwicklungsgeschichte der Blutkörperchen. Arch Heilkd 10:68–102 ╇ 2. Tavassoli M (1980) Bone marrow: the seedbed of blood. In: Wintrobe MM (ed) Blood, pure and eloquent. McGraw-Hill, New York, pp€57–79 ╇ 3. Ehrlich P (1879) Methodologische Beiträge zur Physiologie und Patholgie der verschiedenen Formen der Leukocyten. Z Klin Med 1:553–560 ╇ 4. Ehrlich P (1877) Beitrag zur Kenntnis der Anilinfärbungen und ihrer Verwendung in der mikroskopischen. Technik Arch Mikr Anat 13:263–277 ╇ 5. Wintrobe MM (1980) Blood, pure and eloquent. McGraw-Hill, New York ╇ 6. Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, Kamada N, Ichimaru M, Finch SC, Pisciotta AV et€al (1988) Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol 18:91–96 ╇ 7. Curie E (1937) Madame Curie. Doubleday, Garden City ╇ 8. Layton DM, Mufti GJ (1986) Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. Blut 53:423–436 ╇ 9. von Leube W (1900) Rapid verlaufende schwere Anämie mit gleichzeitiger leukämischer Veränderung des Blutbildes. Klin Wochenschr 37:85–97 10. Luzzatto AM (1907) Sull anemia grave megiloblastica sensa reporto ematologica correspondente (anemia pseudoaplastica). Riv Veneta Med Venezia 47:193 11. Rhoades CP, Barker WH (1938) Refractory anemia: an analysis of one hundred cases. J Am Med Assoc 110:794–796 12. Bomford RR, Rhodes CP (1941) Refractory anemia. Q J Med 10:175–281 13. Sabine JC (1940) A history of the classification of human blood corpuscles. Bull Hist Med 8:696–720, 785–805 14. Chevallier P, LaMotte M, Umdenstock R (1942) Trois cas d’anémie-leucose benzolique. Le Sang 15:391–405 15. Hamilton-Paterson JL (1949) Preleukemia anemia. Acta Hematol 2:309–316 16. Block M, Jacobson LO, Bethard WF (1953) Preleukemic acute human leukaemia. J Am Med Assoc 152:1018–1028 17. Björkman SE (1956) Chronic refractory anemia with sideroblastic bone marrow; a study of four cases. Blood 11:250–259 18. Rheingold JJ (1974) Acute leukemia. Its smoldering phase, or leukemia never starts on thursday. J Am Med Assoc 230:985–986 19. Rheingold JJ, Kaufman R, Adelson E, Lear A (1963) Smoldering acute leukemia. N Engl J Med 268:812–815 20. Rosenthal DS, Moloney WC (1984) Refractory dysmyelopoietic anemia and acute leukemia. Blood 63:314–318
4
R. M. Lowenthal
21. Cohen JR, Creger WP, Greenberg PL, Schrier SL (1979) Subacute myeloid leukemia: a clinical review. Am J Med 66:959–966 22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol 33:451–458 23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189– 199 24. Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131–133 25. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC, Lyon 26. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951 27. Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ (1984) Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 63:1318–1323 28. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251:437– 438 29. Haase D (2008) Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87:515– 526 30. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 31. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59:425–433 32. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74:395–408 33. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52–59 34. Tallman MS, McGuffin RW, Higano CS, Starkebaum G, Collins SJ, Johnston H, Singer JW, Perry DJ, Kunath A (1987) Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis. Am J Hematol 24:93–99 35. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU (1987) Effects of recombinant human granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552 36. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T (1991) Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 37:100–104 37. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549–557
Chapter 2
Susceptibility to MDS: DNA Repair and Detoxification Genes Claire Seedhouse and Nigel Russell
Introduction The myelodysplastic syndromes (MDS) are a collection of heterogeneous disorders arising from a clonal myeloid stem cell. They are characterised by ineffective haematopoiesis and are frequently associated with genetic instability manifested as chromosomal abnormalities. MDS progresses through a pathway of one or more dysplasias and ends in myeloid leukaemia—the risk of developing acute myeloid leukaemia (AML) depends on the subtype of MDS. Similar to other malignant diseases, the stepwise disease progression is likely to be the consequence of the accumulation of mutations, probably due to an increased DNA damage burden and/or reduced ability to deal with the damage. MDS risk has previously been associated with benzene exposure or exposure to a number of other environmental toxins. In addition a subset of patients develop the disease following chemotherapy or radiotherapy treatment for a primary disease (therapy-related MDS (t-MDS)). Mammalian cells have a number of efficient systems designed to metabolise and inactivate harmful genotoxic agents, or if the agents manage to induce damage then complex DNA repair mechanisms effectively remove the damage. Importantly, if the damage is excessive, DNA damage response proteins will trigger the apoptotic pathway to get rid of the cell for the good of the whole organism. These systems are not only required for protection from exogenous damaging agents but also for the constant damage cells receive from endogenous cellular processes, predominantly oxidative stress. MDS incidence increases with increasing age suggesting that the genotoxic burden on DNA eventually reaches a critical level resulting in disease. What, however, predisposes some individuals to the development of MDS when they have encountered a similar level of damage as an individual who remains healthy? A large body C. Seedhouse () Department of Academic Haematology, University of Nottingham, Clinical Sciences Building, Nottingham University Hospitals—City Campus, NG5 1PB Nottingham, UK Tel.: +44-115-8231822 Fax: +44-115-8231820 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_2, ©Â€Springer Science+Business Media B.V. 2011
5
6
C. Seedhouse and N. Russell
of research suggests that the answer, at least in part, is genetic variation in key genes involved in (1) protection of cellular entities from damage and (2) repair of DNA damage. Mutations in these genes are rare but of high penetrance and lead to serious genetic diseases; one example of a disease arising from mutations in DNA repair genes is Fanconi Anaemia which carries a strong predisposition to MDS. Much more common are genetic polymorphisms that occur in many of the genes which function to protect our genomes. This chapter aims to summarise research published on polymorphisms in detoxification and DNA repair genes in MDS. Therapy-related MDS is rarely investigated alone but is commonly grouped with therapy-related AML and indeed t-AML and t-MDS are now classified together by the World Health Organisation. There is a great deal of research that has been done on polymorphisms in t-AML/MDS (reviewed in Seedhouse and Russell [67]), so we will concentrate on work performed on de novo MDS samples and only positive associations of polymorphisms with t-AML/MDS will be discussed.
Detoxification Pathways The first line of defence to genotoxic agents is detoxification—this should occur before the agents are able to damage cellular molecules. Metabolism of endogenous and exogenous agents occurs by the same pathways and is divided into two phases. Phase I involves activation of substrates into electrophilic intermediates; these reactions are predominantly catalysed by the cytochrome P450 (CYP) protein family, many of which harbour polymorphisms which affect their function. The products of the phase I reactions are highly reactive and liable to cause severe cellular damage and the phase II enzymes (conjugation) are required to inactivate the phase I products. Enzymes that participate in phase II include the glutathione S-transferases (GST) and NAD(P)H:quinine oxidoreductase-1 (NQO1). These enzymes not only detoxify reactive phase I products but also act on genotoxic agents that do not require phase I activation. The balance of phase I and II activity is critical and a consequence of high levels of phase I activity with low levels of phase II activity is the production of deleterious metabolites which will damage cell components, especially DNA. It follows that polymorphisms affecting the function of either phase I or II proteins, or indeed proteins from both phases, may upset the balance of detoxification activity and predispose individuals to high levels of damaging agents.
Phase I: Cytochrome P450 Enzymes The cytochrome P450 superfamily comprises a large and diverse group of membrane-associated haem-proteins divided into 18 families. They are responsible for the metabolism of both endogenous and exogenous substrates, largely via an oxidative reaction, creating highly reactive intermediates that cause damage to DNA
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes
7
unless detoxified by phase II proteins (reviewed in Nebert and Dalton [53]). The CYP proteins can be induced or inhibited resulting in highly variable expression. In addition polymorphisms exist in many of the family members which affect the function of the protein and contribute to high inter-individual variability. The allele frequencies of several of the polymorphic variants have been examined as potential disease risk-factors in MDS populations. CYP2E1 CYP2E1 harbours a C to T single nucleotide polymorphism (SNP) in its 5′ promoter (CYP2E1*5) which is associated with increased transcriptional activity [30]. CYP2E1 is known to play an important role in the metabolism of benzene, exposure to which is a known risk factor to MDS. The CYP2E1*5B polymorphism has been studied to establish whether the variant allele increases susceptibility to benzene poisoning and hence MDS but no association was found [64]. CYP3A4 An A to G SNP is present in the CYP3A4 5′ promoter (CYP3A4*1B). The variant was initially proposed to alter a regulatory element within the promoter with a resulting decrease in activity [63]. Conversely, further biological assays failed to demonstrate specific functional differences between the variant and wild-type alleles [76, 85]. Fabiani et€al. found no risk for MDS associated with CYP3A4*1B [23]. CYP3A5 Two SNPs exist within CYP3A5 (CYP3A5*3 and CYP3A5*6) both of which cause alternative splicing and truncated proteins resulting in the absence of CYP3A5 [40]. The frequencies of these polymorphisms have been studied in a Taiwanese MDS population. There was no difference in the distribution of the CYP3A5*3 allele in MDS when compared to a healthy control cohort and the CYP3A5*6 allele was not found in cases or controls [46]. Significant Findings of CYP Variants in t-AML/MDS A large number of studies have been published examining the distribution of several of the CYP variant alleles in t-AML/MDS (reviewed in Seedhouse and Russell [67]). However, the only significant findings have been concerning the CYP3A4 A to G 5′ promoter polymorphism. The polymorphic variant (CYP3A4*1B) was found to be under-represented in a group of 30 childhood t-MDS/leukaemia samples when compared to a control group of paediatric patients with de novo leukaemia (odds ratio (OR) 0.09; 95% confidence intervals (CI) 0.01–0.87) [24] suggesting that the
8
C. Seedhouse and N. Russell
variant allele may result in a decrease in DNA-damaging reactive intermediates and therefore protect against t-AML/MDS. These results were corroborated by Rund et€al. [65] when comparing healthy controls with adult t-AML/MDS patients.
Phase II: Glutathione S-transferases The glutathione S-transferase (GST) multigene family is a major class of phase II detoxification enzymes. Their substrates are manifold and include environmental mutagens, drugs and products of oxidative stress which may, or may not, be byproducts of a phase I reaction. The mode of action of the GSTs is conjugation of the reactive electrophilic substrates to glutathione. There are at least four cytosolic GST subfamilies: alpha (A), mu (M), pi (P) and theta (T) and functionally relevant polymorphisms exist in each subfamily. GSTM1 and GSTT1 GSTM1 and GSTT1 have attracted considerable interest because both genes are commonly deleted [61, 70]. The homozygous deletion GSTM1 polymorphism exists in approximately 50% of Caucasians and the GSTT1 deletion in 25%; these frequencies differ between races. Most studies examining the cellular consequences of the GSTM1 or GSTT1 deletions point towards reduced detoxification activity resulting in higher levels of DNA damage [15, 32, 73, 86, 87]. A large number of studies have examined the importance of the GSTM1 and GSTT1 deletions in MDS (summarised in Table€2.1) with some finding positive associations for either GSTM1 null, or GSTT1 null, or for the combined GSTM1 and GSTT1 null genotypes with MDS. Dahabreh et€al. have performed a meta-analysis of GSTM1 and GSTT1 deletion polymorphisms in MDS [20]. They identified 13 eligible studies for GSTT1 comprising a total of 1,471 cases and 1,907 controls. Using both fixed and random effects models the GSTT1 null genotype was shown to be significantly associated with an increased risk of MDS (Fixed effects OR 1.44, 95% CI 1.21–1.72, pâ•›<â•›0.0001; random effects OR 1.43, 95% CI 1.09–1.89, pâ•›=â•›0.01). This study provides strong evidence that the GSTT1 null genotype is associated with MDS susceptibility. For GSTM1, ten eligible studies were identified totalling 1,161 cases and 1,668 controls. Neither the fixed or random effects models showed an association between GSTM1 null and MDS. When MDS patients are divided into further sub-groups the majority of studies have shown a trend for the GSTT1 null genotype being more prevalent in the RA/ RARS FAB subtypes than the more aggressive RAEB/RAEB-T subtypes; however no study has reached statistical significance. Within the subgroup analyses one paper of particular interest is by Stavropoulou et€al. [77] who studied a large series of well characterised MDS patients (nâ•›=â•›323) enabling analysis of genotype
48 48 53 33.3 36.9 51 52 42.4 48.5 59.4 16 16 23 46 19 30 6.66 18.1 16 15 15.8 25.3 18.1 10.8 8.8 13.1 7 21 0 6.1
46 21 28 46 21 53 11.1 14.2 22 36 17.9 19.8 24.4 6.1 7.8 5.8 26 33 3 6.8
Control deletion frequency (%)
42 55 55 57.4 36.7 53 70 35.4 47.7 51.6
MDS deletion frequency (%)
Studies showing significant associations with MDS are shaded a Only Caucasian results shown, other racial groups had very low numbers (n<10) b Published gene frequencies of healthy human subjects sorted by race (n>15000)
GSTM1 deletion 92 MDS 201 cancer-free, similar age, sex and race 166 MDS 112 haematologically normal staff and patients 116 MDS 43 healthy volunteers 54 MDS 60 cancer-free, matched for age and sex 49 MDS 102 newborn 128 MDS 239 healthy, similar sex and race a b 73 MDS Garte et al. [26] 302 MDS 330 healthy, matched for age and sex 86 MDS 99 hospitalised controls, matched for age and sex 157 MDS 155 cancer-free, matched for age and sex GSTT1 deletion 92 MDS 190 cancer-free, similar age, sex and race 166 MDS 112 haematologically normal staff and patients 57 MDS 100 haematologically normal staff and patients 59 MDS 50 normal controls 158 MDS 100 blood donors, similar age and sex 116 MDS 43 healthy volunteers 54 MDS 60 cancer-free, matched for age and sex 49 MDS 102 newborn 128 MDS 239 healthy, similar sex and race a b 73 MDS Garte et al. [26] 323 MDS 330 healthy, matched for age and sex 86 MDS 99 hospitalised controls, matched for age and sex 156 MDS 155 cancer-free, matched for age and sex Combined GSTM1 and GSTT1 deletions 49 MDS 102 newborn 128 MDS 239 healthy, similar sex and race 86 MDS 99 hospitalised controls, matched for age and sex a b 73 MDS Garte et al. [26] 116 MDS 43 healthy volunteers 54 MDS 60 cancer-free, matched for age and sex 294 MDS 330 healthy, matched for age and sex
Control population
Table 2.1↜渀 Summary of de novo MDS studies on GSTM1 and GSTT1 polymorphisms
1.2 (0.2–4.7) Not given, non-significant Not given, non-significant 2.86, p < 0.001 1.84 (0.81–4.19) – P = 0.830
4.3 (2.5–7.4) 0.72 (0.4–1.34) Not given, non-significant Not given, non significant Not given, non-significant 2.65 (1.27–5.52) p < 0.01 1.75, not significant 0.7 (0.2–1.8) Not given, non-significant 1.81, p < 0.001 p = 0.518 Not given, non-significant 1.46 (0.82–2.62), p = 0.22
0.8 (0.5–1.3) 0.89 (0.5–1.43) 0.80 (0.62–2.43) 2.70, p < 0.01 0.9. (0.5–1.9) Not given, non-significant 2.32, p = 0.002 p = 0.086 Not given, non-significant 0.73 (0.45–1.17), p = 0.2
OR (95% CI)
[6] [27] [81] [78] [66] [80] [77]
[16] [7] [9] [59] [62] [66] [80] [6] [27] [78] [77] [81] [23]
[16] [7] [66] [80] [6] [27] [78] [77] [81] [23]
Reference
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes 9
10
C. Seedhouse and N. Russell
frequencies within specific cytogenetic groups. They discovered that none of the five patient samples with an isolated 5q deletion were GSTT1-null and also noted that, in a previous publication, there were 0/10 del5q patients who had a GSTT1 null genotype [62]. By increasing their data set to 47 samples (22 of which had an isolated 5q-, 4 a 5q- with one additional abnormality and 21 a -5/del5q as part of a complex karyotype) Stavropoulou et€al. found only two samples with a GSTT1 null genotype. This was highly significant when comparing to MDS samples with other karyotypic abnormalities or to the normal controls. These striking findings were explained by the fact that exposure to organic solvents had previously been associated with chromosome 5q abnormalities and that GSTT1 enzyme activity is required for some organic solvents to form mutagenic metabolites. Hence Stavropoulou et€al. hypothesised that the presence of the GSTT1 gene is not always protective but may confer MDS risk following particular chemical exposure by promoting specific genetic damage. GSTP1 and GSTPA1 The third polymorphic GST which has been widely studied in disease-risk is GSTP1. This gene has a G to A SNP which results in an ile to val amino acid change at codon 105 of the protein [1]. Codon 105 resides in the electrophile-binding site of the GSTP1 protein and the altered properties of the val amino acid affects both the catalytic activity of the enzyme, in a substrate-dependent manner, and its thermal stability. Two studies have been published examining the contribution of the GSTP1-105 polymorphism to de novo MDS risk, the first found no positive association [66], whilst Fabiani et€al. in the latter study found an increased risk of MDS associated with the presence of at least one variant val allele (OR1.66, 95% CI 1.03–2.67; pâ•›=â•›0.04) [23]. Furthermore patients with low/intermediate risk MDS (IPSS risk group low/intermediate-1) had a higher probability of overall survival if they harboured a GSTP1-105€val allele (pâ•›=â•›0.008). Fabiani and colleagues also examined the GSTPA1-C69T promoter variant in their study. This polymorphism has been shown to be correlated with GSTA1 expression [19]. There was no association between the GSTP1A-69T variant and MDS risk. Significant Findings of GST Polymorphisms in t-AML/AML A comprehensive summary of GST polymorphisms in t-AML/MDS can be found in Seedhouse and Russell [67]. Two studies demonstrated significant associations between the GSTT1 null polymorphism and t-AML/MDS disease incidence [2, 66]. In addition Allan et€al. showed that individuals with at least one GSTP-105Val allele were significantly over-represented in t-AML/MDS when compared with either a control or a de novo AML group. The odds ratio was increased if only those patients
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes
11
who had received chemotherapy were considered and further increased in the subgroup of patients who had prior exposure to a known GSTP1 substrate. Subgroup analysis by Haase et€al. [27] also provided interesting results with a highly significant increase in the risk of developing t-MDS/AML following breast cancer treatment when the double GSTM1/GSTT1 null genotype was present. This was further pronounced when considering patients who had been treated with chemotherapy for their breast cancer. NAD(P)H: Quinone Oxidoreductase (NQO1) NQO1 uses NADH or NADPH to catalyse 2- or 4-electron reductions of its quinone substrates thereby producing less reactive hydroquinones. This activity plays a critical role in detoxification preventing the generation of ROS and free-radicals that would otherwise go on to damage DNA and other cellular components. The NQO1 gene has a well studied C to T SNP at position 609 resulting in a pro to ser amino acid substitution at codon 187 [79]. The variant ser-containing protein has negligible enzymatic activity and is no longer inducible in bone marrow cells following benzene metabolite exposure. An allele dosage effect occurs with the ser/ser homozygote having no activity and the pro/ser heterozygote showing intermediate activity between the homozygote variant and wild type proteins [51, 74]. Benzene poisoning is associated with a very strong risk of MDS development and the NQO1 serine allele increases the risk of benzene poisoning [64], there has therefore been interest in the distribution of the NQO1 polymorphism in MDS. Whilst no relationship has been found between the NQO1 SNP and de novo MDS risk [23, 43], these results are contrary to findings from several studies on the therapy-related disease (see below). Significant Findings of NQO1-Pro187Ser in t-AML/MDS Larson et€al. found a significant over-representation of the NQO1-187ser allele in a t-AML/MDS cohort: interestingly 7/8 of the ser/ser homozygotes had abnormalities of either chromosome 5 and/or 7 [43]. Naoe et€al. [52] confirmed these findings in 58 t-AML/MDS patients with the ser variant homozygous genotype conferring an odds ratio of 2.62 (95% CI 2.16–3.08) although chromosome 5 and/or 7 abnormalities were not over-represented in their variant homozygote samples.
DNA Repair Cells encounter constant attack from molecules which can damage DNA. Efficient detoxification mechanisms limit cellular damage but, even so, DNA cannot be entirely spared and therefore complex pathways are present to repair DNA damage
12
C. Seedhouse and N. Russell
and minimise its deleterious effects. The balance of DNA repair is critical—whilst too little repair can result in the acquisition and persistence of mutations and genetic instability, too much repair can be equally harmful by inhibiting the apoptotic pathway and enabling a cell with badly damaged DNA to attempt repair, possibly misrepair and survive. DNA damage is known to accumulate with age and eventually overloads the repair systems leading to haeamatopoietic stem cell (HSC) exhaustion. A number of studies using mouse models have effectively demonstrated the importance of DNA repair genes, involved in a number of different repair pathways, in maintaining HSC function (reviewed in Niedernhofer [55]). MDS is primarily a disease of the elderly and some cases can occur following large genotoxic insults such as chemotherapy drug treatment. If the damage levels sustained with increasing age or genotoxic insult are unrepaired and reach a certain threshold, protective cell senescence or apoptosis should be triggered. If these mechanisms fail then the genomic instability may prime stem cells for further mutation development and functional cellular abnormalities ultimately resulting in MDS and/or leukaemia. There is a significant body of research demonstrating high levels of DNA damage in MDS samples. Increased levels of the major oxidative damage product, 7,8-dihydro-8-oxoguanine (8-oxoG), have been found in MDS patient bone marrow samples when compared to normal bone marrow controls [33] and increased levels of oxidised pyrimidine nucleotides are seen in CD34+ enriched MDS bone marrow samples compared to either CD34− MDS samples or CD34+ bone marrow cells from normal subjects [60]. Novotna et€al. have also shown higher levels of oxidative damage and genetic instability in samples from MDS patients when compared to age matched controls [56, 57]. It is not clear whether the increased DNA damage is a cause, or a result, of the MDS disease. Whilst genetic instability is one of the main prerequisites for disease development, once the disease is established iron overload in transfusion-dependent patients and reactive oxygen species generation from inflammation also have to be considered among important factors in determining the burden of DNA damage. Whatever the case, the additional DNA damage burden means that aberrant activities of DNA repair genes are likely to be particularly important in MDS.
Double Strand Break Repair DNA double strand breaks (DSBs) are the most important class of DNA damage because, if unrepaired, they can result in a loss of genetic material, chromosome abnormalities and possibly cell death. The two major mechanisms that repair DSBs are the homologous recombination and non-homologous end-joining pathways. Non-homologous End Joining Non homologous end joining (NHEJ) is active in all phases of the cell cycle and is considered to be the most important DSB repair pathway in mammalian cells. In
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes
13
NHEJ the DSB is recognised by the Ku70/Ku80 heterodimer which then forms a complex with DNA-PKcs. Following recruitment of further proteins and DNA end processing, a XRCC4-ligase IV complex re-ligates the break. A number of patients have been reported who have a mutation in the ligase IV gene—Ligase IV syndrome—and bone marrow abnormalities, including MDS, are amongst the many clinical disorders (reviewed in Chistiakov et€al. [17]). Polymorphisms in NHEJ genes have been identified but have not been studied in either de novo MDS or t-AML/MDS. However a recent study found differences in the expression of several of the NHEJ proteins in MDS samples [22]. Expression of ligase 4 was significantly elevated in MDS bone marrow samples compared to control bone marrow with the high expression appearing to be associated with a good risk karyotype. Conversely, the Ku70 protein levels were significantly lower in patients with a good risk karyotype. Homologous Recombination Homologous recombination (HR) repair is a tightly regulated, high-fidelity process. It uses a second, intact copy of the chromosome as a template to copy the information lost at the DSB site. A number of polymorphic genes involved in the pathway have been studied in the context of MDS. RAD51 and XRCC3 RAD51 is a central protein in the HR repair pathway binding to DNA and promoting ATP-dependent homologous pairing and strand transfer reactions. XRCC3 also participates in the pathway interacting with, and stabilising, RAD51. Polymorphisms are present in the RAD51 and XRCC3 genes. RAD51 has a G to C polymorphism at position −135 of the 5′ promoter of the gene [83]. Characterisation of the RAD51 promoter demonstrated that the −135 variant C allele was associated with increased promoter activity [29]. However, a further study suggested that the effect of the polymorphism was due to alternative splicing within the RAD51 5′-untranslated region [4]. The substitution of C for G abolishes a splice site resulting in low transcript levels of the longer RAD51 isoform (isoform 2). The authors suggested that as isoform 2 lacks a translation-inhibitory GC-rich region then it would be expected to have increased translation efficiency. As the polymorphic variant results in less isoform 2, subsequently, a reduction in RAD51 protein may occur. The XRCC3 gene is also polymorphic and a thr to met substitution occurs at codon 241 [72]. Whilst the variant protein has been shown to complement the DNA repair defect in a XRCC3-deficient cell line [5], further work determined that the variant protein was unable to apoptotically eliminate aberrant cells with mitotic defects resulting in genetic instability [45]. Two studies have found no differences in the distribution of the RAD51-G135C and XRCC3-thr241met polymorphisms in MDS samples compared to controls
14
C. Seedhouse and N. Russell
[10, 23]. Baumann et€al. also found no difference if the two polymorphisms were analysed in combination. In t-AML/MDS we found an over-representation of the RAD51-135C allele when compared with a control group (OR 2.66, 95% CI 1.17– 6.02, pâ•›=â•›0.02) [69]. Whilst there was no difference in the distribution of the XRCC3 polymorphism, when we looked at the combination of variant RAD51 and XRCC3 alleles we found a prominent synergistic effect resulting in an odds ratio of more than 8 (OR 8.11, 95% CI 2.22–29.68, pâ•›=â•›0.002). BLM, TOP3A and RMI1 Bloom syndrome is a rare autosomal recessive disorder characterised by growth retardation, sensitivity to light and a predisposition to the development of many cancers including leukaemia and MDS. BLM is a RecQ helicase which prevents illegitimate recombination in mitotic cells. The BLM gene is mutated in Bloom syndrome resulting in an elevated frequency of exchange between homologous chromosomes and sister chromatids. BLM interacts physically and functionally with both topoisomerase IIIa (TOP3A) and RMI1/BLAP75 (reviewed in [75]. Polymorphisms in BLM, RMI1 and TOP3A have been studied in MDS. RMI1 harbours a G to A polymorphism which results in a ser to asn change at codon 455 of the protein. Ser455 is evolutionarily conserved however the functional consequences of the polymorphism are unknown [13]. The presence of the polymorphic asn residue was demonstrated to be a risk factor for MDS (OR 1.9, 95% CI 1.1–3.3) [13]. Interestingly the effect was stronger in those patients over the age of 65 years which the authors suggested may reflect the fact that mitotic recombination increases with age and aberrations of proteins involved in this process may therefore be expected to have an increased influence as mitotic recombination increases. A second study by the same group examined a further 26 polymorphisms in RMI1, BLM and TOP3A in a mixed group of MDS and AML samples (37% MDS; 12% AML secondary to MDS; 51% AML). Of particular attention when analysed singly were TOP3A GA rs12945597 where the homozygous variant was associated with a 4.6-fold increase risk of MDS/AML (95% CI 1.7–14) and BLM AC rs6496724 for which the variant homozygote was less frequent in MDS/AML (OR 0.34, 95% CI 0.12–0.95) [14]. Following analyses of multiple myeloma, bladder and breast cancer samples in addition to the MDS/AML cohort, combinations of polymorphisms were chosen. The TOP3A rs12945597 A allele in combination with the BLM rs2532105 variant T allele resulted in an odds ratio of 2.4 for MDS/AML risk (95% CI 1.1–5.4). None of the functional effects of the polymorphisms, if any, are known.
Base Excision Repair: hOGG1 The base excision repair (BER) pathway corrects individually damaged bases which can occur via a number of different mechanisms but predominantly via
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes
15
oxidation. The major product of oxidative damage to DNA is 8-oxoG. 8-oxoG is highly mutagenic as it has a tendency to mispair with adenine thereby generating GC to TA transversions. The human glycosylase responsible for repairing this base adduct is hOGG1 (reviewed in Klungland and Bjelland [36]). A SNP exists at position 1,245 of the hOGG1 gene resulting in a ser to cys amino acid change at codon 326 in exon 7 of the corresponding protein. The cys-encoding protein has been shown to have a reduction in its repair activity compared to the wild type ser protein [38]. Jankowska et€al. have provided a comprehensive analysis of the importance of 8-oxoG in MDS including the genotyping of 146 MDS patients for the hOGG1 ser326cys polymorphism [33]. When comparing the distribution of the hOGG1 SNP in MDS to that of a cohort of 350 controls, significantly increased risks for MDS were found for both heterozygote (OR 1.7, 95% CI 1.1–2.5, pâ•›=â•›0.02) and homozygote cases (OR 2.8, 95% CI 1–7.2, pâ•›=â•›0.05). The cys allele was associated with conferring a particularly strong risk for advanced MDS and additionally there was a significant positive relationship between the presence of the cys allele and the frequency of chromosomal abnormalities (pâ•›<â•›0.02). The authors also compared hOGG1 mRNA expression between the different hOGG1 genotype groups with the carriers of hOGG1-cys326 exhibiting significantly higher hOGG1 levels when compared to the wild type hOGG1 ser/ser cases (pâ•›=â•›0.008). They suggested that this could be due to a feedback mechanism attempting to compensate for the reduced activity of the cys allele. XRCC1 also participates in the BER pathway acting as a scaffold and recruiting other BER proteins to the repair site. A common variation in the gene substitutes arg for met at position 399 of the protein, a region which comprises the BRCT domain [72]. The variant Gln residue has been shown to result in significant conformational changes to the XRCC1 protein [50] and a large number of studies have shown that cells harbouring the variant gln allele have a decreased capacity to repair DNA damage resulting in increased DNA damage levels [8, 21, 41, 44, 47, 82, 84]. We have demonstrated that the presence of a variant XRCC1399 gln allele was actually protective for t-AML/MDS (OR 0.44, 95% CI 0.20– 0.93, pâ•›=â•›0.03) [68]. We consider this result indicates a strong gene-environmental interaction. The genotoxic therapy a patient receives for their primary condition is likely to cause very high DNA damage levels in some HSCs. Cells with reduced BER capacity, that is a XRCC1-399gln allele, are more likely to be driven towards apoptosis whilst the wild type cells may attempt repair but misrepair resulting in mutations and a clone which can initiate t-AML/MDS. This geneenvironment (XRCC1-399gln: high DNA damage) hypothesis is supported by a study of XRCC1-399gln in non-melanoma skin cancer which is also associated with high levels of DNA damage; similar to t-AML/MDS a protective effect of the gln allele was found [54]. Furthermore in a meta-analysis of XRCC1-399 in smoking-related cancers, the variant gln allele was found to confer an increased risk in light smokers, but was protective among heavy smokers who presumably have high levels of DNA damage [31].
16
C. Seedhouse and N. Russell
Nucleotide Excision Repair Whereas BER removes the products of minor structural base damages, nucleotide excision repair (NER) removes bulky damages which distort the DNA helix. The NER repair pathway consists of removing segments of ssDNA containing the bulky lesion followed by repair synthesis by a DNA polymerase and ligation. Kuramoto et€al. measured the mRNA expression levels of several genes involved in the NER pathway, namely ERCC1, ERCC3, ERCC5 and XPC, and found a reduction in expression in at least one gene in more than 20% of the MDS samples when compared to normal samples. Additionally, patients with high risk MDS were more likely to have a reduction in NER gene expression [42]. The authors suggested that such a decrease in DNA repair gene expression may predispose individuals to chromosomal instability and underlie the pathophysiology of the disease. The ERCC2 (XPD) gene harbours a lys to gln change at codon 751 [72]. Like many of the polymorphisms in DNA repair genes the functional consequences of the ERCC-751gln variant allele are still unclear and a review of the literature by Clarkson and Wood [18] questions whether a causal relationship between the ERCC2 gene and reduced DNA repair occurs; instead the SNP may be in linkage with another functional SNP. Whatever the consequences, the ERCC2-751gln homozygote variant has been associated with a significant increase of developing chemotherapy-induced t-AML/MDS (OR 2.22, 95% CI 1.04–4.74) [3].
Mismatch Repair Mismatch repair (MMR) corrects mismatched DNA bases that can result from misincorporation errors that have avoided polymerase proof-reading activity during DNA replication. In addition MMR can also process some types of DNA damage. MMR is reasonably easy to study because deficiencies in the pathway result in an elevated rate of mutations which can be measured in simple repetitive DNA sequences (microsatellites). There have been a number of studies which have searched for MMR deficiency (microsatellite instability; MSI) in both de novo MDS and t-MDS/AML. A summary of the de novo MDS studies is shown in Table€2.2. Noteworthy is the study by Kaneko et€al. (Table€2.2) because serial samples from the same patients were analysed demonstrating that MSI, when it occurs, is an early event and may then contribute to the pathogenesis of MDS. There are also a large number of studies looking at the incidence of MSI in t-AML/MDS (reviewed in Seedhouse and Russell [67]). The incidence in the tAML/MDS samples is much higher (approximately 50%) than for de novo MDS suggesting that a prerequisite of MSI in MDS is a significant burden of DNA damage. Along these lines is work done on the development of AML/MDS following azathioprine immunosuppressive treatment after organ transplant: Offman et€ al. proposed that AML/MDS development may reflect the selection and expansion of MMR-deficient clones within the bone marrow which are resistant to drug-induced damage. The lack of MMR is expected to lead to the accumulation of mutations
2╅ Susceptibility to MDS: DNA Repair and Detoxification Genes Table 2.2↜渀 Summary of microsatellite instability (MSI) studies in de novo MDS Number of samples Number of loci studied (up to) % of samples with MSIa 6 4 33 19 10 16 9 22 11 12 12 8b 7 14 0 23 18 4b 29 10 0b 23 9 0b
17
Reference [34] [35] [39] [71] [12] [49] [48] [28]
The proportion of loci showing MSI differs between studies. Results are shown for two or more loci displaying MSI and results indicate further samples have MSI at just one locus a
b
which may subsequently result in a clonal haematopoietic disorder [58]. Further support of the importance of MMR in t-AML/MDS is a study showing that the variant allele of the MSH2 IVS12-6 T to C polymorphism [25] is over-represented in t-AML/MDS patients who had previously received alkylating therapy (OR 4.02, 95% CI 1.4–11.37) [88]. Strikingly both of the t-MDS/AML variant homozygotes had MSI, although not all of the MSI-positive samples had the polymorphism. The functional consequence of the polymorphism is unknown, although it resides in the splice acceptor site of exon 13 and may therefore alter splice site recognition.
Discussion Protection from DNA damage, either by preventing (detoxification or apoptosis) or repairing it, is paramount in keeping our cells healthy and this is particularly so for haematopoietic stem and progenitor cells which often come into close proximity to damaging agents. An accumulation of unrepaired genomic damage in HSCs will results in an increased risk of a clonal stem cell disease. MDS is a disease characterised by DNA damage and genetic instability, a state that is expressed as gross karyotypic abnormalities in 50% of patients. Whilst many polymorphisms only have subtle functional effects, gene-environment interactions are likely to magnify these effects making polymorphisms worthwhile of study. We are now accumulating evidence demonstrating a contribution of polymorphisms in detoxification pathways and DNA repair pathways to MDS susceptibility, however there is still more work to be done.
Sample Size and Controls for Polymorphism Studies Much of the work on susceptibility to MDS has focused on polymorphisms in the DNA repair and detoxification genes. Many of the polymorphic genes have only been investigated in single small studies, whilst those polymorphisms which have
18
C. Seedhouse and N. Russell
been assessed by more than one group have produced contradictory results. The answer in improving this body of work is by increasing sample sizes; very large cohorts of well characterised MDS patients are needed. In this respect we are participating in a large European study in which we have already collected more than 1,000 MDS samples and determined the genotypes at a number of polymorphic sites. Many sources of control samples have been used in the studies described herein. Appropriately matched controls, whilst often not easy to obtain, are an absolute requirement for epidemiological studies. However, we also consider it important to compare subgroups within MDS and suggest that this will help improve our knowledge on understanding MDS genetic susceptibility. For example are some polymorphic variants more prevalent in high risk MDS? Or does a particular polymorphism confer risk to a specific cytogenetic abnormality such as the GSTT1 5qstory? There are many research avenues still to be followed.
Functional Consequences of Polymorphic Variants A further caveat in polymorphism studies is the lack of data regarding their functional effects. Whilst many of the detoxification gene variants have been categorically shown to have reduced activity, for most of the DNA repair polymorphisms it is not known whether the sequence variant is functionally significant and more research into this question is required. The possibility of linkage disequilibrium between polymorphisms should also be considered.
Combinations of Polymorphisms Another area of importance, only possible with very large studies, is the combination of variant genotypes. Detoxification and repair processes are complex and more than one protein/pathway can detoxify or repair a particular entity. This functional redundancy illustrates the critical importance of these processes and also poses the question of whether we are likely to see a noteworthy susceptibility to MDS if just one variant gene is studied. It is much more probable that MDS would result from the accumulation of minor phenotypic abnormalities caused by more than one variant protein. A few studies combining detoxification and repair genes have already been published in t-AML/MDS with the achievement of high odds ratios for the combinations [11, 69], although the number of samples was small. Once again, large sample sizes are required for adequate power for combination studies because the more polymorphisms combined the smaller the subgroups. High throughput genotyping techniques will aid this goal. We also suggest that such studies should be hypothesis-driven rather than a ‘fishing’ exercise where a lot of statistical tests upon a sample cohort are prone to a degree of false positivity. The hypothesis may take the form of aberrant detoxification genotypes with variant DNA repair genotypes of
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes
19
Bone marrow Stem cell
DNA damaging agents Efficient detoxification
Efficient DNA repair
Inefficient detoxification (Phase I and/or II) resulting in DNA damage
Aberrant DNA repair (HR, NHEJ, BER, NER, MMR)
Mutated cells
Clonal expansion
MDS
Fig. 2.1↜渀 Pathway to MDS. Possible mechanism of increased susceptibility to MDS. Deficient detoxification mechanisms increase the amount of DNA damage which aberrant DNA repair mechanisms fail to repair. The resulting genetic instability may result in clonal expansion of mutated stem cells resulting in MDS
proteins expected to repair the particular damage resulting from the aberrant detoxification, or instead variants of more than one gene that are able to detoxify the same substrate or repair the same damage type (Fig.€2.1).
Which Polymorphic Genes Confer the Greatest Susceptibility to MDS? We still do not know the answer to this question. Whilst GSTT1 appears to play a role and evidence is accumulating suggesting that members of the BLM complex may also be important, much of the data is contradictory and significant findings
20
C. Seedhouse and N. Russell
often only generate odds ratios of between one and two. This is a long way from the relative risk factor of ten suggested by Knudsen et€al. [37] as a safety factor to allow for individual susceptibility. We are of the opinion that we are unlikely to find high risks associated with single gene studies but that the study of more than one gene from the detoxification/DNA repair pathways would be more successful. Hopefully larger studies and combination assessments will soon allow us to conclusively identify those genes which play the most important role in conferring susceptibility to MDS. Acknowledgements╇ The authors are very grateful to the Nottinghamshire Leukaemia Appeal and the James Skillington Challenge for funding for their research.
References ╇ 1. Ali-Osman F et€al (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–10012 ╇ 2. Allan JM et€al (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 98:11592–11597 ╇ 3. Allan JM et€al (2004) Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104:3872–3877 ╇ 4. Antoniou AC et€ al (2007) RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81:1186– 1200 ╇ 5. Araujo FD et€ al (2002) Variant XRCC3 implicated in cancer is functional in homologydirected repair of double-strand breaks. Oncogene 21:4176–4180 ╇ 6. Arruda VR et€al (2001) Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol 66:383–388 ╇ 7. Atoyebi W et€al (1997) Glutathione S-transferase gene deletions in myelodysplasia. Lancet 349:1450–1451 ╇ 8. Au WW et€al (2003) Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111:1843–1850 ╇ 9. Basu T et€al (1997) Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia. Lancet 349:1450 10. Baumann Kreuziger LM, Steensma DP (2008) RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes. Am J Hematol 83:822–823 11. Bolufer P et€al (2007) Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 136:590–596 12. Boyer JC et€al (1998) Stability of microsatellites in myeloid neoplasias. Cancer Genet Cytogenet 106:54–61 13. Broberg K et€al (2007) Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma. Cancer Lett 258:38–44 14. Broberg K et€al (2009) Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer 9:140 15. Butkiewicz D et€al (1998) Modulation of DNA adduct levels in human mononuclear white blood cells and granulocytes by CYP1A1 CYP2D6 and GSTM1 genetic polymorphisms. Mutat Res 415:97–108
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes
21
16. Chen H et€al (1996) Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347:295–297 17. Chistiakov DA et€al (2009) Ligase IV syndrome. Eur J Med Genet 52:373–378 18. Clarkson SG, Wood RD (2005) Polymorphisms in the human XPD (ERCC2) gene, DNA repair capacity and cancer susceptibility: an appraisal. DNA Repair (Amst) 4:1068–1074 19. Coles BF et€ al (2001) Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11:663–669 20. Dahabreh IJ et€al (2010) GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis. Int J Cancer 126:1716–1723 21. Duell EJ et€al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965–971 22. Economopoulou P et€al (2010) Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. Ann Hematol 89:233–239 23. Fabiani E et€al (2009) Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes. Leuk Res 33:1068–1071 24. Felix CA et€ al (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 95:13176–13181 25. Fishel R et€al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038 26. Garte S et€al (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239–1248 27. Haase D et€al (2002) Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res 26:249–254 28. Harada S et€al (1998) Microsatellite instability is rare in the clinical course of myelodysplastic syndrome studied with DNA from fresh and paraffin-embedded tissues. J Cancer Res Clin Oncol 124:231–235 29. Hasselbach L et€al (2005) Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol 26:589–598 30. Hayashi S et€al (1991) Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 110:559–565 31. Hung RJ et€al (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 162:925–942 32. Izzotti A et€al (2001) Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J 15:752–757 33. Jankowska AM et€al (2008) Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. Leukemia 22:551–558 34. Kaneko H et€al (1995) Microsatellite instability is an early genetic event in myelodysplastic syndrome. Blood 86:1236–1237 35. Kaneko H et€al (1996) Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation. Leukemia 10:1696–1699 36. Klungland A, Bjelland S (2007) Oxidative damage to purines in DNA: role of mammalian Ogg1. DNA Repair (Amst) 6:481–488 37. Knudsen LE et€al (2001) Risk assessment: the importance of genetic polymorphisms in man. Mutat Res 482:83–88 38. Kohno T et€al (1998) Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 16:3219– 3225 39. Krskova-Honzatkova L et€al (2002) Microsatellite instability in hematological malignancies. Leuk Lymphoma 43:1979–1986 40. Kuehl P et€ al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391
22
C. Seedhouse and N. Russell
41. Kuptsova N et€al (2007) Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 109:3936–3944 42. Kuramoto K et€al (2002) Chromosomal instability and radiosensitivity in myelodysplastic syndrome cells. Leukemia 16:2253–2258 43. Larson RA et€al (1999) Prevalence of the inactivating 609C→T polymorphism in the NAD(P) H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 94:803–807 44. Li Y et€al (2009) Effect of the XRCC1 codon 399 polymorphism on the repair of vinyl chloride metabolite-induced DNA damage. J Carcinog 8:14 45. Lindh AR et€al (2006) Mitotic defects in XRCC3 variants T241€M and D213€N and their relation to cancer susceptibility. Hum Mol Genet 15:1217–1224 46. Liu TC et€al (2002) Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep 9:327–329 47. Lunn RM et€al (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557–2561 48. Ma SK et€ al (2000) Absence of microsatellite instability in primary myelodysplastic syndrome. Int J Mol Med 5:159–163 49. Maeck L et€al (2000) Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations. Br J Haematol 109:842–846 50. Monaco R et€al (2007) Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J 26:541–546 51. Moran JL et€al (1999) A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci U S A 96:8150–8155 52. Naoe T et€ al (2000) Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1 and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute meyloid leukemia. Clin Can Res 6:4091–4095 53. Nebert DW, Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947–960 54. Nelson HH et€al (2002) The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res 62:152–155 55. Niedernhofer LJ (2008) DNA repair is crucial for maintaining hematopoietic stem cell function. DNA Repair (Amst) 7:523–529 56. Novotna B et€al (2008) DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts. Hum Mol Genet 17:2144–2149 57. Novotna B et€al (2009) Oxidative DNA damage in bone marrow cells of patients with lowrisk myelodysplastic syndrome. Leuk Res 33:340–343 58. Offman J et€al (2004) Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104:822–828 59. Okada M et€ al (1997) Glutathione S-transferase theta 1 gene (GSTT1) defect in Japanese patients with myelodysplastic syndromes. Int J Hematol 66:393–394 60. Peddie CM et€ al (1997) Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 99:625–631 61. Pemble S et€al (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300 (Pt 1):271–276 62. Preudhomme C et€al (1997) Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. Leukemia 11:1580–1582 63. Rebbeck TR et€al (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225–1229
2â•… Susceptibility to MDS: DNA Repair and Detoxification Genes
23
64. Rothman N et€al (1997) Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 57:2839–2842 65. Rund D et€al (2005) Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 19:1919–1928 66. Sasai Y et€al (1999) Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Res 23:975–981 67. Seedhouse C, Russell N (2007) Advances in the understanding of susceptibility to treatmentrelated acute myeloid leukaemia. Br J Haematol 137:513–529 68. Seedhouse C et€ al (2002) The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 100:3761–3766 69. Seedhouse C et€ al (2004) Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 10:2675–2680 70. Seidegard J et€al (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A 85:7293–7297 71. Sheikhha MH et€al (2002) High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 117:359–365 72. Shen MR et€al (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608 73. Shields PG et€al (1993) Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 53:3486–3492 74. Siegel D et€ al (1999) Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9:113–121 75. Singh DK et€ al (2009) Roles of RECQ helicases in recombination based DNA repair, genomic stability and aging. Biogerontology 10:235–252 76. Spurdle AB et€al (2002) The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12:355–366 77. Stavropoulou C et€al (2008) Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion. Leukemia 22:1643–1646 78. Sutton JF et€al (2004) Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes. Pediatr Blood Cancer 42:122–126 79. Traver RD et€al (1992) NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52:797–802 80. Tsabouri SE et€al (2000) Increased prevalence of GSTM(1) null genotype in patients with myelodysplastic syndrome: a case-control study. Acta Haematol 104:169–173 81. Varkonyi J et€ al (2008) Glutathione S-transferase enzyme polymorphisms in a Hungarian myelodysplasia study population. Pathol Oncol Res 14:429–433 82. Vodicka P et€al (2004) Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25:757–763 83. Wang WW et€al (2001) A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 10:955–960 84. Wang Y et€al (2003) From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) 2:901–908 85. Westlind A et€al (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201–205
24
C. Seedhouse and N. Russell
86. Wiencke JK et€al (1990) Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res 50:1585–1590 87. Wiencke JK et€al (1995) Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 4:253–259 88. Worrillow LJ et€ al (2003) An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 9:3012– 3020
Chapter 3
Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation H.-P. Horny and P. Valent
Introduction Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells characterised by dysplasia of blood cell precursors, signs of bone marrow insufficiency despite hypercellular marrows, and peripheral cytopenia. Refractory anemia is a key finding in most patients with MDS irrespective of the MDS variant. In advanced MDS, the major differential diagnosis is acute myeloid leukemia (AML) although a broad range of other neoplastic and also non-neoplastic states have been identified as potential mimickers of MDS. The combination of cytomorphology and histology including immunohistochemistry but also cytogenetics is considered as standard approach for diagnosis and subtyping of MDS. While dysplastic features of neutrophilic cells and erythroblasts can best be assessed by cytomorphological investigation of smear preparations, histological analysis of a bone marrow trephine biopsy specimen provides information on the degree of cellularity and fibrosis, but can also reveal minute infiltrates of blast cells, a finding that can not be assessed in bone marrow smears. Moreover, some rare subtypes of MDS that are not defined in the WHO classification system can only be diagnosed histologically: hypocellular MDS (“MDS-hypo”), fibrotic MDS (“MDS-f”) and MDS associated with systemic mastocytosis (SM or SM-AHNMD, respectively). It is strongly recommended that before a diagnosis of unclassifiable MDS (MDS-u) is established such cases should also be evaluated histologically using antibodies against CD34, CD117/KIT, and tryptase.
H.-P. Horny () Institute of Pathology, Escherichstrasse 6, 91522 Ansbach, Germany Tel.: +49-981-488830 Fax: +49-981-4888310 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_3, ©Â€Springer Science+Business Media B.V. 2011
25
26
H.-P. Horny and P. Valent
Materials and Methods The following patient-derived material should be examined in order to establish (or exclude) a diagnosis of MDS: 1. Air-dried smear preparations of blood and bone marrow. 2. Formalin-fixed bone marrow trephine biopsy specimen with a minimum length of 2€cm; for immunohistochemical investigations mild overnight decalcification with edetic acid is strongly recommended. The following stains are recommended for smear preparations: 1. Blood: Wright-Giemsa, naphthol AS-D chloroacetate esterase/CAE (Leder’s stain), and non-specific esterase/NE. 2. Bone marrow: Wright-Giemsa, Prussian blue, CAE, NE. The following stains are recommended for basic histological and immunohistochemical evaluations: 1. Giemsa 2. Prussian blue 3. Gömöri’s silver impregnation 4. CAE 5. Anti-CD34 6. Anti-CD42/61 7. Anti-tryptase 8. Anti-CD117/KIT There is a limited panel of antibodies that should be used in all cases of suspected MDS for immunohistochemical analysis of the bone marrow: 1. Anti-CD34: CD34 is a stem cell-related antigen expressed by normal hematopoietic progenitor cells, by blast cells in neoplastic states and also by endothelial cells. Thus, the staining of blood vessels and sinuses by anti-CD34 serves as perfect internal control. However, it is important to note that CD34 is usually expressed more strongly in endothelial cells than in progenitor/blast cells. Therefore, blast cells can only be visualized by anti-CD34 antibodies when a microwave oven retrieval step has been included. In case of a weak endothelial stain by anti-CD34, a negative blast stain should raise the suspicion of a falsenegative result. Although not all blast cells of all cases of MDS are detected by anti-CD34 it is generally accepted that immunostaining with anti-CD34 provides a perfect tool for the estimation of the numbers of loosely scattered progenitor/ blast cells and to detect even very small compact blast cell infiltrates that are otherwise not detectable in smear preparations. It should be noticed that expression of CD34 by immature megakaryocytes does not reflect overt immunophenotypical atypia but is found more often in neoplastic states of MDS or AML than in the reactive bone marrow. The number of CD34-positive progenitor cells in normal or reactive bone marrow almost never exceeds 1–2% of all nucle-
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical
27
ated cells, and groups or even compact infiltrates of CD34-expressing cells are never encountered in the normal bone marrow. In various myeloid neoplasms, including low risk MDS and myeloproliferative neoplasms, a slight increase in CD34-positive cells is often found. An excess of blast cells is defined as significant increase in CD34-positive cells exceeding 5% of all nucleated cells. A slight or moderate increase in CD34-positive cells is observed in MDS subtypes refractory anemia (RA) with excess of blasts (RAEB-1 and RAEB-2) but also in accelerated phases or incipient blast crisis of myeloproliferative neoplasms. Expression of CD34 by more than 20% of the nucleated bone marrow cells is usually indicative of acute leukemia and is observed in both AML and acute lymphoblastic leukemia/ALL. Altogether, anti-CD34 has proved to be one of the most important immunohistochemical markers in diagnostic hematopathology. In cases with blast cells that are obviously CD34-negative (despite repeated stains), anti-CD117/KIT antibodies are recommended as alternative blast celltargeting reagents. 2. Anti-CD61: CD61 (integrin beta-3) is a platelet-associated antigen expressed by megakaryocytes in all stages of maturation, even by megakaryoblasts. Although it is also expressed on endothelial cells this is not of relevance for immunohistochemical diagnosis. Anti-CD61 enables not only an exact and reproducible quantitative assessment of the numbers of megakaryocytes, but also detection of small groups of normal or atypical megakaryocytes. Cytological atypia can easily be evaluated in CD61-expressing megakaryocytes including immature and even blast forms that cannot be detected in conventional stainings. 3. Anti-tryptase: Tryptase is serine protease predominantly but not exclusively expressed in tissue mast cells. It could be demonstrated that tryptase is also expressed by immature basophilic granulocytes in neoplastic states, including chronic myeloid leukemia and MDS. Anti-tryptase is extremely useful in diagnostic hematopathology and clearly facilitates the estimation of numbers of loosely scattered mast cells. Anti-tryptase is also helpful to detect very small compact mast cell infiltrates, a finding which is essential to establish a diagnosis of SM. However, a tryptase-positive cell is not a mast cell unless coexpression of CD117 (KIT) has been demonstrated. Tryptase and CD117 are antigens found in normal/reactive mast cells in all stages of maturation and in neoplastic mast cells. A round cell expressing tryptase but neither CD117 nor CD34 is not a mast cell but has to be classified as an immature basophil, whereas a tryptase+ round cell that co-expresses CD117 and CD34 represents a myeloblast. However, a spindle-shaped tryptase+ cell can be regarded as mast cell, especially when forming clusters and aggregates which are found almost exclusively in SM. To summarize, a round tryptase-positive cell can be a mast cell, but can also be a basophilic granulocyte or even a tryptase+ myeloblast. A rare finding is the presence of compact infiltrates consisting exclusively of round tryptase-expressing cells. Such infiltrates may be focal or diffuse and have been termed TROCI-bm. TROCI-bm is only observed in myeloid neoplasms but includes a variety of usually very rare disorders like common-type SM (focal type), well-differentiated SM (focal type), myelomastocytic leukemia (diffuse type), basophilic leukemia
28
H.-P. Horny and P. Valent
(diffuse type) and mast cell leukemia (diffuse type). When compact mast cell infiltrates are identified in a patient with MDS, the diagnosis SM-AHNMD/ MDS has to be established. Mast cells in SM usually exhibit an aberrant immunophenotype with expression of CD25, an antigen not found on normal/reactive mast cells.
Classification System of MDS (WHO 2008) 1. Refractory anemia with unilineage dysplasia (a) Refractory anemia (RA) (b) Refractory neutropenia (RN) (c) Refractory thrombocytopenia (RT) 2. Refractory anemia with ring sideroblasts (RARS) 3. Refractory cytopenia with multilineage dysplasia (RCMD) 4. Refractory anemia with excess of blasts (RAEB) 5. MDS associated with isolated del(5q) 6. MDS, unclassifiable (MDS-u) 7. Childhood MDS Rare subvariants not included in the WHO classification system but with characteristic histomorphological features: 1. Hypocellular MDS (“MDS-hypo”) 2. MDS with fibrosis (“MDS-f”) 3. MDS associated with systemic mastocytosis (SM-AHNMD/MDS) Note╇ Histological evaluation of a bone marrow trephine biopsy specimen is recommended for all subtypes of MDS. However, the investigation is crucial for the following subvariants: MDS-u, MDS-hypo, MDS-f and SM-MDS. The typical histomorphological features of the main subtypes of MDS are listed in the Table€3.1. Table 3.1↜渀 Morphological features of MDS Diagnosis Cell NG EP MEG BC FIB Iron RA + − + − − − + − +â•›+ − − − +â•›+ RARS +â•›+ RAEB +â•›+â•›+ +â•›+ + −/+ +â•›+ + + RCMD +â•›+ + + + − − +â•›+ MDS del(5q) + − − +â•›+ − − + MDS-hypo −â•›− −â•›− −â•›− −â•›− + −/+ + MDS-f +/+â•›+ + + + + +â•›+ +â•›+ +â•›+â•›+ marked increase, +â•›+ moderate increase, + slight increase, − normal or absent, −â•›− decreased, CELL cellularity, NG neutrophilic granulocytpoiesis, EP erythrocytopoiesis, MEG megakaryocytes, FIB fibrosis
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical
29
General Considerations Although morphological aspects of MDS may vary even within a defined subvariant the common denominator is at least a unilineage dysplasia of a major myeloid cell line. Regarding neutrophilic cells the most common atypia is hypolobation of the nucleus in a significant proportion of circulating granulocytes. Such cells are termed “pseudo-Pelger” cells. In the rare event that all neutrophils exhibit hypolobation this is not MDS but is indicative of the inborn Pelger-Huet anomaly. The most important anomaly detected in the erythroid series in MDS are ring sideroblasts exhibiting at least a semicircular often a complete circular arrangement of siderin particles around the nucleus in the Prussian blue stain. In RA with ring sideroblasts (RARS), ring sideroblasts must represent at least 15% of all nucleated erythroid cells. A very characteristic abnormality of megakaryocytes is a marked hypolobation of their nuclei. When most or all megakaryocytes are hypolobated, MDS with isolated del(5q) is the most likely diagnosis. Histological evaluation of a bone marrow trephine biopsy specimen should be regarded as standard diagnostic approach in all patients with suspected MDS. The following findings are to be recorded in every patient: 1. Cellularity (Figs.€ 3.1, 3.2): Moderate to marked hypercellularity is found in most patients with MDS, but hypocellular variants have been described in up to 10% of cases. MDS-hypo is almost always a secondary disease occurring after radio- and/or chemotherapy. Estimating the degree of cellularity is crucial in all
Fig. 3.1↜渀 Myelodysplastic syndrome. An extremely hypercellular bone marrow contains an increased number of atypical small megakaryocytes and a prominent left-shifted erythrocytopoiesis. Neutrophilic granulocytpoiesis seems hypoplastic. Histopathological aspects allow a diagnosis of a myeloid neoplasm to be favored but definitive subtyping is not possible. Regarding the cytomorphological aspects on blood and bone marrow smears a diagnosis of refractory cytopenia with multilineage dysplasia was established. H&E
30
H.-P. Horny and P. Valent
Fig. 3.2↜渀 Myelodysplastic syndrome. A slightly hypercellullar bone marrow with left-shifted neutrophilic granulocytopoiesis and erythrocytopoiesis dominates the picture. Loosely scattered megakaryocytes are atypical but occur in normal numbers. Naphthol AS-D chloroacetate esterase (CAE) histochemistry nicely allows to confirm the aspect of a disturbed microarchitecture but rules also out the presence of compact (CAE-negative) blast cell infiltrates. Based on conventional bone marrow histology alone a myelodysplastic syndrome can be suspected but definitive diagnosis and subtyping are not possible. Immunostaining with anti-CD34 revealed a slight increase in loosely dispersed blast cells ranging between 5 and 10% of nucleated bone marrow cells (not depicted). Diagnosis of refractory anemia with excess of blasts (RAEB-1) was established. CAE
patients. The age of the patient must be taken into consideration as the physiologic cellularity of the marrow varies markedly in different age groups. 2. Microarchitecture: Alterations in the microarchitecture of the bone marrow may be subtle but are present in almost all patients with MDS. Common findings are prominent peritrabecular proliferation zones of the neutrophilic granulocytopoiesis, varying size of erythroid cell clusters, and grouping (not clustering) of megakaryocytes. Note that such findings alone are not sufficient to establish a diagnosis of MDS. 3. Reticulin fibers (Figs.€3.3a, b): In many cases of MDS there is a mild often focal reticulin fibrosis while marked fibrosis is rarely seen. The rare cases with reticulin fibrosis as leading feature may be termed MDS-f. 4. Iron stores (Fig.€3.4): In almost all patients, MDS is associated with a marked or even extensive hemosiderosis. Note that the Prussian blue stain in histological sections often yields lower amounts of siderophages than the Prussian blue stain in bone marrow smears in the same patient. Depletion of iron stores is almost incompatible with the primary diagnosis of MDS. 5. Neutrophilic granulocytopoiesis: Neutrophilic granulocytopoiesis is almost always increased and left-shifted with accumulations of immature cells in peritrabecular and perivascular sites. Perivascular proliferation zones have been misleadingly termed “atypically localized immature precursor” cells (ALIP) a finding which is usually very hard to detect or reproduce in modern times
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Fig. 3.3a, b↜渀 Myelodysplastic syndrome. Silver staining allows to determine the degree of reticulin fibrosis. a Depicts a focal slight increase in reticulin fibers while b shows a marked diffuse reticulin fibrosis. Reticulin fibrosis is a very non-specific finding seen in variuos reactive and neoplastic states. While a shows a case of refractory anemia (RA), b represents one of the rare cases of true MDS with fibrosis (MDS-f) especially there was no increase in blast cells or clustering of megakaryocytes. Gömöri’s silver impregnation
Fig. 3.4↜渀 Myelodysplastic syndrome. In a moderately hypercellular bone marrow an increased number of siderophages can easily be detected. Moderate to marked siderosis is almost always seen in MDS but also in reactive states of anemia of chronic didease. On the basis of cytomorphological aspects on bone marrow smears this case was subtyped as refractory anemia with multilineage dysplasia (RCMD). Prussian blue
31
32
H.-P. Horny and P. Valent
Fig. 3.5↜渀 Myelodysplastic syndrome. Hypercellular bone marrow with markedly dilated sinuses is shown. Note a very pronounced increase in small immature to blast-like clustering megakaryocytes that are only detectable by an appropriate immunostaing with anti-CD61. Also note the prominent erythrocytopoiesis with signs of intravascular hematopoiesis. The neutrophilic granulocytopoiesis is hypoplastic. This case was originally diagnosed as MDS-f due to focal marked fibrosis but rather represents refractory anemia with excess of blasts (RAEB). Anti-CD61 (ABC method)
of immunhistochemistry. However, a complete maturation arrest is not found unless the disease has progressed to overt AML. 6. Erytrocytopoiesis: In most patients, erythropoiesis is increased (hyperplastic) and irregularly distributed with unusually varying size of the erythra. There is also marked left-shifting, but cellular atypia is difficult to recognize in histological sections. Ring sideroblasts cannot be identified in histological sections because mitochondrial iron deposits are destroyed during routine processing in water-containing fixatives (in contrast to the lysosomal hemosiderin). 7. Megakaryocytes (Fig.€3.5): There is almost always an irregular distribution of megakaryocytes with a tendency to group together, but true clusters are usually not seen in MDS. Immature megakaryocytes are often found in increased numbers in MDS. The hypolobated small megakaryocytes characteristic for MDS with isolated del(5q) are easily detectable in histological bone marrow sections. 8. Mast cells: Increased numbers of loosely scattered mast cells are a common feature in MDS while the association with systemic mastocytosis (SM-AHNMD) characterised by compact infiltrates is rarely detected. In a few cases, a slight increase of spindle-shaped loosely scattered mast cells exhibiting an aberrant immunophenotype and expression of CD25 is present. In such cases, SM-MDS should only be diagnosed when the activating point mutation KITD816V is also detected thus enabling the diagnosis of SM to be based on three minor diagnostic criteria. 9. Basophilic granulocytes: Increased numbers of basophilic granulocytes are found in many cases of MDS. Although basophils cannot be seen in routinely processed trephine biopsy specimens because their specific granules are water-soluble
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical
33
( in contrast to the likewise metachromatically reacting mast cell granules), it is possible to visualize these cells by their peculiar immunophenotypical characteristics. Small round tryptase-positive cells not coexpressing CD117 (KIT) are basophils (and not mast cells). An increase in basophils is almost exclusively seen in neoplastic states but not pathognomonic for MDS. Highest numbers of tryptase-expressing small round cells are seen in chronic myeloid leukemia. There are two antibodies recognizing specific basophil antigensand that can be applied in all cases of suspected basophilia: anti-basogranulin (BB1) and anti2D7. Both markers work well in paraffin-embedded bone marrow sections but are not commercially available. 10.╇Blast cells (Fig.€ 3.6a–d): The number of CD34-expressing progenitor cells/ blast cells varies in MDS patients. In case of CD34-negative blasts, CD117/ KIT can be recommended as an alternative blast cell marker.
Figs. 3.6a–d↜渀 Myelodysplastic syndrome. Figures 3.6a–d cover the aspects of immunostaining with anti-CD34. a Shows a case of MDS with a significant diffuse increase in loosely scattered CD34+ blast cells without forming groups or clusters. Quantitatively this case fulfills criteria of refractory anemia with excess of blasts (RAEB-1). b Shows a case with marked in increase in CD34+ blast cells forming dense aggregates. RAEB-2 transforming into overt AML was diagnosed here. c and d Exhibit a case of hypocellular MDS. c Reveals an overview with dilated sinuses, subtotal depletion of blood cell precursors and some CD34+ blast cells. d Depicts another marrow space of the same case with a significant increase in blast cells illustrating the difficulties to separate MDS-hypo with excess of blasts (RAEB-2) from overt AML. Anti-CD34 (ABC method)
34
H.-P. Horny and P. Valent
Altogether, typical cases of MDS are histologically characterised by a hypercellular bone marrow with left-shifted neutrophilic granulycytopoiesis and erythrocytopoiesis, atypical megakaryocytes and increased iron stores.
Differential Diagnoses MDS has to be separated from a great variety of reactive and neoplastic states. It should be emphasized that MDS is a disease of the elderly patient (median: about 70 years) and characterised by signs of bone marrow insufficiency with cytopenia in at least one major bone marrow lineage (usually refractory anemia). Regarding morphology alone the list of reactive states includes the following: 1. Myeloid hyperplasia 2. Granulomatosis 3. Aplastic syndromes 4. Vitamin B12 and/or folic acid deficiency 5. Congenital disorders: dyserythropoietic anemia 6. Viral infections: HIV and parvovirus B19 7. Cytoreductive therapy 8. Hemopoietic growth factors In order to avoid misinterpretation of morphological findings it is crucial to be aware of the case history and all available hematological parameters. Some of the above mentioned disorders are perfect mimickers of MDS exhibiting major cytological atypia of erythroblasts (giant proerythroblasts) in parvovirus B19 infections and the often marked cytological atypia of all blood cell precursors encountered in vitamin B12 deficiency. It is noteworthy to be aware of the fact that cytological atypia encountered in vitamin B12 deficiency may be more pronounced than ever seen in true MDS. In some cases of MDS small granulomas are detected without other indication of a systemic granulomatosis. This phenomenon is best termed as paraneoplastic granulomatosis. Aplastic syndromes may be extremely difficult to be separated from hypocellular (secondary) MDS without immunostainings (antiCD34!). In the following a list of neoplastic states is presented. All these diseases can be easily interchanged with MDS making it necessary to strictly observe defined morphological criteria and all available hematological/cytogenetic data before a diagnosis of MDS is established definitively: 1. AML 2. Acute panmyelosis with myelofibrosis 3. Systemic mastocytosis (SM-AHNMD) 4. Hairy cell leukemia 5. MDS/MPN: RARS-T, chronic myelomonocytic leukemia 6. Primary myelofibrosis 7. Megakaryoblastic leukemia
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical
35
Separation of MDS from AML is crucial and mainly depends on the number of blast cells: 1. MDS other than RAEB: <5% blasts 2. MDS RAEB-1: >5% <10% blasts 3. MDS RAEB-2: >10% <20% blasts 4. AML: >20% blasts Although these parameters appear to be simple to be assessed it may be extremely difficult to reliably determine blast cell numbers in daily routine practice. It is of major prognostic and therapeutic significance to be sure that blast cell numbers are below the threshold of 20% of all nucleated bone marrow cells. An advantage of the histology is that even small groups or infiltrates of CD34-expressing blast cells can be detected signalling an adverse prognostic event with rapid progression into AML in many patients. Even more challenging is the separation of MDS, especially MDS-f, from acute panmyelosis with fibrosis which represents a very rare subtype of AML on the one hand and from megakaryoblastic leukemia (FABM7) which also exhibits almost always marked fibrosis and therefore was termed acute myelosclerosis in previous times on the other. Acute panmyelosis shows blastic transformation of all three major myeloid cell lines and accordingly an increase in myeloblasts, megakaryoblasts (which may dominate the picture) and para-proerythroblasts while megakaryoblastic leukemia shows a marked increase only in megakaryoblasts. Since megakaryoblasts are not a prominent feature in MDS-RAEB the diagnosis should be possible after appropriate immunostaining using at least antibodies against CD34, CD61 and glykophorin A (as an erythroid antigen of diagnostic relevance for immunohistochemistry). Primary myelofibrosis (formerly: agnogenic myeloid metaplasia or chronic idiopathic myelofibrosis) may mimick MDS, especially MDS-f, at first glance but presence of groups and clusters of highly pleomorphic megakaryocytes and a significant splenomegaly definitively excludes MDS. Systemic mastocytosis may morphologically mimick MDS and granulomatosis but may also be associated with MDS in the setting of a SM-AHNMD. It should be noticed that true SM-MDS is much less frequent than other subtypes of SMAHNMD like SM-CMML or SM-AML. All major subvariants of MDS have been observed in SM-MDS. Presence of compact mast cell infiltrates and activating point mutation KITD816V are definitive proof of SM while reactive increase in mast cells (= mast cell hyperplasia) never is associated with compact mast cell infiltrates and/or KITD816V. Clinically, malignant lymphoma may also mimick MDS. This is especially true for hairy cell leukemia which almost always shows marked cytopenia. However, presence of splenomegaly and diffuse-compact infiltration of bone marrow by neoplastic medium-sized B cells often with wide pale cytoplasm enables the definitive diagnosis to be made. Disorders belonging to the group of MDS/MPN may be very difficult to be separated from MDS because by definition blood cell precursors exhibit signs of atypia. Formerly, the most frequent subtype of MDS/MPN was even included amongst
36
H.-P. Horny and P. Valent
MDS: chronic myelomonocytic leukemia (CMML). Using stains like UE or antiCD14/CD163 to visualize a significant increase in monocytes/promonocytes in blood and bone marrow is sufficient to assess or exclude CMML since a marked increase in monocytes is not a characteristic feature of MDS. It should be pointed out that diagnosis of MDS and its separation from all potential differential diagnoses is dependent on (1) a reasonable amount and quality of the bone marrow biopsy specimen, (2) good quality smears (including at least five unstained ones), (3) peripheral blood smears, (4) and sufficient information about all relevant clinical and laboratory findings.
orphology of MDS Subvariants with Special Emphasis M on Histopathological Aspects (Subvariants 1.–6. Are Defined by FAB/WHO Criteria) 1. Refractory Cytopenia (RC): RC must not be diagnosed on the basis of histopathological bone marrow findings alone. Moreover, refractory neutropenia and refractory thrombocytopenia are recently defined very rare subentities of RC. Therefore there is very limited if any experience regarding their histomorphological features in routinely processed bone marrow biopsy specimens. Since cytological atypia of neutrophilic cells and erythroblasts cannot be recognized with certainty in histological sections RC of all types should be diagnosed in bone marrow smear preparations considering the presence of significant cytopenia (for at least 6 months), exclusively unilinear cytological atypia and cytogenetic abnormalities as major criteria. Cytological atypia without cytopenia or significant cytopenia without major dysplasia both do not allow such cases to be classified as MDS but should rather be put in categories like idiopathic dysplasia of unknown significance (IDUS) or idiopathic cytopenia of unknown significance (ICUS). Regarding histopathology in RC the bone marrow is almost always hypercellular with marked hemosiderosis. RC is mostly a diagnosis of exclusion, in particular an increase in CD34+ blast cells and significant fibrosis are not compatible with a diagnosis of RC. 2. RC with Multilineage Dysplasia (RCMD): RCMD belongs to the more common subtypes of MDS. Histopathological aspects include a marked hypercellularity of bone marrow in most cases. There is a left-shifted atypical neutrophilic granulocytopoiesis. In most patients, erythrocytopoiesis is prominent but not strongly increased. The number of megakaryocytes is usually slightly increased with a tendency to form small groups. Megakaryocytes may exhibit marked cytological atypia seen in histological sections of bone marrow. Megakaryocyte clusters and an increase in CD34+ blasts are not found in RCMD. The density of retculin fibers is often slightly increased but a significant fibrosis is not observed. RCMD must be diagnosed definitively only when significant cellular
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical
37
Fig. 3.7a, b↜渀 Myelodysplastic syndrome. Cytology in a Pappenheim stain reveals a hypercellular bone marrow with prominent erythrocytopoiesis which is normoblastic and markedly left-shifted. Note the abundance of basophilic erythroblasts and proerythroblasts. There is no excess of blast cells. Prussian blue stain shows a significant increase in ring sideroblasts enabling a diagnosis of “Refractory anemia with ring sideroblasts” to be established
atypia of more than one major myeloid cell line is observed in bone marrow and blood smears. 3. Refractory Anemia with Ring Sideroblasts (RARS; Figs.€ 3.7a, b): Since the pathognomonic ring sideroblasts can only identified in bone marrow smears but not in routinely processed trephine biopsy specimens RARS must not be diagnosed on the basis of a histological investigation of bone marrow alone. In contrast to the lysosomal hemosiderin mitochondrial iron deposits of ring sideroblasts are destroyed during processing. Cytological atypia, in particular of neutrophilic cells and megakaryocytes are not a prominent feature of the disease. Since ring sideroblasts are also found in patients with lead intoxication, the diagnosis of RARS in younger adults should only be made after having excluded lead-induced dysplasia. The histological picture of the bone marrow shows an increased left-shifted normo- or slightly macroblastic erythrocytopoiesis and a marked hemosiderosis. A differential diagnosis of hemolytic anemia
38
H.-P. Horny and P. Valent
or even of a hemophagocytic syndrome is not possible in most cases unless reticulocyte counts are taken into consideration. Reticulocytosis clearly favors a reactive state of hemolytic anemia. Number of CD34-positive blast cells is not increased and there is also no significant reticulin fibrosis. Usually there is a marked increase in loosely scattered reactive mast cells whereas SM associated with RARS is rarely seen. The number of megakaryocytes is usually normal or slightly increased and there is a left-shifted neutrophilic granulocytopoiesis. In the rare cases with excess of ring sideroblasts and significant thrombocytosis this is not true RARS but rather a special and recently defined entity belonging to the myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) termed RARS-T. RARS-T has found to be associated with the presence of the activating point mutation JAK2-V617F which is very rarely seen in RARS. 4. Refractory Anemia with Excess Blasts (RAEB): Pending on the number of blast cells two types of RAEB must be separated: (1) RAEB-1 with blast cell numbers >5% but <10%, and (2) RAEB-2 with blast cell numbers >10% but <20%. Blast cell numbers exceeding 20% of nucleated bone marrow cells allow a diagnosis of AML to be made. Since in almost all cases of RAEB blast cells express CD34 diagnosis and subtyping of the disease are not only possible but often crucial in histological bone marrow sections. It is not a very rare finding when small groups or infiltrates of blast cells are detected, especially in RAEB-2. Neutrophilic granulocytopoiesis is usually markedly atypical and left-shifted. Cytological atypia of erythroblasts and megakaryocytes are common, the number of megakaryocytes varies greatly. Using antibodies against platelet-associated antigens like CD61 enables detection of megakaryoblasts which are never seen in reactive states. Iron stores are increased and the degree of reticulin fibrosis is often low to moderate. 5. MDS with isolated del(5q) (Fig.€3.8): Although this seems a cytogenetic-based diagnosis the morphology of megakaryocytes is quite characteristic allowing a diagnosis of MDS with del(5q) to be established or at least strongly suspected
Fig. 3.8↜渀 Myelodysplastic syndrome. Bone marrow histology shows an abundance of small evenly distributed megakaryocytes expressing CD61. There are no groups or clusters of megakaryocytes. Note the uniform hypolobated nuclei of megakaryocytes which is seen only in MDS with del(5q)
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical
39
from histological investigation of the bone marrow. Almost all megakaryocytes which are loosely scattered throughout appear to be immature exhibiting hypoor even non-lobated round nuclei. An increase in blast cells and reticulin fibers are not found in most cases of MDS-del(5q). Moreover, cytological atypia of neutrophilic cells and erythroblasts is minimal or even missing while slight hypoplasia of erythrocytopoiesis is common. 6. Unclassifiable MDS (MDS-u): MDS-u is a waste-basket for a few rare hematopathological findings that do not allow to be put in one defined category of MDS or another myeloid neoplasm like MDS/MPN. Accordingly, a common histological picture of the bone marrow does not exist for MDS-u. It is therefore strongly recommended in every patient with suspected diagnosis of MDS-u to investigate a bone marrow trephine biopsy specimen in order not to miss any underlying reactive or neoplastic process undetectable in smear preparations, for example hypocellular MDS, mastocytosis, or even hairy cell leukemia. 7. Hypocellular MDS (MDS-hypo) (Fig.€ 3.6a–d): MDS-hypo is not listed as a separate entity in the WHO system of classification but represents a distinctive morphological subvariant of the disease with bad prognosis. Not more than 10% of MDS cases belong to the hypocellular variant which can only be recognised histologically while smear preparation of the marrow show a dry tap. The cytopenia is often very severe. MDS-hypo is almost always secondary event in contrast to the other categories of MDS and seen after radiochemotherapy with an interval up to 20 years. MDS-hypo is definitively recognizable when an increase in CD34-positive blast cells is present thus enabling a refined classification of MDS-hypo RAEB type. Since the paucicellularity of the bone marrow does not allow any statements about the presence of cytological atypia of the blood cell precursors immunostaining with anti-CD34 is of crucial importance in all hypocellular bone marrows. Usually the clear-cut distinction between MDS-hypo RAEB-2 and hypocellular AML is not possible because the constant presence of lymphocytes, plasma cells and macrophages in such hypoplastic marrows interferes with precise quantitative statements concerning the blast cell numbers amongst all nucleated blood cell precursors. 8. Fibrotic MDS (MDS-f): MDS-f is an ill-defined subvariant of MDS regarding both degree of fibrosis and separation from other MDS subtypes. For diagnosis of MDS-f at least a moderate diffuse increase in reticulin fibers should be present. Fibrosis has been described as an adverse prognostic feature in MDS patients. However, many cases of MDS-f show an excess of blast cells (quantitatively allowing them to be put into categories RAEB-1 or RAEB-2, respectively). The term myelofibrosis should not be used to describe MDS-f in order to avoid misleading interpretation as primary myelofibrosis which belongs to the myeloproliferative neoplasms. 9. Systemic mastocytosis associated with MDS (SM-AHNMD): Although a marked increase in mast cells is often seen in MDS, especially in RARS, an association of MDS and SM is rare. Almost all defined subtypes of MDS have been detected in the setting of SM-AHNMD, enabling diagnoses of SM-RCMD, SM-RAEB, or SM-RARS to be established. Diagnosis of SM basically implies the presence
H.-P. Horny and P. Valent
40
of at least one compact mast cell infiltrate as the one and only major criterion. In cases with prominent spindling of mast cells and immunophenotypical anomalies with expression of CD25 the diagnosis of SM can also be established when the activating point mutation KITD816V is detected. It is of major importance to apply an anti-tryptase antibody in all cases of myeloid tumors including MDS not only to be able to detect small mast cell infiltrates indicative of SM but also to find an increase in basophilic granulocytes which is almost never seen in reactive states. However, it has to be considered that basophilia also may occur in other myeloid neoplasms and is very prominent in chronic myeloid leukemia. In addition, in all patients with suspected SM-AHNMD/SM-MDS, KIT mutation analysis should be performed. The diagnosis of SM-MDS represents a challenging one since minor cellular atypia can also be seen in SM, in particular its smoldering subtype (SSM) which assumes an intermediate position between indolent and aggressive SM. This emphasizes the necessity to strictly apply defined diagnostic criteria for both SM and MDS before a diagnosis of SM-MDS must be established definitively.
References 1.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199 2. Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ, Thiele J (2008) Myelodysplastic syndromes. In: Swerdlow SH et€al (eds) World health organization classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon 3. Bennett JM (2005) A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 32:S3–S10 4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et€al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 5. Lambertenghi-Deliliers G, Annaloro C, Oriani A, Soligo D (1992) Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk Lymphoma 8:51–55 6. Horny H-P, Wehrmann M, Schlicker HU, Eichstaedt A, Clemens MR, Kaiserling E (1995) QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens. J Clin Pathol 48:291–294 7. Baur AS, Meuge-Moraw C, Schmidt PM, Parlier V, Jotterand M, Delacretaz F (2000) CD34/ QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes. Eur J Haematol 64:71–99 8. Horny H-P, Greschniok A, Jordan JH, Menke DM, Valent P (2003) Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study. J Clin Pathol 56:103–106 ╇ 9. Horny H-P, Sotlar K, Sperr WR, Valent P (2004) Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57:604–608 10. Valent P, Horny H-P, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase T, Kolb H-J, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter B, Sperr WR, Stauder R, Wells DA (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727–736
3â•… Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical
41
11. Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL (1984) Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 58:217–225 12. Oriani A, Annaloro C, Soligo D, Pozzoli E, Cortelezzi A, Lambertenghi Deliliers G (1996) Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. Br J Haematol 92:360–364 13. Horny H-P, Sotlar K, Stellmacher F, Krokowski M, Agis H, Schwartz LB, Valent P (2006) The tryptase-positive compact round cell infiltrate of the bone marrow (TROCI-bm): a novel histopathological finding requiring the application of lineage-specific markers. J Clin Pathol 59:298–302 14. Thiele J, Quitmann H, Wagner S, Fischer R (1991) Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens. J Clin Pathol 44:300–305 15. Agis H, Krauth MT, Böhm A, Mosberger I, Müllauer L, Simonitsch-Klupp I, Walls AF, Horny H-P, Valent P (2006) Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloprolferative disorders. Am J Clin Pathol 125:1–9 16. Agis H, Krauth MT, Mosberger I, Müllauer L, Simonitsch-Klupp I, Schwartz LB, Printz D, Böhm A, Fritsch G, Horny H-P, Valent P (2006) Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific antibody 2D7. J Clin Pathol 59:396–402 17. Orazi A, O’Malley DP, Jiang J, Vance GH, Thomas J, Czader M, Fang W, An C, Banks PM (2005) Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol 18:603–614 18. Imbert M, Nguyen D, Sultan C (1992) Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis. Leuk Res 16:51–54 19. Horny H-P, Sotlar K, Valent P (2007) Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31:1609–1616 20. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et€al (2001) Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World health organization classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues, vol€1. IARC Press, Lyon, pp€61–73
Chapter 4
Diagnostic Criteria and Classification of Myelodysplastic Syndromes Peter Valent, Friedrich Wimazal, Wolfgang R. Sperr and Hans-Peter Horny
Introduction Myelodysplastic syndromes (MDS) are hematopoietic neoplasms characterized by a maturation-defect in myelopoietic progenitor cells, peripheral cytopenia, and clonal instability with an enhanced risk to transform into secondary acute myeloid leukemia (sAML) [2, 4–6, 9, 17, 18]. Until 2001, MDS have primarily been classified according to criteria provided by the French-American-British (FAB) working group [1]. In 2001, the World Health Organization (WHO) has extended and reestablished the MDS classification, and in 2008 an update of this classification was presented [4, 5]. The WHO classification provides robust criteria for the discrimination of MDS variants from each other. In addition, minimal diagnostic criteria for MDS have been proposed in a Working Conference in Vienna in 2006 [26, 27]. These criteria are important and helpful for the discrimination between MDS and all other reactive and neoplastic disorders that can produce cytopenia or/and dysplasia [26, 27]. In most patients with MDS, the bone marrow smear reveals marked dysplasia in one or more major hematopoietic cell lineage/s (erythroid, neutrophilic, megakaryocytic) [1, 2, 4, 5, 16]. Monocytosis or/and an increase in blasts may also be detected [1, 4, 5, 16]. In addition, typical blood count abnormalities such as macrocytic anemia or abnormal neutrophils (Pseudo-Pelger-Huet cells) may be found in these patients. Together, in most patients, the diagnosis MDS can be established quite easily by a thorough examination of blood and bone marrow smears [1, 16]. In other patients, no prominent dysplasia is found but an abnormal karyotype is detected, leading to the conclusion the patient is suffering from MDS [4, 5, 27]. However, there are also patients in whom it is quite difficult to define whether (mild) P. Valent () Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria Tel.: +43-1-40400-5488 Fax: +43-1-40400-4030 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_4, ©Â€Springer Science+Business Media B.V. 2011
43
44
P. Valent et al.
Table 4.1↜渀 Step-wise approach in the diagnosis and prognostication in MDS 1. Minimal diagnostic criteria Establish the diagnosis MDS 2. FAB and WHO classification Establish the disease variant 3. IPSS, WPSS and other scores Establish the risk of AML transformation 4. Patient-related risk factors Estimate survival 5. Therapy-related scores Establish the treatment plan MDS myelodysplastic syndromes, FAB French-American-British working group, WHO World Health Organization, IPSS international prognostic scoring system, WPSS WHO-adapted prognostic scoring system
cytopenia or dysplasia would indeed result from an underlying MDS, a prephase of MDS, or from another hematologic or even non-hematologic disease, especially when the karyotype is normal or is not available [27]. In a group of patients, it may be difficult to discriminate between advanced MDS and AML, or MDS and an overlap (MDS/myeloproliferative) disorder. From a practical point of view, the diagnosis MDS should be established in a step-wise fashion. In a first step, minimal diagnostic criteria have to be documented. Then, the variant, preferably WHO and FAB (but at least FAB) should be defined [25]. In a third step, the patient is examined for individual risk factors and scores, in order to establish the overall risk profile, preferably be IPSS and WPSS. In a last step, treatment-scores are applied to define the optimal therapeutic approach (Table€4.1).
Minimal Diagnostic Criteria Minimal diagnostic criteria for MDS were discussed and proposed in a Working conference in 2006 [27]. By consensus, minimal diagnostic criteria include (1) marked and constant (>6 months) peripheral cytopenia in at least one major hematopoietic lineage (erythroid, neutrophil, platelet), (2) MDS-related bone marrow features, i.e. one or more of the following: dysplasia ≥10% of all cells in one (or more) major hematopoietic lineage(s), ring sideroblasts ≥15%, myeloblasts ≥5%, or an MDS-related karyotype, and (3) exclusion of all other hematopoietic and non-hematopoietic disorders as primary reason for dysplasia and/or cytopenia [26, 27]. Based on this proposal, all patients with suspected MDS must undergo a bone marrow investigation [27]. The diagnosis may be difficult to substantiate in those patients in whom MDS co-exists with another bone marrow neoplasm that can also cause cytopenia or even dysplasia (example: coexisting mastocytosis). In these patients, it is important to look at bone marrow sections to define whether cytopenia could be caused by MDS or (also) by the co-existing disease, and to document additional criteria for MDS [26, 27]. In a group of cytopenic patients with suspected MDS, disease-related criteria are not fulfilled although clinical features are highly suggestive of MDS (e.g. macrocytic transfusion-dependent anemia) [26, 27]. In these patients, it is important to
4â•… Diagnostic Criteria and Classification of Myelodysplastic Syndromes
45
exclude all differential diagnoses and to ask for MDS-co-criteria, including aberrant phenotypes, abnormal stem cell function, and clonality of bone marrow cells [26, 27]. Stem cell function is almost invariably reduced in MDS and is best examined by colony-formation of progenitor cells (CFC) [3, 8, 26, 27]. Notably, a normal CFC count almost excludes MDS, whereas markedly reduced CFC are confirmatory for this diagnosis [8, 22]. In patients with a normal karyotype, monoclonality can be documented by the presence of (somatic) mutations in critical target genes, such as RUNX, RAS, or JAK2 [6, 17, 18, 27, 28]. Another approach is to screen for “monoclonal” patterns in mRNA expression profiles or proteomics [12, 18, 20, 28]. However, these techniques are not standardized and are not specific for MDS. Another approach is to determine cell surface antigen patterns in blast cells and maturing myeloid cells by flow cytometry [14, 27, 29]. Again, results are not specific for MDS but may help in reaching the conclusion the patient is suffering from a myeloid neoplasm resembling MDS [27, 29]. If one or more co-criteria are documented in a cytopenic patient with typical blood findings (e.g. severe macrocytic anemia) and all other causes for cytopenia have been excluded, the provisional diagnosis of MDS can be established even if no dysplasia and no abnormal karyotype are found [27].
ICUS and IDUS: The Diagnostic Interface A diagnostic challenge are patients who do not fulfil minimal diagnostic criteria for MDS but are suffering from constant (>6 months) cytopenia or from unexplained dysplasia without marked cytopenia [25–27, 30]. In these patients repeated investigations of the bone marrow and an extensive search for an underlying disease may be required [25, 27, 30]. Repeated tests may reveal an underlying hematologic or non-hematologic disease or an imminent MDS. If this is not the case, a provisional diagnosis should be established: in those with marked and constant cytopenia (hemoglobin <10€g/dl and/or neutrophils <1,000/µl and/or platelets <100,000/µl) but no evident dysplasia (dysplasia in less than 10% of cells in all three major lines) the diagnosis Idiopathic Cytopenia of Undetermined (Uncertain) Significance (ICUS) should be considered [26, 30]. In those patients who have marked dysplasia (>10% in a major cell lineage) with or without an MDS-related karyotype but no or only mild cytopenia, the term Idiopathic Dysplasia of Undetermined (Uncertain) Significance (IDUS) should be applied [26] (Table€4.2). By definition the presence of both ICUS and IDUS is exclusive since coexistence of these conditions is diagnostic and meets criteria for MDS [26] (Fig.€4.1). Nevertheless, for patients with mild cytopenia (hemoglobin ≥10€g/dl; neutrophils ≥1,000/µl; platelets ≥100,000/µl) but clearly demonstrable dysplasia (>10%), the diagnosis IDUS is appropriate [26]. Some of these patients progress to frank MDS over time, whereas others may progress to a myeloproliferative neoplasm (MPN) or an overlap disease (MPN/MDS) (unpublished observation). All patients with ICUS and IDUS should have a hematologic
46
P. Valent et al.
Table 4.2↜渀 Features defining idiopathic cytopenia (ICUS) and idiopathic dysplasia (IDUS) Term Definition Other features Older patients low EPO level Constant marked cytopeniaa Idiopathic cytopenia of FISH may reveal a small unknown significance No MDS found by criteriab clone in the BM (ICUS) No dysplasia, no karyotypec d No Co-criteria No other disease as reason for cytopenia found No constant marked cytopeniaa Younger patients usually Idiopathic dysplasia of unknown significance detected in a routine No MDS found by criteriab (IDUS) blood test (e.g. Pelger or Dysplasia and/or karyotypec macrocytosis) No other disease as reason for Dysplasia/karyotype detected
MDS myelodysplastic syndromes, EPO erythropoietin, FISH fluorescence in situ hybridization, BM bone marrow a Constant marked: for at least 6 months: hemoglobin <10€g/dl, neutrophils <1,000/µl blood, platelets <100,000/µl b Criteria refer to reference [26, 27] c Diagnostic dysplasia: ≥10% of cells; karyotypes typically found in MDS d If one or more co-criteria are found, the condition should be termed “highly suspective for MDS or a related myeloid neoplasm”
follow up in order to document or exclude evolution to MDS [26, 27, 30]. One important parameter in ICUS-patients is the serum erythropoietin (EPO) level. In most patients with ICUS, serum erythropoietin levels are (inadequately) low even if the kidney function is (otherwise) normal [7, 23, 26]. In these patients, treatment with recombinant EPO can correct the anemia similar to patients with low risk MDS who have a low endogenous EPO level [23]. All in all, it is standard to manage patients with ICUS and IDUS in the same way as patients with low risk MDS [27, 30]. An important diagnostic approach in patients with ICUS is fluorescence in situ hybridization (FISH) of bone marrow interphases [30]. In several of these patients, FISH may reveal the presence of a small population of clonal cells carrying an MDS-related cytogenetic defect [30]. Sometimes, when recorded over time, the size of the clone (number of “FISH-positive” metaphases) increases, bone marrow function (number of CFC) decreases, and MDS can be diagnosed [30]. Similarly, in patients with IDUS, FISH may reveal the presence of an MDS-related cytogenetic abnormality [24]. Although IDUS may not be a rare condition, the numbers of well documented cases are very low [26, 24]. In fact, these patients have only mild or no cytopenia. Several of them are referred because of unexplained macrocytosis or unexplained Pseudo-Pelger-Huet cells in a blood film [24, 26]. Similar to patients with ICUS, patients with IDUS should have a hematologic follow up in order to document or exclude evolution to MDS. This is important as patients with IDUS usually are younger than those with ICUS [24, 26]. Bone marrow investigations should be repeated as soon as cytopenia develops or other signs for an imminent MDS are found in these patients. However, not all patients with IDUS develop an MDS even when recorded over many years [24]. In contrast to patients with
4â•… Diagnostic Criteria and Classification of Myelodysplastic Syndromes
47
Normal Hematopoietic Stem Cell
Clonal expansion of a premalignant progenitor cell population leading to ineffective (impaired) erythropoiesis / hematopoiesis Disease manifestation may depend on EPO production (kidney function↓? androgens↓?)
+ EPOresponsive progenitors
IDUS EPO-response lost +/- blasts ↑ → MDS
EPO production adequate and sufficient to prevent anemia
IDUS no MDS detected as no anemia develops – these patients have dysplasia without cytopenia = IDUS
Inadequate ´EPO-response´ to ineffective erythropoiesis → anemia
Normal hematopoiesis in the healthy elderly
10-30% Low EPO in elderly → Anemia / AOE
+ ICUS LOW RISK MDS often responsive to EPO therapy (15-25% of patients)
ICUS
progression/clonal expansion HIGH RISK MDS (cytopenia found invariably) Further oncogenic hits that lead to maturation arrest and proliferation SECONDARY ACUTE MYELOID LEUKEMIA
Fig. 4.1↜渀 Role of erythropoietin (EPO) production in the manifestation of MDS. Myelodysplastic syndromes are considered to arise from hematopoietic (neoplastic) stem cells and to develop in a step-wise process. Apart from clone-specific factors, also patient-related factors and the specific microenvironment play a role in disease manifestation and disease evolution. In a pre-phase of MDS, the neoplastic clone may first replace normal hematopoiesis but still may not produce anemia, because clonal (sometimes also residual non-clonal) erythroid progenitor cells are responsive to EPO. As long as EPO production is normal in these patients (adequate and able to counteract severe anemia) they will not develop anemia/cytopenia so that criteria for MDS are not fulfilled. These patients are called idiopathic dysplasia of uncertain significance (IDUS). Later, when EPO production declines or clonal progenitor cells no longer respond to EPO, these patients develop frank MDS. EPO production may decrease in the elderly normal population, and may then lead to anemia: this form of anemia has also been termed anemia of the elderly (AOE). If in these patients, a dysplastic clone develops, the patient may rapidly develop overt MDS, and when clonal BFU-E are responsive, these patients will respond to therapy with exogenous EPO. The equation in the hypothesis thus is: IDUS╛+╛ICUS╛=╛MDS
ICUS, the erythropoietin level in patients with IDUS is usually adequate and can increase in response to anemia. Moreover, in patients with IDUS, BFU-E retain responsiveness against EPO (unpublished observation). All these observations point to a pathogenetic model, in which younger individuals develop an MDS-related clone and thus IDUS in a relatively early phase of their life. Most of these sub-
48
P. Valent et al.
jects are not diagnosed because no cytopenia is found despite clonal hematopoiesis. Later, when these patients are older and therefore develop ICUS (or renal anemia), frank anemia occurs and thus an overt MDS is diagnosed, following the equation: IDUS╛+╛ICUS╛=╛MDS (Fig.€4.1) [26]. It seems clear that exactly these patients are those with low risk MDS who respond to exogenous EPO for a certain time period.
Important Differential Diagnoses in Patients with Suspected MDS The diagnosis MDS is based on both MDS-related (positive defining) criteria and exclusion of other disorders as primary reason for cytopenia or dysplasia [26, 27]. The “exclusion criterion” is of importance as also other hematopoietic and non-hematopoietic disorders can present with cytopenia and/or myelodysplasia. In patients with increased blast counts, differential diagnoses include acute myeloid leukemia and MDS/MPN. In patients with low blast counts, important differential diagnoses include aplastic anemia, toxic bone marrow damage, copper deficiency, vitamin B12 or folate deficiency, chronic autoimmune disorders, and chronic infectious diseases including HIV infection. In each case it is mandatory to exclude all these potential differential diagnoses by appropriate investigations [27] (Table€4.3). A bone marrow biopsy with conventional histology and immunohistochemistry is an essential step in the diagnostic work-up in patients with suspected MDS [13, 25, 27]. Likewise, the provisional diagnosis REAB-2 established from a bone marrow smear will change to AML when the pathologist has convincingly documented that the bone marrow contains multifocal disseminated blast cell aggregates or is fully packed with blast cells in a CD34-stained bone marrow section. Bone marrow histology is also crucial for the detection of certain (rare) variants of MDS, such as hypocellular (often secondary) MDS, MDS with fibrosis (MDS-F), and MDS associated with systemic mastocytosis (SM-MDS) [13]. A limited panel of antibodies has been shown to be sufficient for immunohistochemical studies of bone marrow cells in these patients [13, 27]. These include antibodies against progenitor (blast) cells (CD34 and CD117/KIT), antibodies against megakaryocytes (CD42 or CD61), and an antibody against tryptase with which mast cells and immature basophils can be labelled and counted [13]. In those patients in whom no MDS is found and clinical or laboratory feature point to another differential diagnosis such as a lymphoma or hairy cell leukemia, additional antibodies have to be applied.
Classification of MDS A first robust classification of MDS was proposed by the FAB working group [1]. This proposal is still in use since (a) it is independent of cytogenetic findings and (b) the diagnosis can be established rapidly. In addition, the FAB classification is
4â•… Diagnostic Criteria and Classification of Myelodysplastic Syndromes
49
Table 4.3↜渀 Laboratory studies required to exclude differential diagnoses in patients with suspected MDS Peripheral blood – Virus tests (CMV, HIV, HCV, EBV, others) – Auto-antibodies (ANA and others) – T cell receptor rearrangement (neutropenia suspected T/NK neoplasm) – Immunoglobulin rearrangement (suspected lymphoma/NHL) – Lymphoid surface markers by flow cytometry (DD lymphoma or NK neoplasm) – Copper level (in case of gastrointestinal disorder/symptoms) – Serum Tryptase – CFU-GM and BFU-E – TSH, T3, T4 (suspected thyroid disease) – Serum EPO levels and renal function parameters (anemia) – Hepatic function parameters, GOT, GPT, GGT, CHE – Vitamin B12 and folate concentration – LDH, bilirubin, haptoglobin, and PI-linked surface antigens (hemolysis) – Ferritin (in select patients) – Genetic testing for congential cytopenias and related syndromes (examples: GATA1, LPIN2, WAS, RSP19, FANC, BRCA2, DCK1, TERC, TERT, ELA-2, G-CSFR, others) – Somatic mutations: RAS, JAK2, others – Screen for various toxins depending on clinical symptoms and test results Bone marrow – Histology, cytochemistry, and immunohistochemistry – Standard stains on bone marrow smears including MGG and iron stain – Metachromatic stain (toluidine blue or other) – Cytogenetics and if required: FISH – Flow cytometry to detect aberrant immunophenotypes – Mutation analysis: RAS, KIT, JAK2, AML-related fusion genes, others Other parameters and tests – Ultrasound of liver and spleen – Analysis of family members (suspected hereditary disease) – Screen for malformations (suspected congenital cytopenia/syndrome) – Urinary analyses (creatinine clearance) MDS myelodysplastic syndrome(s), CMV cytomegaly virus, HIV human immunodeficiency syndrome virus, HCV hepatitis C virus, EBV Epstein barr virus, ANA anti-nuclear antibodies, NK natural killer cell, NHL Non Hodgkin’s Lymphoma, DD differential diagnosis, EPO erythropoietin, CHE cholinesterase, LDH lactate dehydrogenase, AML acute myeloid leukemia
of prognostic significance. However, the FAB classification has several limitations and does not include the karyotype or other key prognostic parameters. In 2001 the WHO classification has been established [4] and an update was presented in 2008 [5]. In this classification, a cytogenetically distinct variant, the 5q- syndrome, has been included [4, 5]. Today, it is standard to classify all MDS patients according to the WHO proposal. Sometimes, the FAB diagnosis is used as a provisional diagnosis, and as soon as all WHO-parameters have been recorded, the WHO classification is applied. This is of importance, as cytogenetic and molecular markers may reveal AML in suspected high risk MDS (e.g. when an AML-releated translocation
50
P. Valent et al.
is found). Therefore, from an academic point of view it must be regarded standard that in all patients with MDS (at least those with excess of blasts), all AML-related cytogenetic and molecular parameters proposed by the WHO, are applied.
Prognostic Scoring Systems and Additional Risk Factors In previous years, a number of different scoring systems have been proposed by various working groups [2, 23]. These scoring systems include various prognostic factors, some of which are not included in standard scores, such as the lactate dehydrogenase (LDH) level or age. In 1997, the International Prognostic Scoring System (IPSS) was published [10]. This score includes blast counts, cytogenetic abnormalities, and the number of cytopenias, and can still be regarded as gold standard for risk assessment in MDS. It should be pointed out that the IPSS is a superior score for predicting the probability of AML-free survival, whereas several survival-related prognostic parameters have not been included in this score [10]. Another disadvantage of the IPSS is that patients without available karyotype cannot be included. Moreover, the IPSS was established in the pre-WHO era. More recently, a WHO-based scoring system, the WPSS has been established [15]. This score includes transfusion dependence as an important prognostic parameter and may also be applicable in the follow up. Neither the IPSS nor the WPSS included patient-related risk denominators such as age or comorbidity [10, 15]. However, exactly these variables may be key factors predicting survival in elderly patients with MDS [19, 21]. More importantly, such patient-related factors may lead to the conclusion the patient is a candidate for intensive or targeted drug therapy or—on the other hand—may not be eligible. Therefore, we believe that new scores including major patient-related variables should be established, with the aim to better predict overall survival in these patients. Another aim is to improve AML-prediction and related scores by introducing refined cytogenetic analysis [11] and additional disease-related parameters such as the LDH.
redictive Value of Therapy-Related Scores and Their Use P in Treatment Algorithms Today, specific and symptomatic therapy is available for most patients with MDS. In fact, there are several different (more or less) specific drugs and treatment approaches that can be considered in these patients, such as EPO, lenalidomide, demethylating agents (decitabine and azacytidine), polychemotherapy, ATG+CSA, and stem cell transplantation [2, 27]. For most therapeutic agents, factors predicting responses in patients with MDS have been defined (Table€4.4), which is of great importance as MDS is a heterogenous disease and only (sub)groups of patients are responding to certain drugs [2, 6, 27]. For most of these drugs, one or more prognos-
4â•… Diagnostic Criteria and Classification of Myelodysplastic Syndromes
51
Table 4.4↜渀 Factors predicting responses to certain therapies in patient with MDS Drug Factors predicting response Factors making a response less likely EPOâ•›>>â•›100€U/l EPO EPOâ•›<â•›100€U/l Low transfusion frequency Frequent transfusions Low risk MDS High risk MDS, high blast count ATGâ•›+â•›CSA Young patient Old or/and unfit patient HLA DR15 Complex karyotype PNH clone Low risk MDS Lenalidomide 5q- anomaly Complex karyotype (+/− 5q-) 5q- syndrome Increase in blasts Low risk MDS High risk MDS Demethylating agents Complex karyotype, -7 Rapid progression to AML Low risk MDS High risk MDS High-Dose-CT and/ AML-like disease High risk MDS or SCT Young fit patient Higher age, comorbidity Low/normal ferritin level Higher ferritin level CR after induction No CR after induction MDS myelodysplastic syndrome(s), EPO erythropoietin, ATG anti-thymocyte globulin, CSA cyclosporin-A, PNH paroxysmal nocturnal hemoglobinuria, AML acute myeloid leukemia, CT chemotherapy, SCT stem cell transplantation, CR complete remission
tic parameters predicting responses have been identified. Examples are the isolated 5q- anomaly that is highly predictive for responses against lenalidomide, provided that no other cytogenetic abnormalities and no increase in blast cells are found [27]. For other drugs, multi-factor score systems have been developed. These scoring systems are helpful for patient selection and for selection of most effective drugs. Examples are the Nordic-score (EPO-score) that is helpful in patient selection for EPO-therapy, or the transplantation scores that can also be applied to patients with AML. Table€4.4 provides a summary of factors and scores that are helpful for patient selection and drug selection and are thus regarded standard and an essential component in treatment algorithms.
Concluding Remarks and Future Perspectives Although parameters, assays, and score systems have improved markedly over the past two decades, appropriate diagnosis and optimal prognostication of MDS remains a challenge in practice. A recommended approach is to proceed in a step wise fashion: In a first step, the diagnosis MDS is confirmed by minimal diagnostic criteria. In a second step, the FAB and WHO classification is applied to define the disease variant. Then, the IPSS or WPSS are applied for prognostication. If this is not possible, alternative prognostic markers and scores should be employed. Finally, therapy-specific scores including the EPO-score or transplant-score are applied in
52
P. Valent et al.
order to learn what treatment options can be recommended in the individual patient. For patients with ICUS and IDUS, the general recommendation is to manage the patient in the same way as patients who have low risk MDS. These recommendations should facilitate the management and may improve the clinical outcomes in MDS. Acknowlegments╇ Supported by Research Grant “Myelodysplastic Syndromes” of the Medical University of Vienna.
References ╇ 1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et€al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199 ╇ 2. Bennett JM, Komrokji RS (2005) The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 10:258–269 ╇ 3. Berer A, Jäger E, Sagaster V, Streubel B, Wimazal F, Sperr WR et€ al (2003) Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. Ann Hematol 82:271–277 ╇ 4. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et€al (2001) Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues, vol€1. IARC Press, Lyon, pp€61–73 ╇ 5. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et€al (2008) Myelodysplastic syndromes/neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) World Health Organization classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp€88–107 ╇ 6. Fenaux P (2001) Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 73:429–437 ╇ 7. Ferrucci L, Guralnik JM, Bandinelli S, Semba RD, Lauretani F, Corsi A et€al (2007) Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol 136:849–855 ╇ 8. Geissler K, Hinterberger W, Jäger U, Bettelheim P, Neumann E, Haas O et€al (1988) Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes. Blut 57:45–49 ╇ 9. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 87:691–699 10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et€al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 11. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B et€ al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395 12. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP (2002) Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100:3553–3560 13. Horny HP, Sotlar K, Valent P (2007) Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 31:1609–1616 14. Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 32:5–17
4â•… Diagnostic Criteria and Classification of Myelodysplastic Syndromes
53
15. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et€al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510 16. Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R et€al (2008) International working group on morphology of myelodysplastic syndrome. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717 17. Nimer SD (2008) Myelodysplastic syndromes. Blood 111:4841–4851 18. Nolte F, Hofmann WK (2008) Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 87:777–795 19. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D et€al (2010) Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 21:120–125 20. Pellagatti A, Esoof N, Watkins F, Langford CF, Vetrie D, Campbell LJ et€ al (2004) Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 125:576–583 21. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A et€al (2010) Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 21:114–119 22. Tennant GB, Jacobs A, Bailey-Wood R (1986) Peripheral blood granulocyte-macrophage progenitors in patients with the myelodysplastic syndromes. Exp Hematol 14:1063–1068 23. Valent P (2008) Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. Leuk Res 32:1333–1337 24. Valent P, Fonatsch C, Stindl R, Schwarzinger I, Haas OA, Sperr WR et€al (2004) Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. Leuk Res 28:651–655 25. Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U (2009) Meeting report: Vienna 2008 workshop of the German-Austrian working group for studying prognostic factors in myelodysplastic syndromes. Ann Hematol 88:607–611 26. Valent P, Horny HP (2009) Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 39:548–553 27. Valent P, Horny H-P, Bennett JM, Fonatsch C, Germing U, Greenberg P et€al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727–736 28. Valent P, Wieser R (2009) Update on genetic and molecular markers associated with myelodysplastic syndromes. Leuk Lymphoma 4:1–8 29. van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J et€al (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first ELNet working conference on flow cytometry in MDS (Amsterdam 2008). Haematologica 94:1124–1134 30. Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Müllauer L, Sperr WR et€al (2007) Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 31:1461–1468
Chapter 5
Cytogenetics of MDS Detlef Haase, Christina Ganster, Christian Steidl, Katayoon Shirneshan, Friederike Braulke and Julie Schanz
Introduction Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem [1, 2] and stroma cell disorders [3]. Chromosomal anomalies can be identified in 40–60% of de novo cases and up to 90% of secondary MDS. The detection sensitivity of cytogenetic changes in MDS is critically dependent on optimized culture conditions [4, 5]. The karyotype has important diagnostic and prognostic impact and gains more and more influence on therapeutic decisions. The examination of bone marrow cells by cytomorphology and cytogenetics still defines the gold standard for initial diagnosis and documentation of treatment response in MDS patients. The cytogenetic heterogeneity in MDS is profound. In a recent study, we identified clonal karyotype changes in 1,080 (52%) out of 2,072 patients with MDS with a total number of 2,370 clonal chromosomal abnormalities. Grouping and subdividing similar chromosomal abnormalities identified 684 different cytogenetic categories [6]. In future studies, however, it still has to be determined whether distinct cytogenetic abnormalities lead to similar phenotypes and biological features and to which extent additional abnormalities influence prognosis. Therefore it is critical to increase reliability and precision of future prognostic systems by defining the prognostic impact of every given karyotype.
Cytogenetic Features of MDS MDS show a characteristic genetic profile with predominance of unbalanced abnormalities. Most frequently a loss of genetic material with deletions and monosomies can be observed. The most frequent abnormalities leading to a loss of chromosomal D. Haase () Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_5, ©Â€Springer Science+Business Media B.V. 2011
55
56 Table 5.1↜渀 Frequencies of unbalanced chromosome abnormalities in MDS Isolated, n (%)b With one additional Abnormality % Total abnormality, n (%)b incidencea Monosomies/deletions del(5q) 15.1 146 (46.8) 52 (16.7) -7/7q11.1 86 (37.4) 31 (13.5) -18/18q3.8 3 (3.8) 2 (2.6) del(20q) 3.6 36 (48.7) 10 (13.5) -5 3.3 1 (1.4) 4 (5.8) -Y 2.8 41 (70.7) 5 (8.6) -17/17p2.0 1 (2.4) 1 (2.4) -13/13q1.9 4 (12.5) 6 (15) -21 1.6 3 (9.1) 4 (12.1) -12 1.3 0 2 (7.7) del(12p) 1.2 7 (28) 6 (24) 11q1.1 8 (34.8) 4 (17.4) del(9q) 1.1 8 (34.8) 3 (13) -20 1.1 0 0 Partial/complete trisomies +8 8.4 81 (46.8) 37 (21.4) +21 2.2 5 (11.1) 18 (40) +1/1q 1.8 4 (10.8) 6 (16.2) +11 1.4 6 (21.4) 4 (14.3) +19 0.9 4 (22.2) 3 (16.7) +13 0.8 4 (25) 4 (25) +14 0.8 3(18.8) 4 (25) +10 0.6 1 (8.3) 0 +9 0.5 2 (20) 1 (10) a b
D. Haase et al.
As part of complex abnormalities, n (%)b 114 (36.5) 113 (49.1) 73 (93.6) 28 (37.8) 64 (92.8) 12 (20.7) 40 (95.2) 29 (72.5) 26 (78.8) 24 (92.3) 12 (48) 11 (47.8) 12 (52.2) 22 (100) 55 (31.8) 22 (48.9) 28 (75.7) 18 (64.3) 11 (61.1) 8 (50) 9 (56.2) 11 (91.7) 7 (70)
Related to all cases with MDS (n╛=╛2,072), according to Haase et€al. [6] Of cases with the respective abnormality
material are -5/5q-, -7/7q-, -18/18q-, 20q-, and -Y (Table€5.1) [6]. Gain of genetic material by total or partial trisomies is less frequent, but typical karyotypic changes involve chromosomes 1, 8, 11 and 21 (Table€5.1). Loss or gain of genetic material can also be the result of unbalanced translocations which are most frequent in MDS with multiple abnormalities. The higher frequency of loss of genetic material in comparison to gains gives rise to the hypothesis that a major molecular mechanism in MDS is the loss or inactivation of tumor suppressor genes while an oncogeneactivation seems to be less relevant in myelodysplasia. Balanced structural abnormalities like translocations and inversions are rare in MDS. Due to the pronounced genetic heterogeneity research has focused only on the most frequent abnormalities. The molecular background as well as the prognostic relevance of rare abnormalities still remains obscure in most cases and can only be clarified by large multicentric studies [6–9]. Another problem to delineate the prognostic impact of chromosomal changes is complicated by the fact that chromosome abnormalities can occur in three different settings: (1) as isolated abnormalities, (2) together with one addi-
5â•… Cytogenetics of MDS
57
tional change and (3) as part of complex abnormalities with at least two additional cytogenetic alterations. Table€5.1 shows the incidence of the most frequent abnormalities and the frequency of accompanying alterations occuring in our GermanAustrian patient cohort. Further details on cytogenetic prognosis are given below characterizing the most common cytogenetic subtypes.
Distinct Cytogenetic Subgroups 5q-Deletions Chromosome 5q-deletions are the most frequent cytogenetic changes in MDS. They occur in up to 30% of abnormal cases (Table€5.1) [6–9]. This abnormality can be observed in low risk MDS as well as in high risk MDS. The deletions can have variable sizes with breakpoints between 5q12 and 5q34. The common deleted region (CDR) contains the chromosome band 5q31 [10], but two different non-overlapping deleted regions in 5q31 to 5q32 have been assumed. The first more centromeric one is possibly associated with bad prognosis, complex abnormalities, and high-risk-, as well as therapy-related MDS and rapid transformation to AML. The latter area is supposed to be related to the good risk 5q-syndrome [11]. Knowledge about the molecular background of this abnormality is increasing: the CDR could be narrowed to 1.5€Mb containing 40 genes [11]. One of them, a ribosomal subunit protein (RPS14) seems to be a candidate gene [12]. However, not haploinsufficiency of one single gene but the combined haploinsufficiency of several genes in 5q31 might be the decisive pathogenetic mechanism [13]. A true 5q-syndrome is cytogenetically characterized by an isolated deletion of chromosome 5q but can be observed in only 10% of patients with MDS. The clinical course is mild and long-lasting with a very low risk for leukemic transformation. Partial or total monosomy 5 can occur with equal incidences in de novo as well as secondary MDS. However, in a recent meta-analysis monosomy 5 was more frequent in t-MDS while isolated del(5q) was significantly more fequent in de novo MDS [14] (Table€ 5.2). Monosomy 5 nearly exclusively occurs as an element of chomplex aberrations. Chromosome 5 material involed in very complex unbalanced structural rearrangements might be misinterpreted as monosomy 5 [15]. Monosomy 7 Monosomy 7 is the second most frequent distinct chromosome abnormality in MDS occurring in 25% of abnormal cases (Table€5.1) [6, 7, 9]. It is more frequent in advanced MDS and manifests itself as total or partial monosomy. In the latter variable deletions of parts of the long arm were described. In the German-Austrian dataset 36% of cases with monosomy 7 were isolated, 14% displayed one additional abnormality and 50% occurred as part of complex abnormalities [6]. Several distinct regions of common deletions have been identified: 7q22, 7q31-32, and 7q36. A re-
58
D. Haase et al.
Table 5.2↜渀 Incidences (%) of chromosome abnormalities in primary vs. therapy-associated (t)-MDS related to abnormal cases. (According to Mauritzson et€al. [14]) Abnormality MDS t-MDS p-value RT alone Aâ•›±â•›RT A+Tâ•›±â•›RT p-value de novo (nâ•›=â•›252) (nâ•›=â•›44) (nâ•›=â•›115) (nâ•›=â•›73) (nâ•›=â•›1,377) -5 7 16 19 8 n.s. <0.001 18 5q25 25 n.s. 54 22 14 <0.001 Sole 5q13 6 0.001 18 4 1 0.02 -7 12 35 47 27 0.003 <0.001 20 Sole -7 6 12 20 8 0.008 <0.001 0 7q5 10 0.005 14 8 12 n.s. Der(1;7) 2 2 n.s. 0 4 3 n.s. Loss of 5 and/or 7 +8 21 10 9 7 n.s. <0.001 14 Sole +8 13 2 2 0 n.s. <0.001 5 Der(12p) 6 6 n.s. 7 7 4 n.s. -17 4 6 n.s 5 5 6 n.s. Der(17p) 4 7 0.02 5 9 6 n.s. 20q6 5 n.s. 5 5 4 n.s. Sole 20q4 1 0.01 0 2 0 n.s. Complex 24 39 36 37 n.s. <0.001 48 Balanced 14 17 n.s. 23 16 18 n.s. Unbalanced 95 96 n.s. 98 99 92 n.s. n.s.â•›=â•›not significant, RTâ•›=â•›radio therapy, Aâ•›=â•›alkylators, Tâ•›=â•›DNA topoisomerase II inhibitors
gional genetic instability of the long arm of chromosome 7 has been described [16, 17]. It can be assumed that this region harbours a cluster of genes with tumor suppressive features and that a deletion of any part of it has very similar biological consequences. In contrast to some hypotheses in the 5q-deletions as yet no prognostic differences have been elaborated between different regions of deletions [18]. Investigations of the molecular background of monosomy 7-MDS are currently ongoing. Overexpression of HOXA9, PRAME, BMI1, PLAB and the DNA-repair gene BRCA2 and parallel down-regulation of the tumor suppressor genes p21, GATA2, and MAP were observed [19]. Recently, EZH2 was suggested to be a canditate tumor suppressor gene involved in monosmy 7/7q-MDS [20]. In pediatric MDS monosomy 7 is the most frequent cytogenetic change. The prognosis in these cases is poor [21–23]. In a substantial portion of patients with -7/del(7q) a mutagen exposition was documented [14, 24–26]. There is increasing evidence that also secondary MDS and AML following immunosuppressive therapy are associated with monosomy 7 [14, 27, 28]. Trisomy 8 Trisomy 8 can be observed in 12–21% of abnormal cases in MDS (Table€5.1) [6, 7, 14]. It seems to be more frequent (17%) in MDS with transformation to AML
5â•… Cytogenetics of MDS
59
[6]. In 47% of cases trisomy 8 occurred as a sole change, it was combined with one abnormality in 21% and was part of complex anomalies in 32%. The most frequent accompanying abnormality is a deletion of 5q. It was hypothesized that trisomy 8 is not the primary event because in AML, comparison of different karyotypes with trisomy 8 revealed no common characteristic profile of overexpressed genes [29]. In MDS, the size of cell clones with trisomy 8 tends to fluctuate during the course of the disease but is not always correlating with the blast counts or leukemic transformation [30]. The hypothesis of a secondary nature of trisomy 8 was supported by further studies [1, 2]. In cases with a constitutional trisomy 8 mosaicism the trisomy might be regarded as the first mutation in a multistep leukemogenesis process [30]. It was recently demonstrated that trisomy 8 clones show over-expression of the potential autoantigenes Cyclin D1 and Wilms tumor protein (↜WT-1) [19, 31]. CD34+ cells from patients with trisomy 8 furthermore display a pronounced expression of apoptotic markers like caspase-3 and FAS [32]. This phenomenon can be explained by an up-regulation of the antiapoptotic proteins survivin, CMYC and CD1 [33]. Chromosome 17 Abnormalities Abnormalities of chromosome 17 mostly occur as loss of material of the short arm and are observed in <5% of cases with clonal changes in MDS (Table€5.1) [6, 9, 34]. They are associated with advanced disease and an elevated blast count and are more frequent in therapy-associated MDS as compared to de novo MDS (Table€ 5.2) [14]. The great majority of these changes are unbalanced, leading to the deletion of varying parts of the short arm of chromosome 17 with a common loss of the band 17p13 harbouring the tumor suppressor gene TP53. In our German-Austrian database 77% of chromosome 17 changes were part of complex abnormalities, only 12% (n╛=╛12) occurred as isolated anomalies of which isochromosome i(17)(q10) was the most frequent one [6]. Since isolated anomalies of chromosome 17 are rare little is known about their prognostic relevance [9, 35, 36]. TP53 point mutations were associated with poor prognosis and bad response to chemotherapy in AML and MDS [34, 37, 38]. They display, as well as chromosome 17-anomalies in general, a strong association with complex abnormalities [6, 34, 39, 40]. An association with microsatellite instability and thus a replication error phenotype was described [39, 41]. Hence it is likely that TP53 mutations by themselves are causally related to genetic instability and accumulation of cytogenetic and molecular defects in MDS. 20q-Deletions Deletions of 20q including monosomy 20 occurred in 7% of abnormal MDS cases of our dataset (Table€5.1). They were equally distributed in all FAB-subtypes but were very rare in CMML (<1%). Deletions of 20q occurred as sole changes in 49%, with
60
D. Haase et al.
one additional anomaly in 13% and as part of complex alterations in 38%. Monosomy 20 was exclusively (22 of 22 cases) observed in complex abnormal karyotypes. Thus it can be assumed that as in monosomy 5 most if not all of these cases share similar features displaying complex, unbalanced cryptic abnormalities [6]. Recently, a CDR with the size of 10.4€ Mb and two common retained regions (CRR) were identified. The deletion may result in the loss of one or several tumor suppressor genes [42]. However, the target genes still remain unknown although several groups have reported candidate genes in the deleted region [43–45]. Recent activities focus on L3MBTL3 that has putative tumor suppressive functions and is probably involved in chromatin modeling and mitotic progression [46]. An isochromosome of the long arm of chromosome 20 with loss of interstitial material [ider(20q)] is a variant of the deletion of chromosome 20q and is a rare abnormality in MDS. Amplification of the genes HCK, TNFRSF6B and DIDO1 included in the CRR associated with loss of tumor suppressor genes in deleted regions could explain tumor progression and possibly the less favourable prognosis of ider(20q) compared with del(20q) [47].
Sex Chromosomes Abnomalities In MDS loss of the Y chromosome can be observed in 5% of abnormal cases (Table€5.1) [6, 7] and is seen with higher frequency in low risk MDS. It is still subject of debate to which extent the loss of the Y chromosome in MDS is an age-related or disease-associated, clonal phenomenon. On the one hand there are data suggesting that in elderly men -Y is not indicative of malignancy [48]. On the other hand several groups found hints that at least under certain conditions loss of the Y chromosome could also be a clonal marker in MDS [49, 50]. It was suggested that even in older males, loss of the Y chromosome in >75% of metaphase cells probably represents a disease-associated clonal population [51]. Furthermore, three different types of karyotype evolution observed in our laboratory as well as by others, clearly support the clonal nature of loss of the Y chromosome: (1) Emergence of cells with loss of the Y chromosome during disease progression in cases with an initially normal karyotype, (2) Emergence of -Y as secondary abnormality and (3) Emergence of secondary abnormalities in cells with loss of the Y chromosome in cases with an initial mosaic of normal and -Y cells (↜own unpublished observation). It thus can be concluded that at least under certain conditions loss of the Y chromosome is a clonal abnormality with relatively high frequency in MDS but also occurring in other hematologic malignancies. Candidate genes are not known as yet. Non-constitutional loss of one X chromosome as the sole cytogenetic change is a rare but recurrent abnormality observed in MDS. In the German-Austrian dataset isolated monosomy X occurred in only 4 of 1,080 patients with abnormalities and four further patients had monosomy X in combination with one additional abnormality [6]. The molecular background of this abnormality is not known.
5â•… Cytogenetics of MDS
61
Balanced Abnormalities Balanced abnormalities are rare in MDS. The most frequent balanced abnormalities belong to a group of changes affecting the chromosome bands 3q21 (↜RPN1) and 3q26 (↜EVI1) such as inv(3)(q21q26), translocations t(1;3)(p36;q21) (fusion of MEL1/RPN1), t(3;3)(q21;q26), and t(3;21)(q26;q22) (↜EVI1/RUNX1). Their estimated incidence in MDS is <5% up to 10% of abnormal cases [18, 52, 53]. Heterogeneous translocations involving the MLL-gene localized on chromosome band 11q23 can be observed in <2% of abnormal cases in MDS, often in therapyassociated cases. A translocation t(5;12)(q33;p12), leading to the fusion of ETV6 and PDGFRB, can be observed in <1% of patients with CMML [54]. Another rare balanced translocation involves chromosome bands 3q25.1 (↜MLF1) and 5q34 (↜NPM1), resulting in a fusion protein, NPM-MLF1 [55, 56]. Translocations t(8;21) (q22;q212) with a fusion of RUNX1T1 on 8q22 and RUNX1 on 21q22, one of the most frequent clonal chromosome abnormalities in AML, have been described very rarely in MDS and could be misdiagnosed AML [57–59]. Pericentric inversion of chromosome 16 associated with AML M4Eo has been observed as well in rare cases of mostly advanced MDS [57, 60]. Chromosomal Manifestations of Gene Amplifications Gene amplifications in hematologic diseases can occur as extrachromosomal DNA (so-called “single or double minutes”) as well as so-called “homogeneously staining regions” attached to or inserted into chromosomes. In AML these rare findings have an incidence of <1% while there is no report about the exact frequency in unselected MDS cohorts. Chromosomal gene amplifications may occur as the sole karyotypic change or in association with chromosome abnormalities like 5q-deletions, trisomy 4 or trisomy 8 [61–63] but most frequently they are associated with complex changes. FISH analysis allows identification of genes within amplified regions. The genes most frequently amplified in MDS are MLL in 11q23, RUNX1 in 21q22 and MYC in 8q24 [64–66]. Such amplifications show an association with bad prognosis and therapy-related MDS/AML (Figs.€5.1, 5.2, 5.3) Independent Clones Independent (unrelated) clones showing completely different cytogenetic abnormalities occurring in one and the same patient are rare in hematologic malignancies, with a frequency of 0.9–7.2% of cases [67–73]. The frequency of independent clones was significantly higher in t-MDS (6.2%) as compared to de novo MDS (3.0%; pâ•›<â•›0.01) [69]. The incidence of distinct abnormalities observed in independent clones was comparable to the common MDS cohort, except of an overrepresentation of trisomy 8 [6, 7, 9]. The most common pattern of abnormalities in independent clones was the combination of del(5q) and trisomy 8 [69]. Complex
62
D. Haase et al.
Fig. 5.1↜渀 MLL-amplification (four fusion signals) in interphase cells in a case of t-MDS after breast cancer with complex abnormalities
Fig. 5.2↜渀 Multicolour FISH metaphase of the same case (Fig.€5.1) with complex abnormalities and a large marker chromosome containing three copies of MLL
5â•… Cytogenetics of MDS
63
Fig. 5.3↜渀 Giemsa-banded karyogram of the same metaphase
abnormalities in at least one of the clones are infrequent, occurring in 4.5% of independent clones (↜own data, not published). The majority of patients (88%) display only two different clones. Interestingly, 89% of cases show unbalanced abnormalities exclusively [69]. Unfortunately, the prognostic impact of independent clones in MDS remains unclear as yet. Complex Chromosome Abnormalities According to ISCN-criteria complex chromomosome abnormalities are defined by the parallel existance of at least three independent abnormalities within one cell clone [74]. Complex abnormalities can be observed in 15% of all MDS patients (30% of all abnormal cases) [6, 7, 9]. They may represent the final step of a multistep process with sequential accumulation of abnormalities, called karyotype evolution. In most of these cases the aberration numbers exceed the threshold of three by far and cell-to-cell variations occur. It is conceivable that in many cases the process leading to complex abnormalities and genetic instability must proceed rapidly and likely involves defective DNA-repair and cell cycle control comparable to the situation in DNA-repair deficiency syndromes. Recent results of gene expression analyses in patients with MDS and complex chromosome abnormalities support these assumptions [40]. In a substantial portion of patients with complex abnormalities
64
D. Haase et al.
exposition to therapeutically applied mutagens can be derived from the medical history [25, 75]. There is a strong association of complex alterations with unbalanced structural abnormalities affecting most frequently chromosomes 5q and 7q. Genomic gains were observed for chromosome 8/8q, 11q and 21q [76]. Mutations of TP53 have been observed in up to 90% of patients with AML and complex abnormalities [40]. Recently, array comparative genome hybridization (aCGH)-analyses facilitated to unravel complex karyotype changes [77]. Karyotype Evolution In the vast majority of cytogenetic MDS studies investigations are focused on one distinct observation time point only, most often that of initial diagnosis. As MDS is a very dynamic disease at the morphologic, clinical and genetic level, it can be reasonably hypothesized that karyotype evolution (KE) could be indicative of disease progression, hence influencing therapy decision. The model of multistep pathogenesis in MDS [78–80] is based on the findings that MDS is a clonal stem cell disease [2, 6, 78, 79] and that karyotype abnormalities are only the second step following acquisition of clonality [81]. It was suggested that there are primary abnormalities leading to specific gene rearrangements and secondary changes that result in largescale genomic imbalances and are important in tumor progression [82]. As yet it is uncertain whether a distinct sequence or the amount of genetic changes accounts for disease progression [82]. On the cytogenetic level a stepwise progression manifests itself as an evolution of the karyotype, characterized by (a) the acquisition of a clonal abnormality in cases with an initially normal karyotype, (b) the expansion of a cell clone with a given abnormality or (c) the occurrence of secondary abnormalities in cases with a distinct primary karyotypic change. Johansson and Mitelman analysed the Catalog of Chromosome Aberrations in Cancer [71] and identified the most frequent secondary abnormalities related to seven primary abnormalities (Table€5.3) [82–84]. Karyotype evolution is also studied by repeated analyses of the karyotype during the course of the disease (Table€5.4). The earliest systematic study of KE in MDS patients was conducted by Tricot in 1985, defining four distinct reproducible patterns of disease evolution (Fig.€5.4) [85]. Considering the results of seven studies the incidence of KE in MDS ranges between 12% and 47% of patients examined sequentially (Table€5.4) [84–91]. ObTable 5.3↜渀 Primary and secondary abnormalities in MDS. (According to Johansson et al., Mallo et al., and Steidl et€al. [82–84])
Primary abnormality der(1;7)(q10;p10) der(3q21/q26) del(5q) -7 +8 del(20q)
Secondary abnormalities +8 -7 -7,+8, del(12p), der(17p), +21, -18/18q-, -Y del(20q), +8, +21 del(5q), -7, +8, -17/der(17p), +22, -Y -7/del(7q), +8, +21
5â•… Cytogenetics of MDS
65
Table 5.4↜渀 Abnormalities gained during transformation to AML Number of patients Gained abnormalities % Of patients with karyotype with karyotype evolution/entire cohort evolution 5q-, -7/7q-, +8, complex abnormalities 21% 121/577 Abnormalities of chromosomes 2, 4, 7, 8, 7 10, 11, 17, and 21 inv(3), +8, +9, +13, +21, del(11p) 39% 7/18 12% 15/126 +1, der(1;7), t(1;18), +2, del(2q), del(5q), -5, +6, -7, +8, del(9q), +der(11) t(11;21), del(12p), +13, +14, +15, del(17q), r(18), -20, del(20q), +21, del(21q), -21, -Y, + mars 27% 17/63 dup(1q), del(1q), del(1p), del(3q), -5, -6, -7, add(7q), add(7p), +6, +8, -9, del(9q), add(10q), +10, -11, +11,╛+╛12, +13, +14, der(17), inv(16), -16, -18, +19, del(20p), +21, + mars t(1;5), t(1;7;8),+5, +8, t(8;20), t(11q23), 33% 10/30 +14, +15, 17p+, -16, +21, +22, -X, -Y t(1;3), del(5q), -7, +8, 9q+, -17, -18, 20% 9/46 18q-, +21, -21, +22
References [84] [89] [90] [91]
[86]
[88] [85]
viously the incidence of KE is depending on the composition of the patient cohorts as well as on the duration of observation time. In all analyses the occurrence of KE was associated with a dismal prognosis and leukemic transformation. In a recent multicentric analysis of our own German-Austrian group KE was observed in 155/577 patients with MDS (27%). Additional anomalies occurred in bone marrow blasts
AML -7/7q-, complex
D
Sole 5qtrisomy 8 C
5q-, + complex B
sole 5q-
normal karyotype A t
Fig. 5.4↜渀 Patterns of evolution in MDS modified according to the proposal by Tricot et€al. [85]
66
D. Haase et al.
121 patients (21%) and in 34 patients (6%) the abnormal clone expanded. In the latter patient subgroup the most frequent abnormalities were del(5q) (nâ•›=â•›9) and trisomy 8 (nâ•›=â•›7). The most frequent abnormality types later acquiring additional changes were complex (nâ•›=â•›22) or double anomalies (nâ•›=â•›11). KE was observed in 70 patients (12%) with an initially normal karyotype. The most frequent secondary abnormalities were -7/7q- (nâ•›=â•›23), del(5q) (nâ•›=â•›11) and trisomy 8 (nâ•›=â•›11). Patients with initially normal karyotype and KE had a significantly shorter survival in comparison to those with a stable normal karyotype [84]. KE could also be observed in vitro in long term bone marrow cultures from MDS patients and it was suggested that the expansion of small latent subclones could contribute significantly to leukemic transformation [92–94]. Other genetic abnormalities occurring during MDS evolution and associated with worsening of prognosis and leukemic transformation are double minutes [62, 95], telomere shortening [96], N-RAS gene mutations [87, 90], FLT3 internal tandem duplications [97], KIT mutations [98] and loss of heterozygosity on chromosome arms 6q, 7p, 10p, 11q, 14q, and 20q [99]. Microsatellite instability, a marker of defective mismatch-repair, was rarely observed in MDS appearing mostly early during the course of the disease and was not associated with disease progression in most cases examined [99–102]. New therapeutic options influencing the natural course of the disease will complicate studying the spontaneous evolution of MDS in the future. However, novel therapies warrant a narrow-meshed genetic monitoring of disease progression to better define the best time point for therapeutic decision and intervention. Since the potential sequence of traumatizing bone marrow biopsies is limited due to ethical reasons alternative methods allowing for a complete surveillance of the development of MDS are urgently required. Our group recently demonstrated the value of comprehensive FISH-analyses of circulating CD34 cells for such purposes [103]. A multicentric prospective diagnostic trial is currently under way to examine whether this method is appropriate for an initial diagnostic screening, to trace KE and to quantitate therapy response in two to three month intervals. On strength of these preliminary data generated by this technique, we remain hopeful to significantly increase our knowledge about genetic evolution in MDS. Cytogenetics in Therapy-Associated MDS Differnces of chromosomal abnormalities in primary vs. therapy-associated (t)MDS are shown in Table€5.2. With 37–50%, the aberration rate is much lower in de novo MDS [7–9, 14, 104, 105] compared to 82–94% in t-MDS [14, 25, 106]. Complex abnormalities and unbalanced chromosome 5- and/or 7-alterations were found to be significantly increased in t-MDS, while sole 5q-, trisomy 8 and sole 20q- were underrepresented [14, 25, 106]. Furthermore an increased frequency of dicentric chromosomes was observed in therapy-related MDS and AML compared to de novo cases [107]. Amplifications of MLL and RUNX1 were identified as rare but recurrent cytogenetic findings in t-MDS [108, 109].
5â•… Cytogenetics of MDS
67
FISH-Analyses in MDS Cytogenetics in MDS is increasingly not only based on chromosome banding analysis alone but also on the use of different fluorescence in situ hybridization (FISH)techniques. Several studies have shown the usefulness of molecular cytogenetic techniques, such as FISH with specific probes for centromeric regions or distinct chromosomal loci (Fig.€5.1) and methods for the delineation of the whole chromosomal complement like spectral karyotyping (SKY) or multicolor FISH (M-FISH) (Fig.€5.2) to detect and more accurately define abnormal karyotypes. These studies demonstrate that FISH analysis can provide additional useful information in a substantial portion of cases.
Value of FISH as a Supplement to Banding Analyses There are several diagnostic situations where FISH proved to be a worthwhile supplement to banding analyses. These are (1) detection of cryptic abnormalities in cases with a seemingly normal karyotype by banding, (2) search for additional cryptic abnormalities in cases with a known chromosome abnormality, (3) the detection of chromosomal abnormalities in cases with no metaphases or metaphases of only minor quality and (4) more detailed characterization of complex abnormalities.
FISH in cases with a normal banding karyotype Occasionally occurring cryptic chromosomal mutations may be undetectable by banding analyses because of a poor bone marrow sample or preparation, bias of metaphase analysis, “true” cryptic/submicroscopic mutations, or lack of dividing neoplastic cells. Approximately 50% of MDS patients have normal results by conventional cytogenetic analysis, thus it was examined by several groups whether FISH panel tests can be utilized to identify overlooked or cryptic cytogenetic abnormalities. FISH panel tests on MDS patients with normal karyotype detected clonal abnormalities in 16–18% of patients [110, 111]. These patients showed a worse prognosis in comparison to patients without cryptic chromosomal changes [110]. In some cases it was observed that distinct cell clones were traced in interphase cells by FISH but could not be detected by banding analyses relying on dividing cells [112, 113]. This might be explained by differences in the proliferative capacity of normal versus abnormal cells. Comparison of Metaphase Cytogenetics and Interphase FISH By comparing banding analyses and examination by FISH, different detection frequencies were reported: Using FISH analysis, a Chinese group confirmed 3/46 cases
68
D. Haase et al.
of total or partial monosomy 7 that were previously detected by banding analyses, but found 6/46 additional cases with -7 or del(7q) [114]. A Swedish group confirmed monosomy 7 in 10/123 cases previously karyotyped and found only 4/123 further cases with a cryptic monosomy 7 [115]. In another study in 3/30 cases (10%) FISH analysis detected trisomy 8 which was not found by banding analysis [116]. By banding analyses, an Italian group detected clonal changes in 13/40 (32.5%) of patients while FISH with a panel of probes traced abnormalities in 14/40 (35%). The combination of both techniques increased the detection rate up to 40% [117]. In an ECOG study, a cytogenetic abnormality was detected by metaphase analysis in 37.5% of 48 patients while the FISH panel detected clonal changes in 35.4%. The authors concluded that interphase FISH is nearly as sensitive as banding analyses of metaphases [118]. Different clone sizes in cells with a 5q-deletion in interphase versus metaphase could be related to a different rate of mitoses in cells carrying or not the 5q deletion pointing to a low proliferation and a high apoptotic rate of the abnormal cell clone. As some cryptic abnormalities are detected by FISH only, and other abnormalities are detected by chromosome banding only, both methods should be combined. The International Cytogenetic Working Group of the MDS Foundation recently has launched an international multicentric prognostic trial to evaluate interphase FISH in comparison with conventional cytogenetic studies to detect chromosome abnormalities in peripheral blood and bone marrow of patients with MDS [119]. Characterization of Complex Abnormalities The wide variety of complex chromosomal aberrations (CCA) in patients with MDS is often difficult to define by conventional banding cytogenetics alone. Molecular cytogenetic techniques such as multiplex FISH (M-FISH) or spectral karyotyping (SKY) allow the comprehensive evaluation of CCA. They allow analyzing the origin of marker chromosomes, revealing cryptic rearrangements, and determining recurrent breakpoints and the structure of derivative chromosomes (Fig.€5.2) [15, 76, 120–124].
FISH-Analysis of Circulating CD34+ cells from Peripheral Blood Usually, chromosomal anomalies are detected in bone marrow cells by cytogenetic analyses of metaphases using conventional banding techniques. Most of these chromosome abnormalities can be detected by FISH-techniques too. To study karyotype evolution and molecular cytogenetic response to therapy with unprecedented accuracy and frequency our group has launched a seminal study to test a novel method to perform long-term highly sequential cytogenetic analyses in MDS patients without exposing the patient to the often unacceptable strain of frequently repeated bone marrow biopsies. The investigations focus on the analysis of CD34+ cells which
5â•… Cytogenetics of MDS
69
are known to circulate in increased numbers in the peripheral blood of patients with MDS [125]. In preliminary data we could demonstrate, that this method is sensitive, reliable, and representative for the clonal cell population found in the bone marrow [103].
FISH in MDS—Conclusions Conventional cytogenetics, FISH panel testing and M-FISH all have their own specific analytical limitations. Conventional cytogenetics often cannot unravel the specific anatomy of marker chromosomes involving multiple rearrangements, and cryptic mutations can be missed or misidentified. Furthermore, it is much dependent on the quality and yield of short-term bone marrow cultures. Locus specific FISH analyses are limited only to the specific chromosomal regions to which the respective probes bind. Thus, mutations involving any other chromosome or other regions on the same chromosome will be overlooked. A great advantage of FISH techniques is the much larger number of cells that can be examined with reasonable expenditure as compared to banding analysis. For a quantification of a clone size with a known abnormality FISH is superior to conventional cytogenetics. The strength of M-FISH is in identifying cryptic translocations and additions. However, the resolution of M-FISH is limited, and subtle translocation events as well as smaller deletions, insertions or inversions can be missed. FISH and banding analyses are complementary and a combined application of conventional cytogenetics and FISH techniques adapted to the needs in specific analytical situations and cases significantly improves the diagnostic accuracy, reliability and sensitivity.
Prognostic Meaning of the Karyotype Since one of the earliest prognostic graduations was introduced in 1985 [126], cytogenetics was proven as an independent prognostic factor in large-scaled, multivariate analyses (Table€5.5) [6–9, 91, 104, 105, 120, 126–129], finally resulting in the IPSS score, which actually defines the gold standard in risk assessment in MDS [7]. The IPSS includes bone marrow blast count, peripheral cytopenias and cytogenetics as major prognostic variables to define the risk for overall and AML-free survival. Due to the profound heterogeneity of cytogenetic findings in MDS however, there are still difficulties to classify distinct cytogenetic abnormalities. About 50% of all patients show a normal karyotype, which is associated with a good prognosis [6, 7, 9, 104, 105, 121, 129]. In about 20–25% of patients, one of the most frequent abnormalities (5q-, -7/7q-, +8, 20q-, -Y), associated with an established prognostic significance, occurs [6, 9]. At least 8–18% [6–9] show complex abnormalities at the time of first diagnosis. According to the IPSS cytogenetic classification 14% of patients present with rare abnormalities with an unknown prognostic denotation.
70
D. Haase et al.
Table 5.5↜渀 Incidence and prognostic subgrouping of karyotype abnormalities in MDS References N= Abnormal Favourable Intermediate Unfavourable (%) [126] 174 66 (38) Normal (NN) Complex [128, 135] 144 63 (44) 5q-, 20q+8 -7/7q[127] 169 74 (44) NN, 5q+8 -7/7q[129] 247 106 (43) NN Complex [104] 408 151 (37) NN, 5q-, -Y, -7/7q-, 20q- +8 Complex [105] 401 200 (50) +8 -7/7qComplex [91] 198 75 (38) NN, 5q12p-, +21 Complex, +8, 20q[7] 816 327 (40) NN, 5q-, 20q-, -Y +8, all others Complex, abnormal #7 [9] 968 500 (51) NN, 5q-, 20q-, -Y, 11q-, 3q, +8, +9, t11q, Complex, -7/q-, 12p17pi17q [6] 2,072 1,080 (52) NN, 5q-, 20q-, -Y, +1/1q, Rea 3q, -7/7q-, Complex (>3), +8, 11q-, t1q, t7q, 12p-, +21, t(5q) 11q23, +19, -21 and others =3 anomalies [8] 1,029 485 (45) NN, 5q-, 20q-, -Y +8, other rare -7, 7q-, complex abnormalities
Thus, rare abnormalities are frequent findings in MDS and one of the main future goals in MDS cytogenetics is to define their prognostic relevance.
Distinct Frequent Abnormalities More than half of the MDS patients with clonal chromosomal abnormalities show isolated abnormalities without any additional changes [6, 9]. The prognostic relevance of the most frequent of these abnormalities is known. Deletions within the long arm of chromosome 5 are the most frequent cytogenetic changes in MDS, occurring in 10–30% of all abnormal cases [6–9]. With a median survival of 80 months isolated deletions of 5q are clearly associated with a good prognosis [6–9]. But the prognosis of 5q-deletions in MDS is significantly modified by the number of additional cytogenetic changes [6, 130]. Abnormalities of chromosome 7, appearing in 9–21% [6, 9] of all patients with clonal abnormalities, are associated with a poor prognosis. No significant differences in survival were observed between total and partial monosomy 7. In about 50% of all patients showing a -7/7q-, the abnormality is part of a complex karyotype at the time of first diagnosis with a poor prognosis and a median survival of <6 months [6, 7, 9]. Additionally, more than one third (37%) of all complex abnormal cases (↜own unpublished data) contain this type of abnormality. If monosomy 7 is found isolated or with only one additional abnormality, median survival is 14–16 months [6, 9], indicating an intermediate to poor prognosis.
5â•… Cytogenetics of MDS
71
Trisomy 8 represents the third most frequent abnormality, occurring in 8–16% of all abnormal cases [6, 7, 9]. Median survival in patients with isolated +8 is 19–24 months [6, 8, 9]. Interestingly, patients with trisomy 8 and one additional abnormality show a slightly better prognosis with a median survival of 44 months [6], which can most likely be attributed to the fact that a deletion of 5q is the most frequent accompanying abnormality in these patients (↜own unpublished data). One third of patients with trisomy 8 show complex abnormalities, critically downgrading the prognosis to a median survival <6 months [6, 7, 9]. A deletion of 20q can be observed in 3–4% of abnormal cases [6, 9]. As an isolated abnormality, it is associated with a good prognosis [6–9, 104]. This aberration is very rarely (<1% of cases showing this abnormality) seen in a combination of two abnormalities [6], further data is needed to delineate the prognosis in this subgroup. Prognosis of cases with a deletion of 20q within complex abnormal karyotypes is dismal [6]. Loss of the Y chromosome as an isolated abnormality is associated with a good prognosis and median survival of 36–60 months. In combination with one other abnormality the median survival is 39.0 months [6, 9]. Within a complex abnormal karyotype, -Y is associated with a poor prognosis [6]. A study of the German-Austrian MDS study group (↜own unpublished data) showed no differences in survival or clone size between younger and older patients developing an isolated -Y. Rare abnormalities are detectable in about 15% of MDS patients [6, 7, 9]. They form a heterogeneous group, hence Table€5.6 shows an overview concerning details of their frequency and prognostic impact.
Table 5.6↜渀 Frequency and overall survival in rare abnormalities Abnormality Frequency (%)a MS (months)a t(1q) 0.6/34.7/der(3)(q21q26) 0.5/0.6 19.9/31.6 t(5q) 0.4/4.4/t(7q) 0.6/34.7/del(9q) 0.4/NR/del(11q) 0.9/0.7 15.9/45.6 t(11q) 0.5/0.6 20.0/26.6 del(12p) 0.8/1.3 108.0/NR del(17p) -/0.5 -/NR iso17q -/1.0 -/11.0 +19 -/-21 0.5/32.0/+21 1.1/0.8 108.0/13.9 -X 0.5/56.4/a b
German-Austrian/and Spanish-MDS database [6, 9] International rare abnormalities database [133]
MS (months)b NR NR 34.7 63.1 28.0 NR 21.7 35.0 15.7
72
D. Haase et al.
Double Abnormalities Double abnormalities are less frequent as single or complex abnormalities and occur in 9% of all patients (17% of abnormal cases) [6]. We observed a profound heterogeneity of combinations without recurrent patterns of abnormalities [131]. Due to this heterogeneity, it is challenging to develop a prognostic classification system for double abnormalities (Fig.€5.5). By revising a large database containing 2,664 primary, untreated MDS patients [6, 7, 9, 132], the most reliable system was to integrate double abnormalities into three prognostic subgroups: Double abnormalities including deletions of 5q (favourable), double abnormalities including -7/7q- (unfavourable) and any other combinations of two abnormalities (intermediate). The calculated median survival was significantly different within these groups with 44 months for combinations classified as good, 34 months for intermediate and 14 months for unfavourable. In a multivariate analysis of the data by using age, gender and bone marrow blast count as covariables, the Hazard ratio (normal karyotype as baseline with a HR of
-7/7qn=4
+8 n=6
del(5q) n=49
del(20q) n=3
Fig. 5.5↜渀 Composition of “double abnormalities” using the example of del(5q) in 49 cases. (↜Own unpublished data)
any other n=36
5â•… Cytogenetics of MDS
73
1.0) was 1.14 for double abnormalities including 5q- (p not significant), 1.47 for any double (pâ•›<â•›0.05) and 2.84 for double including -7/7q- (pâ•›<â•›0.01) [133].
Complex Abnormalities Complex abnormalities, defined as three or more independent abnormalities within one cell clone [74], occur in about 15% of all cases [6, 7, 9]. It is well known since the first publications about the prognostic impact of cytogenetics in MDS (Table€5.5) [6–9, 104, 105, 126–129, 134, 135] that complex abnormalities are invariably associated with a poor prognosis. Anyhow, they comprise different prognostic subgroups: patient with exactly three abnormalities show a slightly better prognosis (median survival 16 months) as compared to those with more than three abnormalities (6 months) [6, 131]. In a multivariate approach with age, sex and bone marrow blast count as co-variables, the Hazard ratio was found to be 3.0 in complexâ•›=â•›3 as compared to 5.0 in complex >3 (baseline: normal karyotype), reflecting the impact of the number of abnormalities [133]. Furthermore, complex abnormalities including chromosomes 5 or 7 are associated with a worse prognosis [136] and higher risk for AML-transformation [9]. They show a higher degree of complexity allocating these cases to the group of cases with more than three abnormalities. In summary in cases with complex changes there is a direct correlation between the number of abnormalities and the worsening of prognosis (Fig.€5.6) [6, 133].
Cytogenetics Within the IPSS The IPSS includes the number of peripheral cytopenias, bone marrow blast count and cytogenetics as major prognostic variables of risk stratification in MDS [7]. Abn.per case 0 1 2 3 >3
1,0
Cum. survival
0,8
0,6
0,4
0,2
Fig. 5.6↜渀 Kaplan-Meyer analyses of cytogenetic subgroups defined by the number of abnormalities per case (own data, adapted from [6])
0,0 0,0
100,0
200,0 months
300,0
74
D. Haase et al.
Since its implementation, the weighting of cytogenetics as compared to the other variables, was discussed [137–140]. Most recently, it was suggested that the prognostic relevance of cytogenetics as compared to the bone marrow blast count is underestimated within the IPSS [9, 136, 140]. In order to stratify the cytogenetic risk, the IPSS established six cytogenetic categories and classified them to three prognostic subgroups: favourable (normal karyotype, isolated del(5q), del(20q), -Y), unfavourable (complex abnormalities, any chromosome 7-abnormalities), and intermediate (any other abnormalities) [4]. Abnormalities with an unknown prognostic relevance are summarized within the intermediate subgroup (14% of all patients). Efforts on the improvement of the cytogenetic part of the IPSS need to focus on the characterization of these rare abnormalities. A recent work of the German-Austrian-MDS-study group was able to integrate 92.5% of all patients into 22 cytogenetic subgroups by consistent analysis of rare abnormalities [133]. The main future goal is to create a powerful prognostic tool allowing an optimized risk-stratification for patients suffering from MDS.
Therapeutic Consequences of Cytogenetics Besides allogeneic stem cell transplantation, supportive care used to be the therapeutic standard in patients with MDS. Retinoic acid and cytarabine turned out to be insufficient [141]. However, recently a remarkably high response rate of MDS patients with 5q-deletions to the immunomodulating agent lenalidomide was reported [142]. These encouraging results could be confirmed on the basis of a large multicentric trial [143]. For patients with monosomy 7 conventional intensive chemotherapy bears a high risk of early death and non-response. Even complete remissions frequently are of only short duration with a high risk of early relapse [144]. Thus patients should be treated with allogeneic stem cell transplantation whenever possible although monosomy 7 displays a dismal prognosis in relation to event free survival and relapse rates also for allogenic stem cell transplantation [145]. In recent therapy trials demethylating agents like 5-Azacytidine have turned out to be an attractive therapeutic option for MDS patients with monosomy 7 [146–148]. MDS with trisomy 8 were found to be preferentially responsive to immunosuppressive therapy. The therapeutic effect seems to be related to an indirect effect of immune suppression on the trisomy 8 clone [32, 33, 149]. Furthermore, MDS cells harbouring trisomy 8 show an overexpression of c-myc that leads to an upregulation of survivin and Cycin D1. Knockdown of survivin and Cyclin D1 can eliminate the survival advantage of these cells [33]. Cyclin D1 can also be chemically inhibited by the styryl sulfone On 01910.Na that may prove to be a targeted therapy for patients with trisomy 8 [31]. Phase I/II trials are currently ongoing. For patients with complex abnormalities “AML-like” intensive chemotherapy is not beneficial [144]. Allogeneic stem cell transplantation, the only curative option for these patients, is only feasible for a minority of individuals due to age-related
5â•… Cytogenetics of MDS
75
multimorbidity and organ dysfunctions. However, cytogenetic response has been reported to demethylating [153], deacetylating [134, 150] and immunomodulating agents [143, 151]. Further multicentric clinical trials are needed to confirm these observations.
Conclusion In MDS cytogenetics is indespensible for diagnosis, classification, prognostication and therapeutic decisions and has proven its value during the last three decades. While cytogenetic analyses at initial diagnosis of MDS are frequently performed and are now the basis of genetic research and clinical management in MDS, sequential analyses with the opportunity of studying the phenomenon of karyotype evolution are not performed systematically. New techniques like FISH of circulating CD34+ cells might help to overcome these limiations. Conventional chromosome banding has come to its ages and new methods based on fluorescence in situ hybridization have been developed and are used with increasing frequency. However, it can be concluded from comparative studies that both methods have their own advantages and disadvantages. They cannot replace each other but provide additive supplementary information. Today only their combined use enables an up to date cytogenetic analysis in MDS. The great variability of cytogenetic findings still hampers the prediction of the clinical course in individual patients. However, due to recent international cooperations substantial progress has been made towards a comprehensive cytogenetic prognostic scoring system. Very recently, novel molecular whole genome scanning technologies, comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) arrays have been introduced for a more detailed genetic characterization of MDS and other disorders. In first studies it was demonstrated that these methods can complement conventional cytogenetics as well as FISH by the detection of copy number changes and copy number-neutral loss of heterozygosity [152]. Even at this early timepoint it appears that comparable to FISH-analyses CGH- and SNP-arrays will not make conventional cytogenetics unnecessary but rather will complement the established genetic methods and thus lead to a comprehensive genetic characterization of MDS.
References ╇ 1. Haase D, Feuring-Buske M, Schäfer C, Schoch C, Troff C, Gahn B, Hiddemann W, Wörmann B (1997) Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 11:674–679 ╇ 2. Nilsson L, Astrand-Grundström I, Anderson K, Arvidsson I, Hokland P, Bryder D, Kjeldsen L, Johansson B, Hellström-Lindberg E, Hast R, Jacobsen SEW (2002) Involvement and functional impairment of the CD34+CD38-Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100:259–267
76
D. Haase et al.
╇ 3. Blau O, Hofmann WK, Baldus CD, Thiel G, Serbent V, Schümann E, Thiel E, Blau IW (2007) Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 35:221–229 ╇ 4. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, Stilgenbauer S, Knuutila S, Johansson B, Fonatsch C (2007) Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 46:494–499 ╇ 5. Steidl C, Steffens R, Gassmann W, Hildebrandt B, Hilgers R, Germing U, Trümper L, Haase D (2005) Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leukemia Res 29:987–993 ╇ 6. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kündgen A, Lübbert M, Kunzmann R, Giagounidis AAN, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395 ╇ 7. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 ╇ 8. Pozdnyakova O, Miron PM, Tang GL, Walter O, Raza A, Woda B, Wang SA (2008) Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 113:3331–3340 ╇ 9. Solé F, Luño E, Sanzo C, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Cigudosa JC, Millà F, Ribera JM, Bureo E, Martin ML, Arranz E, Florensa L (2005) Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90:1168–1178 10. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G (1985) The 5q- anomaly. Cancer Genet Cytogenet 17:189–255 11. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, Tosi S, Kasprzyk A, Cheng JF, Jaju RJ, Wainscoat JS (2002) Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 99:4638–4641 12. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR (2008) Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451:335–339 13. Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL, Walshauser MA, Martin MG, Kasai Y, Walter MJ (2009) Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 4:e4583 14. Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Bjork J, Strömberg U, Nilsson PG, Mitelman F, Hagmar L, Johansson B (2002) Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia 16:2366–2378 15. Galvan AB, Mallo M, Arenillas L, Salido M, Espinet B, Pedro C, Florensa L, Serrano S, Solé F (2010) Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia? Leukemia Res 34:1242–1245 16. Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L (1998) Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci U S A 95:3781–3785 17. Tosi S, Scherer SW, Giudici G, Czepulkowski B, Biondi A, Kearney L (1999) Delineation of multiple deleted regions in 7q in myeloid disorders. Genes Chromosomes Cancer 25:384– 392
5â•… Cytogenetics of MDS
77
18. Olney HJ, Le Beau MM (2002) The cytogenetics and molecular biology of myelodysplastic syndromes. In: Bennett JM (ed) The myelodysplastic syndromes: pathobiology and clinical management. Marcel Dekker, New York, pp€89–119 19. Chen GB, Zeng WH, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, Sloand EM, Young NS (2004) Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 104:4210–4218 20. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genet 42:665–667 21. Emanuel PD (1999) Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol 105:852–863 22. Luna-Fineman S, Shannon KM, Lange BJ (1995) Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 85:1985–1999 23. Passmore SJ, Hann IM, Stiller CA, Ramani P, Swansbury GJ, Gibbons B, Reeves BR, Chessells JM (1995) Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 85:1742–1750 24. Levine EG, Bloomfield CD (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47–84 25. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapyrelated acute myeloid leukemia. Blood 86:3542–3552 26. West RR, Stafford DA, White AD, Bowen DT, Padua RA (2000) Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood 95:2093–2097 27. Huebner G, Karthaus M, Pethig K, Freund M, Ganser A (2000) Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. Transplantation 70:688– 690 28. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann C (2005) Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 90:691–693 29. Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T (2006) Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups. Genes Chromosomes Cancer 45:1164–1168 30. Iwabuchi A, Ohyashiki K, Ohyashiki JH, Sasao I, Murakami T, Kodama A, Toyama K (1992) Trisomy of chromosome 8 in myelodysplastic syndrome: significance of the fluctuating trisomy 8 population. Cancer Genet Cytogenet 62:70–74 31. Sloand EM, Pfannes L, Reddy R, Reddy P, Groopman JS, Young NS (2007) Suppression of cyclin D1 by on 01910.Na is associated with decreased survival of trisomy 8 myelodyplastic bone marrow progenitors: a potential targetted therapy. Blood (ASH Annual Meeting Abstracts) 110:822 32. Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP, Barrett AJ, Young NS (2002) Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 100:4427–4432 33. Sloand EM, Pfannes L, Chen GB, Shah S, Solomou EE, Barrett J, Young NS (2007) CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 109:2399–2405 34. Laï JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 9:370–381
78
D. Haase et al.
35. Becher R, Carbonell F, Bartram CR (1990) Isochromosome 17q in Ph1-negative leukemia: a clinical, cytogenetic, and molecular study. Blood 75:1679–1683 36. Mc Clure RF, Dewald GW, Hoyer JD, Hanson CA (1999) Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 106:445–454 37. Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K (1995) TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85:2189–2193 38. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148–3157 39. Horiike S, Misawa S, Kaneko H, Sasai Y, Kobayashi M, Fujii H, Tanaka S, Yagita M, Abe T, Kashima K, Taniwaki M (1999) Distinct genetic involvement of the TP53 gene in therapyrelated leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 13:1235–1242 40. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T (2005) Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 43:227–238 41. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, Zelig O, Yahalom V, Paltiel O, Or R, Peretz T, Ben-Neriah S, Yehuda O, Rachmilewitz EA (1996) Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88:4296–4303 42. Douet-Guilbert N, Basinko A, Morel F, Bris MJ, Ugo V, Morice P, Berthou C, Braekeleer M (2008) Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 87:537–544 43. Bench AJ, Nacheva EP, Hood TL, Holden JL, French L, Swanton S, Champion KM, Li J, Whittaker P, Stavrides G, Hunt AR, Huntly BJP, Campbell LJ, Bentley DR, Deloukas P, Green AR (2000) Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19:3902–3913 44. Roulston D, Espinosa R, Stoffel M, Bell GI, Le Beau MM (1993) Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 82:3424–3429 45. Wang PW, Iannantuoni K, Davis EM, Espinosa R, Stoffel M, Le Beau MM (1998) Refinement of the commonly deleted segment in myeloid leukemias with a del(20q). Genes Chromosomes Cancer 21:75–81 46. MacGrogan D, Kalakonda N, Alvarez S, Scandura JM, Boccuni P, Johansson B, Nimer SD (2004) Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes Chromosomes Cancer 41:203–213 47. Douet-Guilbert N, Laï JL, Basinko A, Gueganic N, Andrieux J, Pollet B, Plantier I, Delattre C, Crépin O, Corm S, Le Bris MJ, Morel F, De Braekeleer M (2008) Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 143:716–720 48. United Kingdom Cancer Cytogenetics Group (UKCCG) (1992) Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chromosomes Cancer 5:83–88 (Erratum in: Genes Chromosom Cancer 85, 411) 49. Wong AK, Fang B, Zhang L, Guo XQ, Lee S, Schreck R (2008) Loss of the Y chromosome— an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? Arch Pathol Lab Med 132:1329–1332 50. Zhang LJ, Shin ES, Yu ZX, Li SB (2007) Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders. Chin Med J 120:2002–2005
5â•… Cytogenetics of MDS
79
51. Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K, Van Dyke DL (2000) Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 27:11–16 52. Bernasconi P (2008) Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions—a review. Br J Haematol 142:695–708 53. Xiao Z, Zhang M, Liu X, Zhang Y, Yang L, Hao Y (2006) MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Leukemia Res 30:332– 334 54. Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307–316 55. Raimondi SC, Dubé ID, Valentine MB, Mirro J, Watt HJ, Larson RA, Bitter MA, Le Beau MM, Rowley JD (1989) Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia 3:42–47 56. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ, Morris SW (1996) The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 12:265–275 57. Estey E, Trujillo JM, Cork A, O’Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S (1992) AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 6:43–48 58. Kojima K, Omoto E, Hara M, Sasaki K, Katayama Y, Nawa Y, Kimura Y, Azuma T, Takimoto H, Harada M (1998) Myelodysplastic syndrome with translocation (8;21): a distinct myelodysplastic syndrome entity or M2-acute myeloid leukemia with extensive myeloid maturation? Ann Hematol 76:279–282 59. Taj AS, Ross FM, Vickers M, Choudhury DN, Harvey JF, Barber JCK, Barton C, Smith AG (1995) t(8;21) myelodysplasia, an early presentation of M2 AML. Br J Haematol 89:890–892 60. Narayanan MN, Geary CG, Harrison CJ, Cinkotai KI, Lewis MJ (1993) Three cases of the myelodysplastic syndrome with pericentric inversion of chromosome 16. Br J Haematol 85:217–219 61. Ohyashiki K, Murakami T, Ohyashiki JH, Kawakubo K, Fujimura T, Iwabuchi A, Toyama K (1995) Double-minute chromosomes appearing in a patient with myelodysplastic syndrome with disease evolution. Cancer Genet Cytogenet 79:169–172 62. Reddy KS, Sulcova V (1997) c-myc amplification in a preleukemia patient with trisomy 4 and double minutes: review of the unique coexistence of these two chromosome abnormalities in acute myelogenous leukemia. Cancer Genet Cytogenet 95:206–209 63. Sambani C, Trafalis DTP, Vessalas G, Politis G, Peristeris P, Nakopoulou L, Giannopoulou J, Michaelidis C, Ayoutantis M, Fantelias GE (1998) Trisomy 6 and double minute chromosomes in a case of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 106:180–181 64. Mohamed AN, Macoska JA, Kallioniemi A, Kallioniemi OP, Waldman F, Ratanatharathorn V, Wolman SR (1993) Extrachromosomal gene amplification in acute myeloid leukemia; characterization by metaphase analysis, comparative genomic hybridization, and semi-quantitative PCR. Genes Chromosomes Cancer 8:185–189 65. Sait SNJ, Qadir MU, Conroy JM, Matsui SI, Nowak NJ, Baer MR (2002) Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndrome: identification of new amplification regions by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 34:42–47 66. Streubel B, Valent P, Jäger U, Edelhäuser M, Wandt H, Wagner T, Büchner T, Lechner K, Fonatsch C (2000) Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. Genes Chromosomes Cancer 27:380–386 67. Han JY, Theil KS, Hoeltge G (2006) Frequencies and characterization of cytogenetically unrelated clones in various hematologic malignancies: seven years of experiences in a single institution. Cancer Genet Cytogenet 164:128–132
80
D. Haase et al.
68. Heim S, Mitelman F (1989) Cytogenetically unrelated clones in hematological neoplasms. Leukemia 3:6–8 69. Johansson B, Billstroem R, Broberg K, Fioretos T, Nilsson PG, Ahlgren T, Malm C, Samuelsson BO, Mitelman F (1999) Cytogenetic polyclonality in hematologic malignancies. Genes Chromosomes Cancer 24:222–229 70. Kobayashi H, Kaneko Y, Maseki N, Sakurai M (1990) Karyotypically unrelated clones in acute leukemias and myelodysplastic syndromes. Cancer Genet Cytogenet 47:171–178 71. Mitelman F (1998) Catalog of chromosome aberrations in cancer, 6th edn. Wiley-Liss, New York 72. Musilová R, Michalová K, Zemanová Z, Brezinová J (1996) Multiple unrelated clones in myelodysplastic syndrome and in acute myeloid leukemia. Cancer Genet Cytogenet 88:141–143 73. Pedersen-Bjergaard J, Timshel S, Andersen MK, Andersen AS, Philip P (1998) Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases. Genes Chromosomes Cancer 23:337–349 74. Mitelman F (1991) ISCN Guidelines for cancer cytogenetics, supplement to an international system for human cytogenetic nomenclature. Karger, Basel 75. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C (2002) Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99:1909–1912 76. Trost D, Hildebrandt B, Beier M, Müller N, Germing U, Royer-Pokora B (2006) Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. Cancer Genet Cytogenet 165:51–63 77. Rücker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Frohling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H (2006) Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 24:3887–3894 78. Boultwood J, Wainscoat JS (2001) Clonality in the myelodysplastic syndromes. Int J Hematol 73:411–415 79. Cermák J, Belicková M, Krejcová H, Michalová K, Zilovcová S, Zemanová Z, Brezinová J, Sieglová Z (2005) The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. Leukemia Res 29:371–379 80. Galili N, Cerny J, Raza A (2007) Current treatment options: impact of cytogenetics on the course of myelodysplasia. Curr Treat Options Oncol 8:117–128 81. Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ (1984) Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 63:1318–1323 82. Johansson B, Mertens F, Mitelman F (1996) Primary vs, secondary neoplasia-associated chromosomal abnormalities—balanced rearrangements vs, genomic imbalances? Genes Chromosomes Cancer 16:155–163 83. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MA, Valencia A, Florensa L, Sanz GF, Haase D, Solé F (2010) Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (in press) 84. Steidl C, Schabla R, Germing U, Hildebrandt B, Noesslinger T, Pfeilstoecker M, Giagounidis A, Kunzmann R, Haas P, Luebbert M, Truemper L, Haase D (2005) Sequential cytogenetic analyses of 577 patients with myelodysplastic syndromes: correlations between initial karyotype, cytogenetic dynamics, and clinical course. Blood (ASH Annual Meeting Abstracts) 106:2531
5â•… Cytogenetics of MDS
81
╇ 85. Tricot G, Boogaerts MA, De Wolf-Peeters C, Van den Berghe H, Verwilghen RL (1985) The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 59:659–670 ╇ 86. Ghaddar HM, Stass SA, Pierce S, Estey EH (1994) Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases. Leukemia 8:1649–1653 ╇ 87. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M, Yamane Y, Inazawa J, Abe T, Kashima K (1994) N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndromes. Leukemia 8:1331–1336 ╇ 88. Horiike S, Taniwaki M, Misawa S, Abe T (1988) Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. Cancer 62:1129–1138 ╇ 89. Lai YY, Qiu JY, Zhang Y, Shi Y, He Q, Dang H, Lu DP (2004) Clinical significance of continuous karyotyping in myelodysplastic syndromes. Zhonghua Xue Ye Xue Za Zhi 25:645– 648 ╇ 90. Tien HF, Wang CH, Chuang SM, Lee FY, Liu MC, Chen YC, Shen MC, Lin KH, Lin DT (1995) Acute leukemic transformation of myelodysplastic syndrome—immunophenotypic, genotypic, and cytogenetic studies. Leukemia Res 19:595–603 ╇ 91. White AD, Hoy TG, Jacobs A (1994) Extended cytogenetic follow-up and clinical progress in patients with myelodysplastic syndromes (MDS). Leukemia Lymphoma 12:401–412 ╇ 92. Daniel CP, Ponting IL, Dexter TM (1989) Growth and development of haemopoietic cells: a deterministic process? Haematol Blood Transfus 32:172–177 ╇ 93. Kanamaru A, Tamura S (1993) Application of long-term marrow cultures for studying the leukemic transformation of myelodysplastic syndromes. Leukemia Lymphoma 11:345–352 ╇ 94. Tamura S, Kanamaru A, Takemoto Y, Kakishita E, Nagai K (1993) Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukemia with trilineage myelodysplasia and with myelodysplastic remission marrow. Br J Haematol 84:219–226 ╇ 95. Michalová K, Cermák J, Brezinová J, Zemanová Z (1999) Double minute chromosomes in a patient with myelodysplastic syndrome transforming into acute myeloid leukemia. Cancer Genet Cytogenet 109:76–78 ╇ 96. Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, Toyama K (1994) Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 54:3557–3560 ╇ 97. Pinheiro RF, de Sá Moreira ED, Silva MRR, Alberto FL, Chauffaille M (2008) FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet 183:89–93 ╇ 98. Lorenzo F, Nishii K, Mortma F, Kuwagata S, Usui E, Shiku H (2006) Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Leukemia Res 30:1235–1239 ╇ 99. Mori N, Morosetti R, Hoflehner E, Lübbert M, Mizoguchi H, Koeffler HP (2000) Allelic loss in the progression of myelodysplastic syndrome. Cancer Res 60:3039–3042 100. Harada S, Komatsu H, Seto M, Ni HP, Xu JH, Hayami Y, Tsuboi K, Wakita A, Nitta M, Kato T, Ueda R (1998) Microsatellite instability is rare in the clinical course of myelodysplastic syndrome studied with DNA from fresh and paraffin embedded tissues. J Cancer Res Clin Oncol 124:231–235 101. Maeck L, Haase D, Schoch C, Hiddemann W, Alves F (2000) Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations. Br J Haematol 109:842–846 102. Tasaka T, Lee S, Spira S, Takeuchi S, Hatta Y, Nagai M, Takahara J, Koeffler HP (1996) Infrequent microsatellite instability during the evolution of the myelodysplastic syndrome to acute myelocytic leukemia. Leukemia Res 20:113–117 103. Braulke F, Schanz J, Jung K, Shirneshan K, Schulte K, Schuetze C, Steffens R, Truemper L, Haase D (2010) FISH analysis of circulating CD34+ cells as a new tool for genetic monitor-
82
104.
105.
106.
107.
108.
109. 110.
111.
112.
113. 114. 115. 116.
D. Haase et al. ing in MDS: verification of the method and application to 27 MDS patients. Leukemia Res 34:1296–1301 Morel P, Hebbar M, Laï JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7:1315–1323 Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, Hirashima K, Hotta T, Kuramoto A, Kuriya S, Miyazaki T, Kakishita E, Mizoguchi H, Okada M, Shirakawa S, Takaku F, Tomonaga M, Uchino H, Yasunaga K, Nomura T (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7:499–508 Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD (1986) Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosome 5 and chromosome 7. J Clin Oncol 4:325–345 Andersen MK, Pedersen-Bjergaard J (2000) Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere. Leukemia 14:105–111 Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J (2001) Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 31:33–41 Andersen MK, Christiansen DH, Pedersen-Bjergaard J (2005) Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML. Leukemia 19:197–200 Bernasconi P, Cavigliano PM, Boni M, Calatroni S, Klersy C, Giardini I, Rocca B, Crosetto N, Caresana M, Lazzarino M, Bernasconi C (2003) Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 17:2107–2112 Rigolin GM, Bigoni R, Milani R, Cavazzini F, Roberti MG, Bardi A, Agostini P, Della Porta M, Tieghi A, Piva N, Cuneo A, Castoldi G (2001) Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 15:1841–1847 Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F (2008) Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q. Haematologica 93:1001–1008 Trost D, Hildebrandt B, Müller N, Germing U, Royer-Pokora B (2004) Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics. Leukemia Res 28:171–177 Shen Y, Xue Y, Li J, Guo Y, Pan J, Wu Y (2001) Detection of monosomy 7 or 7q- in cases of myelodysplastic syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 18:255–258 Jakovleva K, Ogard I, Arvidsson I, Jacobsson B, Swolin B, Hast R (2001) Masked monosomy 7 in myelodysplastic syndromes is uncommon and of undetermined clinical significance. Leukemia Res 25:197–203 Panani AD, Pappa V (2005) Hidden chromosome 8 abnormalities detected by FISH in adult primary myelodysplastic syndromes. In Vivo 19:979–981
5â•… Cytogenetics of MDS
83
117. Romeo M, Chauffaille M, Silva MR, Bahia DM, Kerbauy J (2002) Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leukemia Res 26:993–996 118. Cherry AM, Brockman SR, Paternoster SF, Hicks GA, Neuberg D, Higgins RR, Bennett JM, Greenberg PL, Miller K, Tallman MS, Rowe J, Dewald GW (2003) Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leukemia Res 27:1085–1090 119. Slovak ML, Dewald GW (2008) International Working Group on MDS cytogenetics: October 2007 meeting report. Leukemia Res 32:1329–1332 120. Barouk-Simonet E, Soenen-Cornu V, Roumier C, Cosson A, Laï JL, Fenaux P, Preudhomme C (2005) Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. Cancer Genet Cytogenet 157:118–126 121. Crescenzi B, La Starza R, Romoli S, Beacci D, Matteucci C, Barba G, Aventin A, Marynen P, Ciolli S, Nozzoli C, Martelli MF, Mecucci C (2004) Submicroscopic deletions in 5qassociated malignancies. Haematologica 89:281–285 122. Li JY, Xiao B, Chen LJ, Pan JL, Xu W, Qiu HR, Li L, Xue YQ (2008) An analysis of complex chromosomal aberrations in seven cases of myelodysplastic syndromes by M-FISH and whole chromosome painting. Int J Hematol 88:369–373 123. Mohr B, Bornhäuser M, Thiede C, Schäkel U, Schaich M, Illmer T, Pascheberg U, Ehninger G (2000) Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia 14:1031–1038 124. Van Limbergen H, Poppe B, Michaux L, Herens C, Brown J, Noens L, Berneman Z, De Bock R, De Paepe A, Speleman F (2002) Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes Chromosomes Cancer 33:60–72 125. Vehmeyer K, Haase D, Alves F (2001) Increased peripheral stem cell pool in MDS: an indication of disease progression? Leukemia Res 25:955–959 126. Knapp RH, Dewald GW, Pierre RV (1985) Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clinic Proc 60:507–516 127. Billström R, Thiede T, Hansen S, Heim S, Kristoffersson U, Mandahl N, Mitelman F (1988) Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. Euro J Haematol 41:341–346 128. Nowell PC, Besa EC (1989) Prognostic significance of single chromosome abnormalities in preleukemic states. Cancer Genet Cytogenet 42:1–7 129. Pierre RV, Catovsky D, Mufti GJ, Swansbury GJ, Mecucci C, Dewald GW, Ruutu T, Vandenberghe H, Rowley JD, Mitelman F, Reeves BR, Alimena G, Garson OM, Lawler SD, de la Chapelle A (1989) Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 40:149–161 130. Giagounidis AAN, Germing U, Aul C (2006) Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 12:5–10 131. Steidl C, Schanz J, Le Beau MM, Bennett JM, Germing U, Greenberg PL, Haase D (2007) Coalescence of the German-Austrian and IMRAW cytogenetic MDS databases: modification of patient risk groups. Blood (ASH Annual Meeting Abstracts) 110:2468 132. Schanz J, Slovak ML, Ohyashiki K, Solé F, Mallo MD, Steidl C, Pfeilstoecker M, Noesslinger T, Hildebrandt B, Luebbert M, Andersen MK, Giagounidis A, Valent P, Fonatsch C, Germing U, Haase D (2008) New prognostic data on rare cytogenetic abnormalities in MDS: a collaborative study of the international working group on MDS cytogenetics. Blood (ASH Annual Meeting Abstracts) 112:2688 133. Schanz J, Tuechler H, Solé F, Mallo M, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstoecker M, Noesslinger T, Valent P, Giagounidis A, Luebbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg PL, Germing U, Haase D (2009) Cytogenetic risk features in MDS-update and present state. Blood (ASH Annual Meeting Abstracts) 114:1084
84
D. Haase et al.
134. Braulke F, Schanz J, Steidl C, Truemper LH, Haase D (2007) FISH-Analyses of cirulating CD34+cells in MDS-Patients—a suitable method to measure and predict response to 5-azacytidinie. Blood (ASH Annual Meeting Abstracts) 110:2466 135. Nowell PC, Besa EC, Stelmach T, Finan JB (1986) Chromosome studies in preleukemic states. V. Prognostic significance of single versus multiple abnormalities. Cancer 58:2571– 2575 136. Schanz J, Estey EH, Steidl C, Germing U, Hildebrandt B, Garcia-Manero G, Kantarjian HM, Haase D (2007) Multivariate analysis suggests that the prognostic impact of poor cytogenetics is potentially underestimated in the IPSS. Blood (ASH Annual Meeting Abstracts) 110:248 137. Bennett JM (2005) A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 32:S3–S10 138. Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, Park CJ, Seo EJ, Lee KH (2003) Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 17:305–313 139. Müller-Berndorff H, Haas PS, Kunzmann R, Schulte-Mönting J, Lübbert M (2006) Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol 85:502–513 140. Steidl C, Schanz J, Pfeilstoecker M, Noesslinger T, Hildebrandt B, Kuendgen A, Luebbert M, Kunzmann R, Giagounidis A, Aul C, Truemper L, Krieger O, Stauder R, Mueller T, Wimazal F, Valent P, Fonatsch C, Germing U, Haase D (2007) Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. Clin Leukemia 1:353–356 141. Giagounidis AAN, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M, Heinsch M, Aul C (2005) Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31–q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol 84:389–394 142. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549–557 143. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R, Myelodysplastic S (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465 144. Knipp S, Hildebrand B, Kundgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U (2007) Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110:345–352 145. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA, Barnett MJ (1998) Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92:1910–1917 146. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR, International Vidaza High-Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232 147. Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NSB, Mufti GJ (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937–1944
5â•… Cytogenetics of MDS
85
148. Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M (2007) Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 110:1080–1082 149. Sloand EM, Yong ASM, Ramkissoon S, Solomou E, Bruno TC, Kim S, Fuhrer M, Kajigaya S, Barrett AJ, Young NS (2006) Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A 103:14483–14488 150. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425 151. Giagounidis AAN, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C (2005) Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84:569–571 152. Maciejewski JP, Mufti GJ (2008) Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 112:965–974 153. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following lowdose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349–357
Chapter 6
Molecular Changes in Myelodysplastic Syndrome Florian Nolte and Wolf-K. Hofmann
Introduction Myelodysplastic syndromes (MDS) are heterogenous diseases which are characterized by ineffective hematopoiesis with an increased risk of evolution to acute myeloid leukemia (AML). Diagnosis of MDS is mainly based on morphological findings and cytogenetical analyses. However, little is known about the underlying pathomechanisms causing MDS. MDS in early stages with relatively slow progression to AML might be a prototype of the multistep concept in leukemogenesis with accumulation of cellular and molecular defects during initiation and disease progression. The model of Knudson postulates ‘two hits’ that are required for the development of cancer, e.g. MDS and consecutive AML. This concept bases on the observation in hereditary cancers, that loss or inactivation of one allele rarely is sufficient to result in the development of tumors or expansion of a malignant clone but loss of the corresponding allele or additional alterations are necessary for the penetrance of clonal cells [36]. Since conventional cytogenetics show structural or numerical aberrations in about 50% of MDS patients only, introduction of array based techniques in research was logical and necessary to identify more subtle genomic changes such as cryptic deletions, regions of loss of heterozygosity and uniparental disomy. Moreover, since gene silencing by DNA methylation has been recognized as an important feature in the initiation and progression of human cancer, the development of high density methylation arrays provides the possibility to analyze the methylation status of a vast amount of CpG islands of promoters of (tumor suppressor) genes and genes with a so far unknown role in leukemogenesis.
F. Nolte () Department of Hematology and Oncology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany Tel.: +49-621-383-6955 Fax: +49-621-383-6969 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_6, ©Â€Springer Science+Business Media B.V. 2011
87
88
F. Nolte and W.-K. Hofmann
In the following article we will summarize and describe what is known about molecular changes in MDS and will in particular focus on the ‘new’ high throughput techniques.
onventional Cytogenetics and Fluorescence C In Situ Hybridization Chromosomal aberrations can be detected by conventional metaphase cytogenetics in about 50% of MDS cases. Detection of cytogenetic abnormalities is of prognostic and therapeutic relevance since it has been demonstrated that different abnormalities are associated with varying risks of evolution to AML and have a strong impact on the overall survival in these patients. Moreover, response to certain drugs has been linked to the presence of specific chromosomal aberrations in MDS such as deletion on the long arm of chromosome 5 or monosomy 7. Noteworthy, application of fluorescence in situ hybridization has been shown to provide additional information in MDS patients when conventional cytogenetics was unsuccessful but is of little value when applied in case of a cytogenetically normal karyotype [9]. The different chromosomal aberrations and their consequences are extensively discussed in this book by G. Mufti and D. Haase.
lteration of Signal Transduction and Transcription A Factors Alteration of the RAS Pathway The RAS subfamily consists of the H-, N- and K-RAS genes (along with the RAL and RAP genes). Activating mutations, predominantly of N-RAS (in codons 12, 13 and 61) and less often of K-RAS (in codons 12 and 61), have been found in 10–15% of MDS but up to 40% in more advanced cases, and 15–25% of AML cases. Activation of RAS proteins leads to stimulation of its downstream targets with consecutive activation of transcription factors such as NF-IL6, ELK-1, c-Jun and c-Myc. MDS with mutant N-RAS may be associated with a worse prognosis. Moreover, RAS mutations have been linked to the progression to AML [3, 51, 55–57].
JAK2 Mutations Among the Jak kinase family JAK2 has recently gained a lot of interest since it seems to play a crucial role in the pathogenesis of myeloproliferative syndromes (MPS). Several groups [4, 32, 35] identified a valine to phenylalanin substitution at amino acid position 617 of JAK2 (JAK2V617F). This amino acid substitution is
6â•… Molecular Changes in Myelodysplastic Syndrome
89
due to a G-to-T alteration in exon 12 of JAK2 which is located on the short arm of chromosome 9 [4]. Cells carrying JAK2V617F show a hypersensitivity to cytokines due to a constitutive phosphorylation activity of the kinase that promotes cytokine hypersensitivity [32]. JAK2V617F mutations are infrequent in typical MDS and are found in about 5% of cases [63, 68] (as compared to polycythaemia vera, essential thrombocythaemia and idiopathic myelofibrosis in which JAK2 is mutated in 97, 57 and 50% of cases, respectively). However, JAK2V617F is frequently found in the so called refractory anaemia with ringed sideroblasts and thrombocytosis (RARS-T) and is present in >60% of cases [6, 31, 62, 63, 68, 73, 74]. This entity contributes to the subgroup of overlapping syndromes MDS/MPS of the WHO classification presenting with both hallmarks of myelodysplastic and myeloproliferative syndromes. However, it still remains controversial whether RARS-T corresponds to two different simultaneous entities or to a unique disease.
AML1 Gene The human AML1 gene (also known as CBFA2 or RUNX1) encodes for one of two subunits of the human core binding factor (CBF). It is located on chromosome 21q22. AML1 is normally expressed in all hematopoietic lineages and acts to regulate the expression of various genes playing a pivotal role in myeloid differentiation [30]. Mutations of AML1 occur in about 25% of AML cases (mainly in AML-M0) and are frequently observed in MDS with excess of blasts [24]. Since sole loss of function of AML1 due to AML1 mutations has been shown not to be sufficient to induce MDS/ AML alone second hit events such as epigenetic alterations (methylation, deacetylation) could promote the development of AML1 mutation positive MDS/AML.
EVI1 Gene Ecotropic viral integration site 1 (EVI1) gene encodes for a large nuclear protein which has been shown to act as an aggressive oncoprotein. It is located on chromosome 3q26.2. There exist two forms of EVI1: the 145€kDa EVI1 gene and the larger MDS1/EVI1 gene which is a result of an in-frame splicing. EVI1 and MDS1/EVI1, respectively, are expressed in hematopoietic cells [54]. An inappropriate expression has been implicated in the development and progress of myeloid disorders, either AML or MDS [53]. Overexpression of EVI1 can result from 3q26 rearrangements such as translocations or inversions. However, several groups reported the frequent over expression of EVI1 in MDS without structural alteration of 3q26 [64, 75]. In MDS as in AML patients, EVI1 expression is a very poor prognostic marker and is associated with severe erythropoietin (EPO)-unresponsive anemia [61]. However, the mechanisms by which EVI1 alters gene expression and influences the biology of the disease are not yet fully understood.
90
F. Nolte and W.-K. Hofmann
p53 Gene Alterations of the p53 gene occur in about 10% of MDS [41]. Changes are usually missense mutations of one allele with the second allele being lost. These mutations usually prevent the protein from being able to bind to DNA thus losing its ability to transactivate target genes such as the cyclin dependent kinase inhibitor (CDKI) p21WAF2. Mutations of p53 are associated with progression of the disease and poor prognosis.
TET2 Gene Several groups reported a high frequency of mutations of the tet oncogene family member 2 gene (TET2) in MDS and other myeloid malignancies. TET2 is mapped to chromosome 4q24 and frequently lies within a region of uniparental disomy as detected by SNP arrays. In MDS, TET2 mutations have been detected in 6–30% of MDS cases. Of importance, TET2 mutations have been identified as an independent favorable prognostic marker in MDS. Kosmider and co-workers [37] recently found that TET2 mutations in MDS were associated with a better overall survival after 5€years (77% with TET2 mutations [95% CI: 49–91] vs. 18% without TET2 mutations [95% CI: 4–41]) and a better 3-year leukemia-free survival in TET2 mutated patients (89% [95% CI: 63–97] vs. 63% [95% CI: 48–75]). In addition, the same group provided evidence, that TET2 mutations are in particular frequently found in patients with chronic myelomonocytic leukemia (CMML) [38]. However, the function of TET2 in normal hematopoiesis and leukemogenesis remains unclear. Since TET1 displays demethyl transferase activity TET2 might contribute to the pathogenesis of MDS by altering epigenetic patterns.
Epigenetic Alterations DNA Methylation and Histone Acetylation Methylation of CpG islands within gene promoters is a major epigenetic transcriptional control mechanism that is frequently dysregulated in human cancer and plays a critical role in the transcriptional silencing of tumor suppressor genes in cancer [26]. Several fundamental biological processes can be affected by this epigenetic event in human cancer such as DNA repair, cell cycle control, apoptosis and detoxification. Hypermethylation of CpG islands of genes involved in cell cycle control and apoptosis is a common feature particularly in high risk MDS. The cyclin dependent kinase inhibitors p15INK4b and p16INK4a are rarely mutated or deleted [50], but
6â•… Molecular Changes in Myelodysplastic Syndrome
91
transcription of the p15INK4b gene is often silenced due to abnormal methylation of its promoter region and several studies indicate that roughly 50% of MDS patients show this alteration [59, 71]. Hopfer and co-workers [29] performed lineage specific promoter methylation analysis of key regulator genes involved in cell cycle control, DNA repair, apoptosis and differentiation. They could demonstrate an association of the methylation status of p16, survivin, CHK2 and WT1 with IPSS risk types. Moreover, for specific hematopoietic lineages and differentiation stages a methylation associated mRNA downregulation was shown, which provides evidence that lineage specific methylation followed by gene silencing contributes to MDS specific phenotypes and possibly to the different courses of MDS entities. DNA methylation seems to play a critical role in the progression of MDS into ouvert AML. Jiang and co-workers [34] used DNA methylation microarrays and compared the methylation status of early MDS samples to advanced MDS and AML samples and found an increase of methylated CpG loci in the MDS/AML group. Interestingly, chromosomal aberrations detected by SNP analysis showed no dramatic increase during progression (79% of early stage and 90% of advanced stage MDS). This led to the suggestion, that DNA methylation might be the dominant mechanism for MDS evolution to AML. In contrast to genetic deletions silencing of genes by DNA methylation is a reversible process and the introduction of demethylating agents (e.g. 5-azacytidine and 5-aza-2′-deoxycytidine) in the treatment of high risk MDS yielded encouraging results [10, 13, 66] by improving hematopoiesis and prolonging the survival time. Acetylation of amino acids of the histones catalyzed by histone acetyltransferases (HAT) leads to a destabilization of the histone-DNA interaction which in turn leads to an opening of the nucleosome structure and consecutively to a permission of transcription. These acetyl groups can be removed from histones by histone deacetylases (HDAC) which leads to a stabilization of the local chromatin structure and renders affected promoter sequences inaccessible resulting in silencing of genes in this region [14]. HDAC inhibitors such as valproic acid (VPA) were able to induce differentiation and apoptosis of leukemic cell lines in vitro. Kuendgen et€al. [39, 40] showed that VPA has some effect in MDS. Response rates were high (50%) in patients with a normal blast count in the bone marrow and a low IPSS score. Moreover, since it has been shown that DNA methylation and histone acetylation are closely connected, there is evidence that combination of VPA with demethylating agents has additional effects in advanced stages of MDS and AML [5, 19].
Array Comparative Genomic Hybridization (aCGH) in MDS Array comparative genomic hybridization (aCGH) is based on the comparison of fluorescence intensities between a test sample (e.g. MDS) and a reference sample (e.g. healthy) allowing for identification of copy number changes due to structural variations such as microdeletions.
92
F. Nolte and W.-K. Hofmann
In MDS aCGH can provide additional information by identifying cryptic lesions in MDS patients. In 56% (17/30) of MDS patients Slovak and co-workers found new cytogenetic aberrations [67]. Moreover, in three patients cryptic RUNX1 deletions were found at the time of progression to AML, which underscores the importance of these high density approaches in the further characterization of MDS and identification of prognostic markers and therapeutic targets.
Single Nucleotide Polymorphism (SNP) Analysis in MDS As mentioned above, conventional cytogenetics yield genetic aberrations in only 50% of MDS patients. This may be due to the low resolution of routine metaphase cytogenetics. Moreover, metaphase karyotyping is restricted to dividing cells. Undisputable, the introduction of interphase fluorescent in situ hybridization (FISH) improved cytogenetic analysis. However, FISH utilizes a limited number of probes directed to already known lesions and therefore new chromosomal defects can not be detected. The introduction of high density single nucleotide polymorphism (SNP) microarrays offer the opportunity to perform a global analysis of genomic DNA and provide the possibility to detect so far cryptic lesions since they cover the whole genome and the resolution is much higher irrespective to cell division. Moreover, whole genome analysis by SNP microarrays allows for the detection of loss of heterozygosity (LOH) which arises either via hemizygous deletion, where a DNA segment is lost from one homolog while the other remains at one copy per cell, or uniparental disomy (UPD), wherein the retained homolog is duplicated so as to preserve two total copies per cell at the locus. Both types of somatic LOH have been observed in studies of various cancer types and may explain some of the mechanisms by which tumor suppressor genes are inactivated or activating mutations duplicated. Thus, analysis of recurrent LOH may point toward the presence of important recurrent mutations. Uniparental disomy (UPD) was initially described in developmental disorders. UPD occurs when an individual inherits both copies of chromosome pair from one parent and no copy from the other parent. If the two chromosome copies originate from the father it is called paternal UPD, if it originates from the mother it is called maternal UPD. UPD can occur either as a heterodisomy, in which sequences from both homologues from the transmitting parent are present or as isodisomy which refers to the situation in which two identical segments from the same homologue are present (see Fig.€6.1). In case of germline isodisomy two copies of a recessive mutation can be transmitted, which might result in pathological states. For several diseases homozygosity for a recessive mutation has been described such as cystic fibrosis, hemophila A and congenital adrenal hyperplasia. Heterodisomy as a result of germline alterations can cause abnormalities when the genes within the involved region are imprinted genes. Imprinting describes dif-
6╅ Molecular Changes in Myelodysplastic Syndrome Fig. 6.1↜渀 Uniparental disomy (UPD). UPD can occur due to somatic aberrations either by incomplete mitotic segregation or mitotic recombination. The most frequent mechanism leading to UPD is mitotic recombination, which can lead to UPD of a whole arm of a chromosome, of a part of an arm spanning to the telmere
93
Both parental alleles present
Mitotic recombination
UPD of a whole arm or part to telomere
ferential gene expression which is dependent and specific for the transmitting parent. Disruption of normal imprinting due to UPD has been shown to play a role in several syndromes, such as the Prader-Willi syndrome and the Beckwith-Wiedemann syndrome. Beside the above mentioned germline alterations, UPD can occur due to somatic aberrations either by incomplete mitotic segregation or mitotic recombination. In case of UPD, the karyotype of affected patients appears normal when examined by conventional cytogenetics. This might be one reason why UPD played a minor role in concepts and models of tumorigenesis in the pre-microarray era. The introduction of microarrays allowed to perform high density whole genome SNP analysis and identification of regions displaying copy number changes and regions of copy number neutral changes such as UPD. UPD has been described in various myeloid and lymphoid malignancies and other neoplasms [15, 17, 23, 49, 60, 70].
94
F. Nolte and W.-K. Hofmann
By using 250€K Sty chips Heinrichs et€al. [25] found regions of UPD in 6 out of 33 patients with MDS. Four patients had a normal bone marrow karyotype (in conventional cytogenetics), one patient had a complex karytype and one showed a t(11; 19) translocation. Since all regions of UPD extended entirely to the telomere Heinrichs et€al. suggested, that these regions of UPD resulted from a single recombination event. Remarkably, two patients with a normal karyotype showed regions of UPD on chromosome 7q. Moreover, although these patients had a low risk disease according to IPSS, they showed a deteriorating clinical course, underscoring that aberrations on chromosome 7 lead to a worse outcome. In addition, the presence of cytogenetically indetectable aberrations in MDS even in low risk patients could at least in part explain the wide intra-subtype variations concerning the prognosis despite patients belonging to the same IPSS risk group as impacted by conventional cytogenetics. Moreover, in an additional patient with a normal karyotype a UPD on 3q (the EVI1 gene is mapped to this region) was found and one patient with a complex karytype haboured a UPD on chromosome 17p both of which known to be associated with an adverse prognosis when cytogenetically abnormal. However, no follow up data about these two patients were reported. Compared to other groups, Heinrichs and co-workers [25] found less genomic changes in MDS with a normal ‘conventional’ karyotype and attributed this discrepancy to the lack of paired normal DNA samples in most previous analyses resulting in the detection of inherited copy number changes or regions of apparent homozygosity as somatically acquired genomic alterations within the MDS clone. Table€6.1 gives a brief overview of some regions of UPD in MDS reported so far. Langemeijer and co-workers [42] performed an extensive survey on 102 patients with MDS by using 250€K Nsp chips and sequencing techniques. In five patients they found large aberrations on the long arm of chromosome 4, four of them showed a UPD in this region and one a monoallelic deletion. These alterations could not be detected in a cohort of 1,015 healthy controls. Since the TET2 gene maps to the long arm of chromosome 4 all MDS samples were sequenced for TET2 mutations, which revealed TET2 mutations in 27 of 102 MDS patients (26%). The TET2 gene is ubiquitously and highly expressed in hematopoietic cells with the highest expression in granulocytes. Therefore, TET2 is suggested to function as a tumor suppressor gene. The exact function, however, remains elusive. The highest frequency of UPD in MDS has been reported by Mohamedali et€al. [47]. In 49% of 199 MDS patients they could detect regions of UPD of at least 2€Mb. UPD were most frequent in low risk MDS patients compared to high risk MDS. Furthermore, the same group has recently published data about the high prevalence of TET2 mutations in patients carrying a UPD4q [48]. Of nine patients four displayed a UPD4q24 (all of them had RCMD-RS) and one patient with a refractory anemia (RA) showed a UPD4q28. All of the RCMD-RS patients carried a major TET2 clone, whereas the patient with RA only yielded a very small TET2 mutated clone (13%). Since in CD3+ lymphocytes of one patient a small TET2 background clone was also detectable, it was suggested that TET2 mutations might be rather a first hit according to the Knodson model. Furthermore, Mohamedali et€al. [48]
6â•… Molecular Changes in Myelodysplastic Syndrome
95
Table 6.1↜渀 Regions of uniparental disomy as detected by SNP array analysis in MDS Langemeijer Gondek et€al. Nowak et€al. Mohamedali Heinrichs [21] [52] et€al. [47] et€al. [42] et€al. [25] System used 250€K (Sty) 250€K (Nsp) 250€K (Nsp) 500€K 250€K (Sty) (Nsp+Sty) 500€K (Nsp+Sty) No. of patient 51 (according 102 (according 94 (according 13 (according 119 (according analyzed to WHO) to FAB) to WHO) to FAB) to WHO) 33 (65%) 62 (60%) 38 (40%) 9 (69%) 77 (65%) No. of pts. with normal karytype (NC) (%) UPD total 6 (12%) 9 (9%) 18 (19%) 13 (100%) 55 (46%) (%) 4 (12%) 5 (8%). 8 (21%) 9 (100%) 80 (67%) UPD in NC (%) UPD 7q in NC 2 (6%) 2 (3%) 1 (3%) – – (%) Total UPD4q – 4 (4%) – – 7 (9%) (%) UPD4q in NC 1 (3%) 2 (3%) – – – (%) UPD3q in NC 1 (3%) – 1 (3%) – – (%) – means either not done or no exact data available
hypothesized that TET2 mutations might be restricted to RCMD-RS patients based on the observation that RCMD-RS patients were exclusively affected in their cohort. However, other groups found a high frequency in other myeloid malignancies suggesting that TET2 mutations might be a common initiating defect in myeloid neoplasms. Jankowska and co-workers [33] found TET2 frequently mutated not only in MDS but especially in patients with overlap syndromes (MDS/myeloproliferative neoplasia [MPN]) and secondary AML, a finding which is in accordance to data published by other groups [1, 21]. In conclusion, although only few data on SNP analysis by high throughput techniques have been published, the data reported so far are encouraging, since the use of SNP arrays led to the identification of new genomic alterations and in case of the TET2 gene discovered a new tumor suppressor gene possibly involved in myeloid malignancies.
Gene Expression Analysis by Microarrays in MDS As mentioned previously, diagnosis of MDS relies on morphological and cytogenetical findings. However, morphological diagnosis is often difficult in MDS and depends on the experience of the hematologist and pathologist and in about 50% of
96
F. Nolte and W.-K. Hofmann
MDS cases conventional cytogenetics show a normal karyotype. Gene expression profiling (as SNP analysis or methylation analysis) holds the promise to base the diagnosis on objective criteria such as gene expression patterns and become autonomous from observer-dependent criteria such as blast count and degree of dysplasia. Recently, Mills and co-workers [45] assessed the clinical utility of a microarraybased gene expression profiling (GEP) assay in the diagnosis and subclassification of 16 clinically recognized subtypes of acute and chronic leukemia and found an accuracy for subtyping leukemia of approximately 95%. However, the accuracy concerning MDS subtyping was only 50% whereas discordant samples were either classified as leukemia or “non-of-the-targets” (neither leukemia nor MDS). Interestingly, patients that were categorized as MDS by conventional diagnostics (morphology, cytogenetics) but classified as AML by GEP showed a deteriorating course of their disease with a rapid development of AML. Beside diagnosis, microarray techniques provide the possibility to identify genomic changes not detectable by conventional molecular approaches. Moreover, it has become clear, that altered gene expression of oncogenes or tumor suppressor genes, respectively, is not necessarily due to loss or gain of genetic material (i.e. deletions or amplifications) but a result of promoter methylation or histone deacetylation. Gene expression analysis by high density microarrays became powerfull tools to further elucidated the pathobiology not only of MDS but other hematologic malignancies and cancers. By performing gene expression analysis of isolated CD34+ cells from 122 MDS patients Pellegatti et€al. [58] identified the lymphoid enhancer-binding factor 1 (LEF1) as the most significant differentially expressed gene between early and advanced MDS. Decreasing LEF1 expression levels were associated with disease evolution and Pellagatti et€al. [58] suggested LEF1 as a molecular marker of disease progression. Several attempts have been and will be undertaken to identify gene expression patterns that could predict whether patients will respond to a certain drug or benefit from a chosen treatment. We and others have shown that microarray analysis can provide sufficient data to detect genes or gene patterns which are associated with alterations of specific cellular pathways or signal cascades in tumor cells including MDS [28, 43, 46]. The technique of gene expression profiling can also be used for subclassification of leukemias [65] and lymphomas [2]. However, the rapid progress in microarray techniques might further improve this direction of molecular diagnosis.
Next Generation Sequencing (NGS) The classical automated Sanger sequencing technique has led to major accomplishments in molecular research including the completion of the human genome sequence. Automated Sanger sequencing is referred to as the “first generation”
6â•… Molecular Changes in Myelodysplastic Syndrome
97
technology. Development of newer technologies (referred to as “next generation”) provide the possibility to cheaply sequence the whole genome of many different individuals for example MDS patients in an attempt to enhance our understanding of how (subtle) genetic differences affect health and disease. Different NGS platforms do exist that differ with regard to template preparation procedures (emulsion PCR, solid-phase amplification etc.) and sequencing and imaging techniques (cyclic reversible termination, pyrosequencing etc.). Interested readers are directed to the excellent review by Metzker [44]. The possible impact these new techniques might have on the further research and classification of MDS was recently demonstrated by Grossmann and co-workers who screened 81 patients with chronic myelomonocytic leukemia for oncogene aberrations including the CBL, RUNX1, JAK2, MPL, KRAS, NRAS and TET2 gene [22]. In 12 of these patients known mutations detected by conventional methods (conventional sequencing or melting curve analyses) could be confirmed by NGS. Moreover, in patients without any known mutation either point mutations or large deletions were identified in all candidate genes. In only 20 of 81 CMML patients no mutation could be detected by NGS. These results give an impression what will be possible in the future in further molecular characterization of the MDS and other malignant diseases.
Summary MDS are heterogenous diseases. Several molecular aberrations have been described but none of them are specific for MDS only but occur in other myeloid neoplasms as well (see Table€6.2). The introduction of high-throughput technologies will enable researchers to go into further molecular detail aiming at the identification of subtle molecular defects which will hopefully lead to elucidation of underlying alterations and discovery of potential therapeutic targets. Table 6.2↜渀 Frequent gene mutations in MDS and other myeloid malignancies Gene Myeloid entity MDS AML MPN CMML TET2 JAK2 RAS AML1 ASXL1
10–25% [33, 37] 3% [63, 68] 10–15% [57] 15% [24] 11–17% [7]
12% [11] <5% [72] 15–25% [51] 13–25% [69, 24] 18% [7]
10–15% [11] 74% [35] 0% [18, 27] – 8% [8]
20–40% [11, 37] 6% [35] 57% [27] 19% [12] 43% [20]
RARS-T 26% [16] 79% [63, 68] – – 8% [68]
98
F. Nolte and W.-K. Hofmann
References ╇ 1. Abdel-Wahab O et€al (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144–147 (July) ╇ 2. Alizadeh AA et€al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511 (Feb) ╇ 3. Bacher U et€al (2007) A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92:744–752 (June) ╇ 4. Baxter EJ et€al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061 (March) ╇ 5. Blum W et€al (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884–3891 (Sept) ╇ 6. Boissinot M et€ al (2006) The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 108:1781–1782 (Sept) ╇ 7. Boultwood J et€al (2009) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukaemia. ASH Annu Meet Abstr 114:419 (Nov) ╇ 8. Carbuccia N et€al (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183–2186 (Nov) ╇ 9. Costa D et€al (2010) Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do? Leuk Res 34(11):1437–1441 10. Daskalakis M et€al (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957–2964 (Oct) 11. Delhommeau F et€al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289– 2301 (May) 12. Ernst T et€ al (2010) Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 95(9):1473–1480 (April) 13. Fenaux P et€al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232 (March) 14. Fenrick R, Hiebert SW (1998) Role of histone deacetylases in acute leukemia. J Cell Biochem Suppl 30–31:194–202 15. Fitzgibbon J et€al (2005) Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65:9152–9154 (Oct) 16. Flach J et€al (2010) Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica 95:518–519 (March) 17. Forconi F et€al (2008) Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol 143:532–536 (Nov) 18. Gaidano G et€ al (1993) Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders. Leukemia 7:946–953 (July) 19. Garcia-Manero G et€al (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271–3279 (Nov) 20. Gelsi-Boyer V et€al (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788–800 (June) 21. Gondek LP et€al (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534–1542 (Feb)
6â•… Molecular Changes in Myelodysplastic Syndrome
99
22. Grossmann V et€al (2009) Next-generation sequencing (NGS) in CMML, MDS and AML detects molecular mutations in oncogenes and allows the identification of balanced chromosomal abnormalities with extraordinary sensitivity and specificity. ASH Annu Meet Abstr 114:144 (Nov) 23. Gupta M et€al (2008) Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 47:729–739 (Sept) 24. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, and Inaba T (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103:2316–2324 25. Heinrichs S et€al (2009) Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23:1605– 1613 (Sept) 26. Herman JG, and Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054 27. Hirsch-Ginsberg C et€al (1990) RAS mutations are rare events in Philadelphia chromosomenegative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76:1214–1219 (Sept) 28. Hofmann WK et€al (2002) Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100:3553–3560 (Nov) 29. Hopfer O et€al (2009) Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res 33:434–442 (March) 30. Ichikawa M et€al (2004) Runx1/AML-1 ranks as a master regulator of adult hematopoiesis. Cell Cycle 3:722–724 (June) 31. Ingram W et€al (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 20:1319–1321 (July) 32. James C et€al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148 (April) 33. Jankowska AM et€al (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113:6403–6410 (June) 34. Jiang Y et€al (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315–1325 (Feb) 35. Jones AV et€al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168 (Sept) 36. Knudson AG (1996) Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 122:135– 140 37. Kosmider O et€ al (2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDS). Blood 114:3285–3291 (Aug) 38. Kosmider O et€ al (2009) TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 94(12):1676–1681 (Oct) 39. Kuendgen A et€al (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266–1269 (Sept) 40. Kuendgen A et€al (2005) Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 84(Suppl 1):61–66 (Dec) 41. Lai JL et€al (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 9:370–381 (March) 42. Langemeijer SM et€al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838–842 (July) 43. Lee YT et€al (2001) Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. Blood 98:1914–1921 (Sept) 44. Metzker ML (2010) Sequencing technologies—the next generation. Nat Rev Genet 11:31–46 (Jan)
100
F. Nolte and W.-K. Hofmann
45. Mills KI et€al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063–1072 (July) 46. Miyazato A et€al (2001) Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98:422–427 (July) 47. Mohamedali A et€al (2007) Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110:3365–3373 (Nov) 48. Mohamedali AM et€al (2009) Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 27:4002–4006 (Aug) 49. Mullighan CG et€al (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758–764 (April) 50. Nakamaki T et€al (1997) Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes. Leuk Res 21:235–240 (March) 51. Neubauer A et€al (1994) Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83:1603–1611 (March) 52. Nowak D et€al (2009) Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500€K SNP arrays identifies significant regions of deletion and uniparental disomy. Exp Hematol 37:215–224 (Feb) 53. Nucifora G, Laricchia-Robbio L, Senyuk V (2006) EVI1 and hematopoietic disorders: history and perspectives. Gene 368:1–11 (March) 54. Ohashi H et€al (2001) Relationship between methylation of the p15 gene and ectopic expression of the EVI-1 gene in myelodysplastic syndromes (MDS). Leukemia 15:990–991 (June) 55. Padua RA, West RR (2000) Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol 111:873–874 (Dec) 56. Padua RA et€al (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12:887–892 (June) 57. Paquette RL et€al (1993) N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82:590–599 (July) 58. Pellagatti A et€al (2009) Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 146:86– 90 (June) 59. Quesnel B et€al (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985–2990 (April) 60. Raghavan M et€al (2005) Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 65:375–378 (Jan) 61. Raza A et€ al (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28:791–803 (Aug) 62. Remacha AF et€al (2006) Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 91:719–720 (May) 63. Renneville A et€al (2006) High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 20:2067–2070 (Nov) 64. Russell M et€al (1994) Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 84:1243–1248 (Aug) 65. Schoch C et€al (2002) Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 99:10008–10013 (July) 66. Silverman LR et€al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429– 2440 (May)
6â•… Molecular Changes in Myelodysplastic Syndrome
101
67. Slovak M et€ al (2009) C008 array-based comparative genomic hybridization as a clinical assay for genomic profiling in the myelodysplastic syndromes: validation by comparison with conventional cytogenetics and fluorescence in situ hybridization. Leuk Res 33:S35–S36 (May) 68. Szpurka H et€al (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108:2173–2181 (Oct) 69. Tang JL et€ al (2009) AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 114:5352–5361 (Dec) 70. Tyybakinoja A et€al (2008) Single nucleotide polymorphism microarray analysis of karyotypically normal acute myeloid leukemia reveals frequent copy number neutral loss of heterozygosity. Haematologica 93:631–632 (April) 71. Uchida T et€ al (1997) Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90:1403–1409 (Aug) 72. Vainchenker W, Dusa A, Constantinescu SN (2008) JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 19:385–393 (Aug) 73. Wang SA et€al (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 20:1641–1644 (Sept) 74. Zipperer E et€ al (2008) MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500â•›×â•›10(9)/l. Ann Hematol 87:413–415 (May) 75. Zoccola D et€al (2003) A discriminating screening is necessary to ascertain EVI1 expression by RT-PCR in malignant cells from the myeloid lineage without 3q26 rearrangement. Leukemia 17:643–645 (March)
Chapter 7
Prognostic Scoring in MDS Michael Pfeilstöcker
Introduction The management of patients with Myelodysplastic Syndromes is challenging. This is especially true in present times when a multitude of new promising therapeutic approaches becomes available and change from supportive care only to effective targeted treatment for most of the patients is on the horizon [86]. Difficulties and importance of patient assessment stems at least in part from the high degree of heterogeneity of the many different conditions grouped together under the name MDS based on common characteristics such as morphological findings or genetic changes [3, 39, 84, 89]. Lessons learned from the elucidation of pathophysiological processes as well as insights into the mechanisms of action of new therapies have to be incorporated for optimal patient management. Different pathophysiology in different patients warrants adapted treatment approaches, but choice depends not only from a possible benefit of treatment options, also possible toxicities of interventions have to be considered; the risk-benefit ratio has to be assessed using comparison with the projected natural course of the disease. Pathogenetic processes identified include genetic, epigenetic and immune-mediated mechanisms [86]. Despite these findings, diagnosis of MDS relies still mostly on morphological and clinical features. In absence of methods characterising individual pathophysiological pathways in individual patients and in the light that classifications of MDS do provide prognostic information but still leave space for improvement further instruments have been developed for estimation of patient’s prognosis or prediction of response to specific therapies. New parameters were generally described in a univariate pattern first, later incorporation in so called prognostic scores was performed. Classifications and prognostic instruments for MDS developed in the last decades reflect our ever M. Pfeilstöcker () 3rd Medical Department and L. Boltzmann Institute for Leukemia Research & Hematology, Hanusch Hospital, H. Collinstr 30, 1140 Vienna, Austria Tel.: +43-1-91021-85430 Fax: +43-1-91021-85439 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_7, ©Â€Springer Science+Business Media B.V. 2011
103
104
M. Pfeilstöcker
evolving knowledge of MDS biology and have contributed to the successful implementation of new therapies. They provide the tools for adequate risk evaluation and treatment selection.
Aims and Criteria for Prognostic Factors The aims of prognosis may be defined by several aspects: the criterion (endpoint), the conditions of prognosis (e.g. type of patients analyzed, time point of testing etc.) and the intended level of use (description of a population series or prognostication in individual patients). The most common criteria used are overall survival and leukaemia free survival [2, 7, 24, 29, 44, 54, 61, 63, 69, 71, 73] whereas most prognostic systems are not specifically adapted to one of them. Further criteria could include disease related mortality and quality of life adjusted survival time, the latter may be especially relevant to patients. Prognostic systems for MDS are almost exclusively based on data of primary and untreated patients. They describe what could be seen as the “natural course of disease”, leaving aside the considerable influence of supportive care. Implicitly this estimates a risk inherent to the disease without considering possible effects of treatment. A comprehensive prognostic system instead would allow for prognosis under different conditions, including not only disease and patient features, but therapeutic options as well [96]. Prognostic systems may be used on the level of individual prognosis or as stratification variables in clinical trials and meta analyses. For individual prognosis current systems only permit estimation within large boundaries [71]. Candidate prognostic factors should meet several criteria. The feature, its measurement and its interpretation should be precisely defined and it should be reliable to measure, common availability and easy assessment are certainly advantages. A rationale linking to clinical outcome is not imperative but desirable. As long as the resulting model is understood as prognostic, without being causally explanatory, the factor needs not to be causal. If the measurement is categorised, categories should be clinically meaningful [97]. Ideally features should be independent of therapeutic options, changing clinical rules or subjective impression of the physician (e.g. when using transfusion needs). Variability in time has to be valuated depending on the aim of the prognostic model. Long term prognosis is preferably based on relatively stable features (e.g. cytogenetics), while short term prognosis may include more condition dependent, and therefore unstable characteristics [87]. Clinical use of a prognostic system combining more than one prognostic feature requires first of all a comprehensible measure of its prognostic power [34], also the target population has to be stated [42], as otherwise physicians cannot responsibly rely on it. Further the model has to be transparent regarding its components and score assignments to prevent “double counting” or neglect of features in a clinical decision based on prognostic system and further characteristics as observed by the physician [60]. Prognostic systems
7â•… Prognostic Scoring in MDS
105
should be validated after its construction and publication, preferably by different researchers at different centers and thus on independent data [73].
Prognostic Factors in MDS A specific diagnostic parameter unequivocally establishing the diagnosis MDS is still lacking [86], such a parameter if meeting the requirements for prognostic factors as described above would represent the ideal prognostic marker. In absence of such a marker surrogate parameters are available, Table€7.1 provides an overview of prognostic markers used or proposed for MDS. Whereas some features such as bone marrow morphology parameters are clearly disease related, others such as age, gender and co-morbidity are clearly patient related. Parameters such as the performance status may be influenced by both consequences of the disease or the presence of co-morbidities. Most parameters may be subject to changes over time (evolution of the MDS disease, acquisition of further co-morbidities, increasing age), whereas others such as gender remain invariable. Parameters can be tested easily and reliably e.g. LDH, whereas others depend on the quality of the sample taken (e.g. bone marrow cellularity) or the subjective judgement of the persons assessing morphological features. Table 7.1↜渀 Prognostic factors in MDS Clinical features Performance status Age Gender Previous therapy (secondary MDS, treatment related MDS) Transfusion dependency Co-morbidity Morphological features Dysplasia, degree of dysplasia, unilineage versus multilineage Blast cell counts (bone marrow, peripheral blood) Cellularity Fibrosis ALIPs Eosinophils, basophils Classifications FAB WHO 2001 WHO 2008 Cytopenias Anemia, neutropenia, thrombocytopenia Chemistry LDH, ferritin Cytogenetics Aberrations Clonal evolution Molecular features Mutations Gene-expression profiles Epigenetics (methylation pattern, etc…) FACS parameters
106
M. Pfeilstöcker
Morphology Morphologic features are used for separation of MDS from other entities and have become hallmarks of MDS classifications [3, 39, 84]. Classifications require bone marrow dysplasia and blast percentages besides other parameters such as cytogenetics and cytopenias. These features not only establish a diagnosis of MDS but also have prognostic significance. When MDS as a distinguishable clinical entity was established, different prognosis of patients according to blast counts was already evident and presence of ringed sideroblasts established an entity with better prognosis compared to refractory anemia [3, 13]. The value of consideration of multilineage dysplasia for prognostic purposes was shown in several case series demonstrating both shorter survival and increased risk of AML evolution [25, 37, 55]. Accordingly RA and RARS were stratified based on the presence of multilineage dysplasia in the WHO 2001 classification [39]. For RARS this stratification was abandoned in the WHO 2008 classification reuniting RARS and RCMD-RS [84]. Bone marrow biopsy can provide further diagnostic and prognostic information. Among others a specific feature—abnormal localization of immature precursors (ALIPs) was proposed as prognostic factor [56]. Another feature is presence of fibrosis in dysplastic marrow. Marrow fibrosis may predict early fatal marrow failure in MDS [5, 49] and increased staining for reticulin has been shown to carry independent prognostic information especially in a distinct subgroup with multilineage dysplasia and high transfusion requirement [16]. Furthermore, the presence of CD34+ cell clusters was confirmed as an independent risk factor for progression to acute leukemia [16].
Cell Counts Cell counts in peripheral blood especially cytopenias such as anemia, neutropenia and thrombocytopenia but also elevated cell counts such as monocytosis have been considered to be of prognostic value since the conception of MDS as an entity [3]. Despite this long experience there is still a debate on the inclusion of cytopenias of specific cell lineage in prognostic systems or on threshold values to be used [2, 7, 24, 29, 44, 54, 61, 63, 69, 71, 73]. Recently the additional prognostic role of eosinophil and basophil counts was observed, eosinophilia and basophilia predicted a significantly reduced overall survival without a significant impact on leukemia-free survival [93].
Other Laboratory Parameters As there is no marker unequivocally specific for MDS, laboratory parameters derived from blood chemistry underlie possible influence from other (patho)physi-
7â•… Prognostic Scoring in MDS
107
ological processes. Examples are measurements of lactate-dehydrogenase (LDH) and ferritin. LDH values may reflect increased cellular turnover in the bone marrow and therefore disease activity of MDS, but may also be influenced by concomitant heart or liver diseases. Ferritin as a possible marker of iron overload due to changes in iron metabolism and chronic transfusion in MDS may also be increased in inflammation and infection. Despite these limitations the prognostic value of both parameters has been demonstrated: LDH is a prominent feature in the Düsseldorf scoring system [2]. Its prognostic power has been examined as a static and dynamic variable [94, 95] and has been used to add prognostic significance to the International prognostic scoring system (IPSS) [26]. The Spanish group showed in a large retrospective study that iron overload reflected by increased ferritin values is of independent prognostic importance [74] although there is still ongoing debate on this topic [10, 81].
Cytogenetics Chromosomal aberrations are a hallmark of MDS, identified in approximately half of all de novo MDS patients [62]. Due to the heterogeneity of the disease the MDS literature harbours an ever increasing number of recurrent abnormalities [32, 77]. The worse prognosis of complex cytogenetics has been established early and introduced into prognostic scores [61, 69]. In addition specific favourable single aberrations such as del(5)(q) [91], molecularly characterised in 2008 [18], or del(20)(q) [92] were described. Patients with isolated del(5)(q) and specific characteristics (<5% blasts in the bone marrow without Auer rods, thrombocytosis, typical dysmegakaryopoiesis, macrocytic anemia), named 5q- syndrome in the WHO classification [39, 84] typically have a low frequency of progression to AML and favourable survival compared with other MDS subgroups. Specific aberrations may carry different prognostic significance according to the complete karyotype. The good prognosis of isolated del(5)(q) is reversed if this aberration is part of a complex karyotype [28]. In the IPSS all chromosome 7 aberrations were set in the poor risk group [29]. This seems confirmed for monosmy 7, but not for translocations involving the long arm of this chromosome [32]. Finally recurrent cytogenetic aberrations were grouped according to their prognostic significance. The number of patients included in the case series used for establishing cytogenetic prognostic groups aberrations enables the refinement of cytogenetics as prognostic factor. Whereas the significance of complex karyotype was derived from series of less than 400 patients [61, 69], about the same number of patients that was used to construct the piscore [71], a purely cytogenetic score; more than 800 patients were included for establishing the more comprehensive IPSS [29], that identifies three cytogenetic subgroups. Further multicenter collaboration enabled identification of 684 different cytogenetic categories in 2,124 patients [32] that may be grouped in four or five prognostic subgroups [33]. Cytogenetics is a key variable of currently used MDS prognostic scoring systems, both the pres-
108
M. Pfeilstöcker
ence and type of chromosomal alteration are of importance. In the IPSS a normal karyotype or evidence of -Y, del(5q), or del(20q) is classified as good risk, while the presence of chromosome 7 or complex abnormalities represents poor risk. All other abnormalities, constituting a very heterogeneous group, are considered intermediate risk [29]. The same criteria are also used in the WHO based prognostic scoring system (WPSS) [54]. Significance of the WPSS validates the IPSS risk groups, but more advanced cytogenetic risk data suggest, that an improved prognostication for MDS may be achieved by inclusion of more detailed cytogenetic data [32, 33, 77]. Cytogenetic evolution may be associated with a more progressive clinical course. A study on 153 patients showed that cytogenetic evolution significantly affected overall and progression free survival independently of other prognostic variables, interestingly del(7)(q) was the only secondary chromosomal defect which significantly affected progression free survival whereas trisomy 8 had only a moderate influence [4]. Besides prognosis, in recent years the specific predictive significance (i.e. predicting response to therapy) of certain aberrations has become evident. Positive predictive value has been described for del(5)(q) in transfusion dependent low or intermediate risk patients as a predictor for response to the immunomodulatory drug lenalidomide. In these cases not only hematologic responses, but also frequent cytogenetic remissions can be achieved [20, 51, 52]. Additional chromosomal aberrations as described above have also influence on the predictive information. In complex karyotypes involving del(5)(q) responses to lenalidomide treatment were more modest [52]. Evidence of a complex karyotype also predicts poor response to chemotherapy [46]. Interestingly epigenetic therapy with 5-Azacitidine retains a significant benefit also in cytogenetic subgroups previously considered high risk [21]. Concerning methodology, using cytogenetics as prognostic factor in MDS warrants standard metaphase cytogenetic analysis with certain quality standards [83]. Fluorescence in situ hybridization (FISH) may be useful to assess chromosomal changes in MDS not detected by standard cytogenetic analysis, particularly in cases with insufficient numbers of metaphases. However only alterations at defined loci can be detected by FISH, and specific FISH findings cannot rule out further aberrations. Therefore at present this technique can only be used as adjunct of conventional cytogenetics also in the setting of prognostication. Current MDS prognosis systems do not yet incorporate FISH or other molecular analyses.
Further Genetic Prognostic Factors The knowledge on MDS pathophysiology has been improved further during the last years. This is in part due to the refinement of methods elucidating these mechanisms. Classic Metaphase cytogenetics has been complemented by FISH as described above. A higher resolution allowing detection of minimal deletions is ob-
7â•… Prognostic Scoring in MDS
109
tained by the SNP array technology. In addition gene expression profiling (GEP) has also been used in MDS. All new methods have been used to find new relevant pathways of MDS pathobiology as well as tools for separating MDS from other diseases or establishing meaningful MDS subtypes. A possible prognostic or predictive value has also been investigated. So identification of prognostic relevant deletions by SNP arrays has been demonstrated: Uniparental disomy on 4q was identified in a proportion of low risk MDS with normal cytogenetics with prognostic relevance in the univariate setting [59]. GEP studies have seperated MDS samples from normal ones or AML and identified new MDS relevant genes. Some studies were able to correlate profiles with conventional prognostic factors or scores [11, 35, 58, 70, 88]. In the MILE Study correlation of GEP defined MDS with cases according to classic morphologic classification was only observed in 50% of MDS (versus 90% in AML), others having an GEP of AML or “none-of-the-targets samples” type. However, in those identified as MDS a significant correlation of these samples with prognosis was observed, allowing the establishment of a classification model with prognostic relevance [57]. GEPs may also carry a predictive value, as shown for the erythroid response to lenalidomide in del(5)(q) patients [17], data still to be confirmed. A number of single genetic alterations have been assessed also for their predictive and prognostic significance. An example is the TET2 gene that has been analysed in different hematopoietic neoplasias [14, 85]. Its function—conversion of methylcytosine residues to the respective hydroxymethyl forms—has recently been elucidated [47], therefore a role in epigenetic instability has been proposed [23]. In MDS prognosis is better in patients carrying a mutated TET2 [48], of interest is a possible additional predictive effect for response to epigenetic therapy [38, 40]. Space restrictions do not allow a further comprehensive review of all genes found to be relevant in at least some MDS cases, for further data see chap. 7 (molecular changes in myelodysplastic syndromes) and [86]. The field of epigenetics has attained wide interest especially due to effective therapeutic interventions using epigenetic therapies [19]. In MDS development dynamic changes of DNA-methylation have been demonstrated [36]. DNA methylation as one of the epigenetic mechanisms can be assessed by different methods: screening methylation patterns of individual genes or assessment of whole methylation profiles of bone marrow cells. Results have been tested for a possible prognostic or predictive use: first data showed, that median overall survival in patients with MDS correlates with the methylation status of p15INK4b [72], a prognostic role of methylation was confirmed in many other genes such as FZD9 [41]. As a possible predictive factor DNA hypermethylation has been shown to be associated with poor response to intensive chemotherapy in older patients with high-risk MDS [30]. Concerning prediction of response to demethylating agents reduced methylation of phosphoinositide-phospholipase C beta1 was associated with clinical response in high risk MDS [22], however data presented at ASH 2009 could not achieve prediction of response using global DNA methylation measurements [6]. So a clear correlation of methylation with response to methylating agents cannot be considered to be definitely established to date.
110
M. Pfeilstöcker
FACS Flow cytometry can help in the diagnostic process of MDS and standardization of flow methods in MDS is underway: several cytometric scoring systems have been proposed [12, 53, 76], the recently published report of an ELN working conference describes a consensus on sampling, handling and processing as well as definitions of minimal combinations of antibodies to define dysplasia [90]. Flow results correlate well with morphology, subclassification and prognostic factors, but further prospective validation and standardization in multicenter studies is still required. Particularly in patients otherwise considered low risk flow cytometry could be beneficial [76], but sensitivity and specificity are still inconsistent in different series [67]. FACS analysis has not yet been included in the WHO classification system, but will certainly add prognostic information in the future.
Transfusion Dependency As stated above cytopenias are of prognostic importance, and anemia at time of diagnosis was included in scoring systems such as the IPSS [29]. The Pavia group showed that transfusion dependency resulting from anemia significantly decreases probability of survival in MDS [8]. This increased mortality risk may be secondary to reduced bone marrow efficiency due to MDS or to sequelae of transfusion therapy such as iron overload when inadequate chelation therapy is present. Including development of transfusion dependency during the course of the disease as prognostic factor was not only significantly associated with shorter survival but also with increased risk of leukemic evolution, reflecting the likelihood of an adverse biology of the disease as contributing factor [55]. On the other hand chronic transfusions increase the risk of iron overload, which may affect survival due to cardiac or hepatic complications as well as the toxicity of labile plasma iron. So iron overload is being discussed as an independent prognostic factor [10, 74, 75]. The data on the prognostic value of transfusion dependence in MDS has been used for generation of a new prognostic scoring system (WPSS) [54]. In addition also a predictive impact of transfusion history on the outcome of allogeneic transplantation for MDS was suggested [1].
Patient Related Factors: Age, Gender, Performance Status, Comorbidity Age and gender per se affect overall survival of humans independently of disease associated factors. Early studies evaluating age and/or gender as prognostic factors
7â•… Prognostic Scoring in MDS
111
in MDS had yielded significant results [2, 61, 75]. In addition in the original IPSS publication, age and gender were analyzed and discussed [29]. Their additional predictive importance was stated, but not quantified in the scoring system as disease related factors were considered more important than patient related factors. Morbidity and mortality rates in MDS patients are higher than those of age-matched normal subjects because of complications related to cytopenia [8], still age and gender modulate MDS prognosis, addition of these factors may improve prognostication [66]. Performance status is correlated with the outcome of chemotherapy or stem cell transplantation in MDS or AML [31, 43]. Lower performance status which may prevent eligibility for aggressive therapies is more prevalent in elderly patients and may be the consequence of pre-existing comorbidities. Disregarding specific therapies these co-morbidities may influence overall survival in MDS patients independently of disease specific prognostic factors. Pre-existing comorbidity scores developed for other clinical situations such as the hematopoietic cell transplant comorbidity index (HCTCI) [78] or the Charlson co-morbidity Index (CCI) [9] have been applied for MDS [79, 98] and MDS specific co-morbidity scores have been developed [15]. Taken together, geriatric assessment should be included in treatment decisions for MDS: age alone should not be considered a surrogate marker for functional decline or co-morbidities; there is still a need to improve co-morbidity scoring systems, individualized risk-assessment, and treatment algorithms for elderly patients with MDS [80].
Combinations of Prognostic Factors: Prognostic Scores Role of Classifications in Prognostication The aim of the development of classifications was to create meaningful sub-entities for clinical decision making. This includes also prognostic significance, but other features such as grouping patients by morphologic similarities or pathological findings were also of importance. Factors that per se also carry prognostic information in the univariate setting as described above in “Prognostic factors in MDS” were used in classifications: in the original FAB classification [3] bone marrow or peripheral blasts, ring sideroblasts and monocytes were used, in the first WHO classification multilineage dysplasia, del(5)(q) were added and blasts considered in a more differentiated way [39]. Applying very stringent criteria led to a high number of unclassified cases [65], therefore in the revision of WHO in 2008 besides further refinements cases with unilineage dysplasia were specified [84]. The prognostic value of classifications has been validated in large patient cohorts [25, 27, 37, 45, 50, 55, 64, 65] and there is still ongoing refinement [89]. While classification systems including prognostic factors are widely used, they do not always provide sufficient prognostic information and do not eliminate the need to use prognostic scores for prognostication and clinical decision making.
112
M. Pfeilstöcker
Prognostic Scoring Systems In parallel to the development of classifications prognostic factors have been combined in so called prognostic scoring systems. Early scores like the Bournemouth score included only cell counts and percentage of blasts in bone marrow [63], the Spanish score included age [75], later LDH was included in the Düsseldorf score [2], as well as histopathologic features [7, 56]. When the prognostic significance of cytogenetics became apparent, these data were incorporated in the Lille score and Lausanne-Bournemouth score [61, 69]. International Prognostic Scoring System (IPSS) In 1997 the international prognostic scoring system (IPSS) was developed, based on a regression model including data from 816 patients with primary MDS [29]. It represents still the most widely used prognostic score for MDS at least in the context of clinical trials. It is based on bone marrow blasts percentage, number of cytopenias and three then newly defined cytogenetic risk groups: a normal karyotype or evidence of -Y, del(5)(q), or del(20)(q) is classified as good risk, while the presence of chromosome 7 or complex abnormalities represents poor risk. All other abnormalities are arbitrarily considered intermediate risk. The IPSS discriminates four risk categories with distinct survival and risk of AML evolution: Table€ 7.2, Fig.€7.1. The prognostic significance of the IPSS has been validated on independent study populations [e.g. 26, 71]. In a comparison with historic scores, the IPSS had the highest prognostic power of all scores tested [71]. Despite this improvement the limitations of the IPSS have to be taken into account when using this score. Generally it is only applicable using data from the time of diagnosis and it has not been validated for patients with secondary MDS. In addition the IPSS is a prognostic score and has no predictive relevance regarding specific therapies. Some limitations that offer opportunities for future improvements are founded in the limitations of the initial data. Analysis of larger databases has Table 7.2↜渀 IPSS. (Adapted after Greenberg et€al. [29]) 5–10 – Bone marrow <5 blasts (%) Poor risk Intermediate Cytogenetics Good risk Complex or chromorisk Normal some 7 aberrations -y, 5q-, 20q- All others 0/1 2/3 Number of cytopenias Hbâ•›<â•›10, ANCâ•›<â•›1,500, PLTâ•›<â•›100,000 Scoring points 0 0.5 1.0 Risk group Sum of points
Low 0
Intermediate-1 Intermediate-2 0.5–1.0 1.5–2.0
11–20
21–30
1.5
2.0
High 2.5–3.5
– –
7â•… Prognostic Scoring in MDS
113
Fig. 7.1↜渀 Survival (a) and freedom from AML evolution (b) of MDS patients related to their classification by the IPSS for MDS: Low, INT-1, INT-2, and High (KaplanMeier curves). (Reproduced with permission from Greenberg [29])
International MDS Risk Classification 100 90
Survival
80 70
percent
60
Low
267 pts
Int-1
314 pts
Int-2
179 pts
High
56 pts
50 40 30 20 10 0
a 100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 years AML Evolution
90 80 70
percent
60 50
Low
235 pts
Int-1
295 pts
Int-2
171 pts
High
58 pts
40 30 20 10 0
b
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 years
increased our knowledge on the prognostic significance of cytogenetic abnormalities: whereas noncomplex rare cytogenetic abnormalities were assigned intermediate risk in the IPSS—a very heterogenous category, data presented from the German Austrian MDS study group analysing 2,124 MDS patients enabled recognition of infrequent aberrations and their assignment to prognostic subgroups [33]. Currently
114
M. Pfeilstöcker
an improved cytogenetic score is being developed. Observation during longer follow up periods than the ones used in the original IPSS cohort, may provide the explanation why there should be a redistribution of the weight of bone marrow blasts versus cytogenetic risk groups in terms of score points which should be considered when deliberating refinements of the IPSS [82, 87]. Besides these adjustments using modified parameters already included in the IPSS, addition of further parameters, that have shown their possible utility in univariate analyses may increase its prognostic power: elevated lactate dehydrogenase (LDH) identified as an additional prognostic variable was used to refine the IPSS [26]. The IPSS+LDH was capable of separating a new group of “verylow-risk” patients. In addition, for patients in the Int-2 and high-risk groups, adding LDH as prognostic factor led to significant stratifications of these prognostic groups. Similarly addition of age and gender may be used to refine the IPSS. Risk factors for the four IPSS prognostic subgroups can be modified according to age and gender thus contributing to an improved and more individualized prognostication [66]. WHO Based Prognostic Scoring System WPSS The IPSS was developed on patients classified according to the FAB classification [29]. While the IPSS remains significant within WHO subgroups, there is redundancy: similar blast intervals are used in IPSS and WHO, peripheral cytopenias in IPSS are reflected in the number of dysplasias in WHO, only cytogenetics besides del(5)(q) provide additional prognostic information in the IPSS. In addition the WHO classification reclassifying RAEBt as acute leukemia leads to a substantial loss in the population the IPSS was initially based upon, especially in the higher risk groups. Therefore the development of an WHO based prognostic scoring system (WPSS) was performed (Tab.€7.3) [54]. Factors already included in the WHO subgroup or in the IPSS such as cytopenias, cytogenetic risk factors (the same subgroups as in the IPSS) and bone marrow blast counts were used. According to the data on the importance of transfusion dependency this feature replaced anemia. The WPSS discriminates five prognostic groups ranging from very low to very high risk with significant differences for overall and leukemia free survival. In patients older than 70 years survival for very low-risk MDS was comparable to that of the general population. Addressing the problem of identifying higher risk patients in “low risk” groups, this is accomplished by means of inclusion of multilineage dysplasia and transfusion need. The WPSS also allows for repeated assessment, providing a time-dependent score, enabling reassessment of the prognosis of a patient during the course of the disease and at time of progression. The WPSS publication has a learning sample/validation sample design offering internal validation of the score and has been independently validated as well [68]. However, in the light of further developments the final role of the WPSS remains open. Especially the fact that it still uses the limited cytogenetic subgroups of the IPSS warrants further improvements.
7â•… Prognostic Scoring in MDS
115
Table 7.3↜渀 WPSS. (Adapted after Malcovati et€al. [54]) WHO subtype RA, RARS RCMD, RCMD-RS Intermediate risk Cytogenetics Good risk All others Normal -y, 5q-, 20qTransfusion No Yes requirement Scoring points 0 1 Risk group Sum of points
Very low 0
Low 1
RAEB-1 RAEB-2 Poor risk Complex or chromosome 7 aberrations 2
Intermediate High 2 3–4
3 Very high 5–6
Ongoing Improvement of Scoring Systems The problem of limited applicability of scores in the low risk subgroups as well as the need for dynamic scores allowing for reevaluation in patients with a prolonged life span has been also addressed by a further scoring systems by the MD Anderson group [24, 44]. Patients were assessed at time of referral not at time of diagnosis, therefore validation with patients at time of diagnosis is needed. In addition the upcoming cytogenetic data will have to be integrated. On the basis of the IPSS requiring refinement, the proposal of the WPSS and upcoming additional prognostic features an international working group has been convened to assess the utility of prognostic information and to finally construct a new improved scoring system. Probably at the International MDS Symposium 2011 first results may become available.
Conclusion: Use of Prognostication for Clinical Decision Making This review reflects the steady progress in prognostication for MDS. Different prognostic tools utilized over the years in clinical trials implicates that it can be a challenge to compare their results. Recently a more homogeneous use of classifications and prognostic criteria has been applied in clinical trials but knowledge of inclusion criteria used is still of importance for interpretation of study data. Prognostic scores have been improved over years and data are available showing the additional utility of additional approaches for further advances in this field. Collaboration of many centers is warranted to include as many patients as possible in validation studies in order to achieve meaningful results and to establish a comprehensive approach to prognostication also facilitating planning and performing clinical trials. Prognostic scores are only part of a meticulous patient assessment necessary before making therapeutic decisions. This assessment should include secure confirmation of the diagnosis MDS, a correct classification on the basis of expert morphology, the evaluation of prognostic factors, the consideration of predictive factors and assessment of comorbidity. As seen in this review the boundaries between these fields overlap, and we can expect changes and further developments as our
116
M. Pfeilstöcker
knowledge on MDS will improve. At the time being the development in the field of prognostication so far has greatly benefited our MDS patients.
References ╇ 1. Alessandrino EP, Della Porta MG, Bacigalupo A et€al (2010) Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 95(3):476–484 ╇ 2. Aul C, Gattermann N, Heyll A et€al (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1:52–59 ╇ 3. Bennett JM, Catovsky D, Daniel MT et€al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199 ╇ 4. Bernasconi P, Klersy C, Boni M et€al (2010) Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Ann Hematol 89:545–551 ╇ 5. Buesche G, Teoman H, Wilczak W et€al (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313–322 ╇ 6. Byun HM, Triche T, Kim HJ et€al (2009) Genome-wide DNA methylation analysis of patients with myelodysplastic syndrome after azacitidine treatment. Blood (ASH Annual Meeting Abstracts) 114:600 ╇ 7. Cassano E, Giordano M, Riccardi A et€al (1990) Myelodysplastic syndromes: a multiparametric study of prognostic factors and a proposed scoring system. Haematologica 75:141– 145 ╇ 8. Cazzola M, Malcovati L (2005) Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med 352:536–538 ╇ 9. Charlson ME, Pompei P, Ales KL et€al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383 10. Chee CE, Steensma DP, Wu W et€al (2008) Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 83:611–613 11. Chen G, Zeng W, Miyazato A et€al (2004) Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 104:4210–4218 12. Cherian S, Moore J, Bantly A et€al (2005) Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 64:9–17 13. Coiffier B, Adeleine P, Viala JJ et€al (1983) Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer 52:83–90 14. Delhommeau F, Dupont S, Della Valle V et€al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289–2301 15. Della Porta MG, Kuendgen A, Malcovati L et€al (2008) Myelodysplastic syndrome (MDS)specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood (ASH Annual Meeting Abstracts) 112:2677 16. Della Porta MG, Malcovati L, Boveri E et€al (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27:754–762 17. Ebert BL, Galili N, Tamayo P, Bosco J et€ al (2008) An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 5:e35
7â•… Prognostic Scoring in MDS
117
18. Ebert BL, Pretz J, Bosco J et€al (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451(7176):335–339 19. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159 20. Fenaux P, Giagounidis A, Selleslag D et€al (2009) RBC transfusion independence and safety profile of lenalidomide 5 or 10 mg in Pts with low- or Int-1-risk MDS with Del5q: results from a randomized phase III trial (MDS-004). Blood (ASH Annual Meeting Abstracts) 114:944 21. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et€ al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232 22. Follo MY, Finelli C, Mongiorgi S et€al (2009) Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 106(39):16811–16816 23. Ganetzky RD, Jankowska AM, Prince C et€al (2009) TET2 mutation status is associated with distinct hypermethylation patterns; a marker of epigenetic instability? Blood (ASH Annual Meeting Abstracts) 114:215 24. Garcia-Manero G, Shan J, Faderl S et€al (2008) A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22:538–543 25. Germing U, Gattermann N, Strupp C et€ al (2000) Validation of the WHO proposal for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983–992 26. Germing U, Hildebrandt B, Pfeilstöcker M et€ al (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223–2231 27. Germing U, Strupp C, Kuendgen A et€al (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596–1604 28. Giagounidis AA, Germing U, Haase S et€al (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromesand del(5q) including band q31. Leukemia 18:113–119 29. Greenberg P, Cox C, LeBeau MM et€al (1997) International system for evaluating prognosis in myelodysplasticsyndromes. Blood 89:2079–2088 (Erratum in Blood 91:1100, 1998) 30. Grövdal M, Khan R, Aggerholm A et€al (2007) Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 13:7107–7112 31. Gupta V, Chun K, Yi QL et€al (2005) Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 103:2082–2090 32. Haase D, Germing U, Schanz J et€al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395 33. Haase D, Schanz J, Tuechler H et€al (2009) Updated cytogenetic risk features in MDS—present state. Leuk Res 33(Suppl 1):S9–S10 (10th Int Symp MDS abstracts) 34. Hemingway H, Riley RD, Altman DG (2009) Ten steps towards improving prognosis research. BMJ 339:b4184. doi:10.1136/bmj.b4184 35. Hofmann WK, de Vos S, Komor M et€al (2002) Characterization of gene expression ofCD34+ cells from normal and myelodysplastic bone marrow. Blood 100:3553–3560 36. Hopfer O, Komor M, Koehler IS et€al (2007) DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. Exp Hematol 35:712–723 37. Howe B, Porwit-MacDonald A, Wanat R et€al (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270
118
M. Pfeilstöcker
38. Itzykson R, Kosmider O, Cluzeau T et€al (2010) Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS. Blood (ASH Annual Meeting Abstracts) 2010 116: Abstract 439 39. Jaffe ES, Harris NL Stein H, Vardiman JW (eds) (2001) WHO classification of tumours: pathology and genetics of haematopoietic and lymphoid tissues. IARC Press, Lyon 40. Jankowska AM, Shaik M, Cazzolli H et€ al (2009) Impact of TET2 mutations on responsiveness to demethylating agents in MDS. Blood (ASH Annual Meeting Abstracts) 114:1606 41. Jiang Y, Dunbar A, Gondek LP, Mohan S et€al (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315–1325 42. Justice AC, Covinsky KE, Berlin JA (1999) Assessing the generalizability of prognostic information. J Ann Intern Med 130:515–524 43. Kantarjian H, O’Brien S, Cortes J et€ al (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106:1090–1098 44. Kantarjian H, O’Brien S, Ravandi F et€al (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351–1361 45. Kerkhofs H, Hermans J, Haak HL et€al (1987) Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65:73–81 46. Knipp S, Hildebrand B, Kündgen A et€al (2007) Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110:345–352 47. Ko M, Huang Y, Jankowska AM, Pape UJ et€al (2010) Impaired hydroxylation of 5– methylcytosine in myeloid cancers with mutant TET2. Nature (in press) 48. Kosmider O, Gelsi-Boyer V, Cheok M et€al (2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDS). Blood 114:3285–3291 49. Lambertenghi-Deliliers G, Orazi A, Luksch R et€al (1991) Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 78:161– 166 50. Lee J-H, Lee J-H, Shin Y-R et€al (2003) Application of different prognostic scoring systems and comparison of the FAB and WHO classification in Korean patients with myelodysplastic syndromes. Leukemia 17:305–313 51. List A, Dewald G, Bennett J et€al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465 52. List A, Kurtin S, Roe DJ et€al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549–557 53. Malcovati L, Della Porta MG, Lunghi M et€al (2005) Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 19:776–783 54. Malcovati L, Germing U, Kuendgen A et€al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510 55. Malcovati L, Porta MG, Pascutto C et€al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594–7603 56. Maschek H, Gutzmer R, Choritz H et€al (1994) Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haematol 53:280–287 57. Mills KI, Kohlmann A, Williams PM et€al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063–1072 58. Miyazato A, Ueno S, Ohmine K et€al (2001) Identification of myelodysplastic syndromespecific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98:422–427
7â•… Prognostic Scoring in MDS
119
59. Mohamedali A, Gäken J, Twine NA et€al (2007) Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110:3365–3373 60. Moons KG, Altman DG, Vergouwe Y et€al (2009) Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338:b606. doi:10.1136/bmj.b606 61. Morel P, Hebbar M, Lai JL et€al (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7:1315–1323 62. Mufti GJ (1992) Chromosomal deletions in the myelodysplastic syndrome. Leuk Res 16:35– 41 63. Mufti G, Stevens JR, Oscier DG et€al (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59:425–433 64. Müller-Berndorff H, Haas PS, Kunzmann R et€al (2006) Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol 85:502–513 65. Nösslinger T, Reisner R, Koller E et€ al (2001) Myelodysplastic syndromes, from FrenchAmerican-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98:2935–2941 66. Nösslinger T, Tüchler H, Germing U et€al (2010) Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 21:120–125 67. Ogata K, Della Porta MG, Malcovati L et€ al (2009) Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 94:1066–1074 68. Park MJ, Kim HJ, Kim SH et€al (2008) Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol 81:364–373 69. Parlier V, van Melle G, Beris P et€al (1995) Prediction of 18-month survival inpatients with primary myelodysplastic syndrome: a regression model and a scoring system based on the combination of chromosome findings and the Bournemouth score. Cancer Genet Cytogen 81:158–165 70. Pellagatti A, Esoof N, Watkins F et€al (2004) Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 125:576–583 71. Pfeilstöcker M, Reisner R, Nösslinger T et€al (1999) Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106:455–463 72. Quesnel B, Guillerm G, Vereecque R et€al (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985–2990 73. Reynolds T (2001) Prognostic models abound, but how useful are they? Ann Intern Med 135:473–476 74. Sanz G, Nomdedeu B, Such E et€al (2008) Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 112:640 75. Sanz GF, Sanz MA, Vallespí T et€ al (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74:395–408 76. Scott BL, Wells DA, Loken MR et€al (2008) Validation of a flow cytometric scoring system as a prognostic indicator for post transplantation outcome in patients with myelodysplastic syndrome. Blood 112:2681–2686 77. Solé F, Luño E, Sanzo C et€al (2005) Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90:1168–1178
120
M. Pfeilstöcker
78. Sorror ML, Maris MB, Storb R et€ al (2005) Hematopoietic cell transplantation(HCT)specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919 79. Sperr WR, Wimazal F, Kundi M et€al (2010) Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS study group. Ann Oncol 21:114–119 80. Stauder R, Nösslinger T, Pfeilstöcker M et€al (2008) Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Cancer Netw 6:927–934 81. Steensma DP (2009) Myelodysplasia paranoia: iron as the new radon. Leuk Res 33:1158– 1163 82. Steidl C, Schanz J, Pfeilstöcker M et€al (2007) Growing evidence for an underestimation of poor-risk cytogenetics in the International Prognostic Scoring System in myelodysplastic syndromes. Clin Leuk 1:353–356 83. Steidl C, Steffens R, Gassmann W et€al (2005) Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. Leuk Res 29:987–993 84. Swerdlow SH, Campo E, Harris NL et€ al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon 85. Tefferi A, Lim KH, Abdel-Wahab O et€al (2009) Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23:1343–1345 86. Tefferi A, Vardiman W (2009) Myelodysplastic syndromes. N Engl J Med 361:1872–1885 87. Tüchler H, Makrai A, Nösslinger T et€al (2008) At which interval should prognosic scores for preleukemic duration and survival in myelodysplastic syndromes be reevaluated? Onkologie (DGHO abstracts) 31(Suppl 4):170 88. Ueda M, Ota J, Yamashita Y et€ al (2003) DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol 123:288–296 89. Valent P, Horny HP, Bennet JM et€al (2007) Definitions and standards in the diagnosis and treatments of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727–736 90. van de Loosdrecht AA, Alhan C, Béné MC et€al (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 94:1124–1134 91. Van den Berghe H, Cassiman JJ, David G et€al (1974) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251:437–438 92. Wattel E, Laï JL, Hebbar M et€al (1993) De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leuk Res 17:921–926 93. Wimazal F, Germing U, Kundi M et€al (2010) Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer 116:2372–2381 94. Wimazal F, Sperr WR, Kundi M et€al (2001) Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res 25:287–294 95. Wimazal F, Sperr WR, Kundi M et€ al (2008) Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol 19:970–976 96. Windeler J (2000) Prognosis—what does the clinician associate with this notion? Stat Med 19:425–430 97. Wyatt JC, Altman DG (1995) Commentary: prognostic models: clinically useful or quickly forgotten? BMJ 311:1539–1541 (Dec) 98. Zipperer E, Pelz D, Nachtkamp K et€al (2009) The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 94:729–732
Chapter 8
Flow Cytometry in Myelodysplastic Syndromes C. Alhan, T. M. Westers, G. J. Ossenkoppele and Arjan A. van de Loosdrecht
Introduction Maturation and differentiation of hematopoietic cells is a tightly controlled process, leading to highly conserved levels of antigen expression at different stages of development. In myelodysplastic syndromes (MDS), progenitor cell formation is affected resulting in deviation from the normal level of antigen expression in the (im) mature myelo-monocytic, erythroid and megakaryocytic cell lineages [29, 38, 42]. The gold standard for the diagnosis of MDS is the detection of dysplastic features in the erythroid, megakaryocytic and/or myeloid cell lineages in the bone marrow (BM) by morphology. Dysplasia can be very mild and in combination with a normal karyotype, the diagnosis of MDS can be challenging. In a consensus report from a working conference on MDS, flow cytometric analysis of cytopenic patients with inconclusive BM morphology and cytogenetics is included as a tool to establish a diagnosis of MDS [48]. Flow cytometry is based on intrinsic physical qualities of the cells such as size, corresponding with forward light scatter (FSC) and cytoplasmic granularity, corresponding with sideward light scatter (SSC). Furthermore, by labeling cells with fluorochrome-conjugated monoclonal antibodies it is possible to detect surface, cytoplasmic or nuclear antigens. Flow cytometry can detect minimal aberrancies in the differentiation of myelomonocytic cell populations by changes in antigen expression in BM of MDS patients that are otherwise not detected by morphology [42]. Since new therapeutic strategies are emerging for MDS, a more refined diagnostic and prognostic procedure is of importance. In this chapter the principles of flow cytometry in MDS and the value of flow cytometry for the diagnosis and prognosis A. A. van de Loosdrecht () Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands Tel.: +31-20-444-2604 Fax: +31-20-444-2601 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_8, ©Â€Springer Science+Business Media B.V. 2011
121
122
C. Alhan et al.
of MDS will be discussed with emphasis on technical issues and aberrancies that can be detected.
Flow Cytometric Evaluation of Dyspoiesis in MDS Application of flow cytometry for the diagnosis of MDS requires knowledge of changes in antigen expression in normal hematopoietic cell differentiation. Hematopoiesis is a tightly regulated process in which antigen expression patterns are highly conserved [51]. In MDS disturbances in hematopoiesis can be associated with disruption of antigen expression patterns [46, 53]. In a consensus document from the European LeukemiaNet (ELN) working group for standardization of flow cytometry in MDS, a minimal combination of antibodies is proposed to analyze dyspoiesis in the (im)mature myelo-monocytic cell compartments, Table€8.1 [50]. The aberrancies in hematopoiesis that can be observed in MDS are the expression of lymphoid antigens on myeloid cells, over, under and/or loss of antigen expression, the expression of immature antigens on mature cells and vice versa and abnormal differentiation patterns between antigens. However, non-clonal disorders such as vitamin deficiency related anemia can cause (transient) immunophenotypic changes in the BM that can also be found in MDS. Although some of the aberrancies that can be detected in MDS are not specific for MDS, the accumulation of aberrancies might discern MDS from non-clonal cytopenias [27, 30]. Antigen expression levels are defined as aberrant in MDS if a 0.5log decrease or increase is found as compared to antigen expression levels from hematopoietic cells of healthy individuals. Table 8.1↜渀 Combination of markers as recommended by the ELN working group for the standardization of flow cytometry in MDS. (van de Loosdrecht et€al. [50]) Erythroid CD71/CD235a/CD117 Optional: CD105, CD34/CD117, CD36 Myeloid progenitors CD34 in combination with CD117/CD11b/HLA-DR/CD15 Lineage infidelity markers: CD5, CD7/CD13, CD19, CD56 Optional: CD123, TdT Lymphoid progenitors CD34/CD19 Optional: CD10/CD19/CD38, TdT, CD79a Maturing myeloids CD11b/CD13/CD16, CD11b/CD117/HLA-DR/CD10, CD34 in combination with CD5, CD7, CD15, CD19, CD56, CD33/CD14 Optional: CD65, CD123 Monocytes CD11b/HLA-DR, CD34 in combination with CD5, CD7, CD19, CD56, CD64/CD14, CD33/CD14, CD33/CD36 Optional: CD64/CD36 A minimum panel for the diagnosis and/or prognosis of MDS. The common leukocyte antigen CD45 should be combined with the antigens that are listed in the table. The subpopulations in the BM should be gated based on CD45 and SSC
8â•… Flow Cytometry in Myelodysplastic Syndromes
123
Most studies analyze dyspoiesis in BM samples of MDS patients, although there is some data on flow cytometric analysis of peripheral blood (PB) in MDS. Analysis of aberrancies in antigen expression levels of mature cell populations in PB might be of value to diagnose MDS patients [7]. Increased expression of CD13 on mature neutrophils has been associated with an adverse clinical outcome [26]. In a study that compared PB with BM, antigen expression levels of CD36, CD56 and CD117 on neutrophils and monocytes differed between PB and BM [21]. The threshold for abnormal expression of CD56 and CD117 was higher in BM than PB. However, aberrancies in antigen expression levels of neutrophils and monocytes of MDS patients were more frequent in BM than in PB. The analysis of circulating myeloid progenitors in PB of MDS patients might hold prognostic significance [6]. Furthermore, it should be kept in mind that the nomenclature for cells that is used in morphology might not be applicable in flow cytometry. For example, an immature cell might be denominated as a blast by morphology and as a myeloid progenitor cell by flow cytometry. These and other studies demonstrate that disregulation of hematopoiesis in MDS can not only be detected by morphology but also by flow cytometry as will be discussed in detail below.
Myeloid Progenitors Flow cytometry can be used to identify distinct subpopulations of myeloid progenitor cells based on antigen expression levels. CD45 is a leukocyte common antigen and is expressed on all leukocytes. In combination with SSC, CD45 is a powerful means to delineate lymphocytes, monocytes, maturing myeloid cells and myeloid progenitors in normal BM. Normal myeloid progenitors are identified by CD45dim expression, low SSC, heterogeneous expression of CD34 and CD117, CD13, CD33, HLA-DR and absence of CD11b. CD34 is expressed on the most immature myeloid, lymphoid and erythroid cells and is rapidly lost at an early stage of differentiation. Immature myeloid and erythroid progenitors express CD117 and lose expression during myeloid and erythroid differentiation. CD13 is expressed at the myeloid progenitor stage, decreases during myeloid differentiation and is increased on the most mature myeloid cells to the level of expression on myeloid progenitors. All myeloid cells express CD33. Maturing myeloid cells have highest CD33 intensity compared with immature and mature myeloid cells. HLA-DR is lost at an early stage during myeloid differentiation. It is recommended to use a combination of antibodies, for the following reasons. B cell progenitors express CD34 and these should be excluded from myeloid progenitor analysis. Furthermore, B cell progenitors express CD19 and can be distinguished from myeloid progenitors by lower SSC properties and lower CD45 expression as compared to myeloid progenitors. Basophils are also low in SSC and CD45dim but can be identified by absence of HLA-DR and bright expres-
124
C. Alhan et al.
sion of CD123. Therefore, the combination of markers that is recommended by the ELN working group for the standardization of flow cytometry in MDS to identify myeloid progenitors is by using scatter properties and CD45 in combination with CD34/CD117/HLA-DR and CD34/CD123/HLA-DR and CD11b/HLA-DR, Table€8.1 [50]. A combination of antibodies is also necessary to identify myeloid progenitors because CD45 and/or CD34 expression on myeloid progenitors can be aberrantly decreased or absent in MDS [31, 36, 37, 40, 49, 54]. Aberrancies that can be detected in the immature myeloid compartment are listed in Table€8.2 [23]. A common finding in MDS is the aberrant expression of antigens on immature myeloid cells that are normally expressed on mature myeloid cells, such as CD11b and/or
Table 8.2↜渀 Common immunophenotypic aberrancies in MDS. (The table is adapted from a meeting report on definitions and standards in the diagnosis and treatment of MDS [23, 48, 54, 50]) Common phenotypic abnormalities detected by flow cytometry in MDS Myeloid progenitors Increased, decreased or absent CD45 expression Increased, decreased or absent and/or homogenous CD34 expression Homogenous CD117 expression Asynchronous expression of CD11b and/or CD15 Decreased or absent HLA-DR, CD13 and/or CD33 expression Expression of lymphoid associated antigens: CD2, CD5, CD7, CD19 and/or CD56 Decreased CD38 expression Absolute and relative increase in the number of myeloid progenitors B cell progenitors Absolute and relative (to myeloid progenitors) decrease in B cell progenitors Maturing myeloid cells Decreased CD45 expression Abnormal relationship patterns of myeloid antigens CD11b, CD13 and CD16 Hypogranularity characterized by decreased SSC Decreased or absent CD33 expression Asynchronous expression of CD34 and/or HLA-DR Expression of lymphoid associated antigens: CD5, CD7, CD19 and/or CD56 Maturing monocytes Decreased CD45 expression Abnormal relationship patterns of CD11b and HLA-DR, CD13 and CD16, CD14 and CD33 Increased, decreased or absent CD11b, CD13, CD14, CD16, CD33 and/or HLA-DR Expression of CD34 Expression of lymphoid antigens: CD2, CD5, CD7, CD19 and/or CD56 Absolute and relative increase in the number of monocytes Maturing erythroid cells Abnormal expression of CD34 CD45 and/or CD117 Decreased CD71 expression Absolute and relative increase in the number of immature erythroid cells Persistent low levels of CD71 expression on CD235a positive erythroid precursors The most relevant and commonly described aberrancies that can be detected in MDS are described
8â•… Flow Cytometry in Myelodysplastic Syndromes
125
CD7 PE
1
102
103
104 102 10
10
0
0
10
10
1
CD7 PE
103
a
104
CD15. HLA-DR expression can be absent and common myeloid markers such as CD13 and CD33 may be decreased or absent as well [4, 9, 20, 31, 33–35, 49, 54]. Lymphoid antigens such as CD2, CD5, CD7, CD19 and CD56 may be aberrantly expressed on myeloid progenitors in MDS. In normal BM, a small subset of early myeloid progenitors can express CD7. To ensure that lineage infidelity markers are truly expressed on myeloid progenitors, a myeloid marker should be added in the antibody combination with CD45 and CD34, Fig.€8.1 [12]. In BM from patients treated with growth factors and in regenerating BM, CD5 and CD56 may be expressed at low levels on normal (immature) myeloid and monocytic cells [52].
100
101
102
103
100
104
101
104
4 3
10
104
1
10
2
CD7 PE
10
103 102 10
10
0
0
10
10
1
CD7 PE
103
CD13 FITC
CD34 APC
b
102
100
101
102
CD34 APC
103
104
100
101
102
103
104
CD13 FITC
Fig. 8.1↜渀 Aberrant CD7 expression on myeloid progenitors in MDS. To analyze CD7 expression on CD34+ myeloid progenitors it is important to combine the analysis with CD13. Panel a shows CD34+ cells from an healthy individual with a proportion of cells that express CD7. When CD7 is combined with CD13, it is clear that CD7 is expressed on the CD13dim cells. CD7 can be expressed on normal CD13dim and CD34+ cells that are differentiating towards monocytes in the BM of healthy individuals. Therefore, it is important to determine whether CD7 expression is expressed on CD13+ cells. As can be seen in panel b, CD7 is aberrantly expressed on CD13+ and CD34+ cells in the BM of a MDS patient
126
C. Alhan et al.
100
a
1000 800 600
Side Scatter
0
200
400
800 600 400 0
200
SSC-Height
1000
Next to qualitative analysis it is also possible to quantify myeloid progenitors by flow cytometry. Flow cytometric studies that analyzed the percentage of myeloid progenitors show that there is a good correlation between the percentage of myeloid progenitors by flow cytometry with the percentage of blasts by morphology [9, 54]. An underestimation of the percentage of myeloid progenitors by flow cytometry might be caused by peripheral blood contamination. Furthermore, the myeloid progenitors as defined by flow cytometry may not correspond to the blast compartment as defined by morphology. This might be explained by a difference in definition of a myeloid progenitor or blasts. The percentage of myeloid progenitors is defined as increased if 5% or more CD34 positive cells were detected. The cut-off level of 5% is also used by morphology to define an increase in blast percentage. However, the cut-off level to define an increase of myeloid progenitors in MDS by flow cytometry might be lower and should probably be 3% or more [35]. There are indications that an increased percentage of CD34 positive cells as defined by a cut-off of 3% or more is indicative for MDS and might be of prognostic relevance in RCMD(RS) patients [34]. In MDS there is a relative decrease of the percentage of B cell progenitors, defined as SSC low, CD45dim, CD34 positive and CD19 positive, Fig.€8.2 [41]. However, in healthy individuals the relative percentage of B cell progenitors also decreases with ageing. It is of importance that the relative percentage of B cell progenitors in MDS BM is compared with the percentage of B cell progenitors in an age-matched control population in order to qualify it as aberrantly low or decreased. The power of flow cytometry over morphology in MDS lies in the qualitative analysis of antigens rather than quantification of myeloid progenitors.
101
102
CD45 PerCP
103
104
100
b
101
102
103
104
CD45 PerCP
Fig. 8.2↜渀 Myeloid progenitors and B cell progenitors in MDS. A common finding in MDS is a (relative) decrease or absence of B cell progenitors in the BM. In normal BM, lymphoid progenitors (↜purple arrow) can be identified by lower SSC and CD45 properties compared with myeloid progenitors (↜red arrow). In the figures, CD34+ cells are backgated in a CD45 and SSC plot of an age-matched healthy individual (panel a) and MDS patient (panel b). Panel b shows a MDS patient with decreased B cell progenitors
8â•… Flow Cytometry in Myelodysplastic Syndromes
127
Maturing Myeloid Cells In normal BM, neutrophils can be discriminated by intermediate CD45 expression and high SSC properties as compared to lymphocytes. Neutrophils can be distinguished from monocytes that have higher CD45 expression and lower SSC properties compared with neutrophils [51]. By morphology, five stages of neutrophil differentiation can be discerned. The myeloblasts differentiate subsequently from promyelocytes, myelocytes, metamyelocytes, towards band and segmented neutrophils. By flow cytometry, these neutrophil maturation stages can be distinguished by different expression levels of CD11b, CD13 and CD16. Normal neutrophil differentiation patterns are shown in Fig.€8.3. Myeloblasts express CD34, CD117 and a
CD16
CD13
b
CD11b
CD13
CD16
CD16
c
CD16
CD11b
CD11b
CD16
CD11b
CD16
Fig. 8.3↜渀 Neutrophil differentiation in MDS. To analyze neutrophil differentiation patterns it is recommended to use the antibody combination CD11b/CD13/CD45/CD16. Panel a shows neutrophil differentiation in the BM of an healthy individual. The arrows indicate the direction of differentiation of the maturing myeloid cells. Panel b shows neutrophil differentiation in the BM of a low risk MDS patient. As can be seen from CD11b/CD13 pattern, in this case CD13 expression is increased on the immature myeloid cells. The CD13/CD16 pattern is more condensed compared with the pattern of the healthy individual in panel a. Panel c shows neutrophil differentiation in a high risk MDS. The CD13/CD16 pattern is compact and the number of immature myeloid cells is increased (↜leftshift). In the CD11b/CD13 plot there is a proportional decrease in CD11bdim cells and mature CD11b+ CD13+ cells. CD11b is also overexpressed as can be seen from the CD11b/ CD13 and CD11b/CD16 patterns
128
C. Alhan et al.
high levels of CD13 and lack CD11b and CD16 expression. CD11b is absent on promyelocytes, defined by CD117 expression and CD34 absence, and is initially expressed at low levels on myelocytes and is high at the metamyelocyte and segmented neutrophil stage. CD16 follows a similar pattern, but has intermediate expression from the metamyelocyte stage and is highly expressed on mature neutrophils. In contrast, CD13 is present at high levels just before the promyelocyte stage, decreases with differentiation to the myelocyte stage and increases again at the metamyelocyte stage to become highly expressed on segmented neutrophils. The graphic representation of CD11b and CD16, CD11b and CD13, CD16 and CD13 forms three highly conserved patterns for neutrophil differentiation in normal hematopoiesis. The immunophenotypic aberrancies that can be found in MDS in the maturing myeloid or neutrophils are described in Table€8.2. A disturbance in differentiation of neutrophils is reflected by aberrancies in the patterns of myeloid antigens: CD13, CD16 and CD11b, as shown in Fig.€8.3. Hypogranularity, which is reflected by a decreased SSC, is a common finding in MDS (84% of MDS cases) [42]. However, as a single aberrancy it is not specific for MDS. The neutrophil SSC can be assessed by CD45 versus SSC and calculated as a ratio to lymphocyte SSC as an internal reference in the BM. It might be relevant to use the SSC of immature neutrophils compared with mature neutrophils since the mature neutrophil compartment can be influenced by PB contamination [35]. CD33 is expressed dimly on neutrophils in contrast to a bright expression on monocytes. Decreased CD33 expression of both neutrophils and monocytes can be a result of polymorphism and is a common, normal phenomenon. If the SSC of neutrophils is low or decreased and monocytes and neutrophils cannot be separated as distinct populations based on CD45 and SSC properties, CD33 might be discriminatory. CD45 expression may be aberrantly decreased in neutrophils. Abnormalities in the expression of CD13 are also common and might be of diagnostic relevance in MDS [25]. Antigens associated with immaturity such as CD34 and/or HLA-DR can be aberrantly expressed on maturing myeloid cells. Expression of lymphoid antigens can also be detected in the mature myeloid compartment. The expression of a lymphoid antigen on a subset of myelo-monocytic cells might even be of more significance than aberrancies of myelo-monocytic antigens [8].
Monocytic Lineage The added value of flow cytometry in monocytic lineage analysis can be substantial since dyspoiesis in the monocytic lineage is difficult to identify by morphology on the BM level. By morphology, monocytic cells can be identified as myelo/monoblasts, promonocytes and monocytes. Within tissues the monocytes may further differentiate into macrophages. Differentiation from monoblasts to promonocytes is marked by an increase in CD33 expression and loss of CD34 expression with an intermediate expression of CD45. Subsequently, CD45 expression is increased and CD14 and CD11b are gained at the monocytic stage. Furthermore, monocytes retain
104 103 101 100
100 100
a
129
102
CD14 APC
103 102 101
CD14 APC
104
8â•… Flow Cytometry in Myelodysplastic Syndromes
101
102
CD36 FITC
103
104
100
b
101
102
103
104
CD36 FITC
Fig. 8.4↜渀 Monocyte differentiation in MDS. Panel a shows monocytic differentiation in the BM of an healthy individual. The arrow indicates the direction of differentiation. Panel b depicts monocytic differentiation in the BM of a high risk MDS patient. The proportion of monocytes is increased compared with the reference population. CD14 and CD36 are underexpressed or there is an increase of immature monocytes
HLA-DR upon differentiation in contrast to the loss of HLA-DR expression during neutrophil maturation [51]. In MDS, the proportion of monocytes relative to lymphocytes or non-erythroid cells can be increased or decreased. The combination of CD14, CD36 and CD64 enables the detection of immature monocytes. CD14 alone can give an underestimation of the proportion of monocytes in the BM because it is expressed on mature monocytes. Abnormalities in the expression patterns of HLA-DR, CD11b, CD13, CD14 and CD33 are common findings. The aberrant increase, decrease or even lack of expression of CD13, CD14, CD16 or CD33 can be found in MDS, Fig.€8.4. Expression of the immature marker CD34 can persist on mature monocytes. Aberrant expression of lymphoid antigens is observed on monocytes with the exception of CD4 which is commonly weakly expressed on monocytes. CD56 can be expressed on normal activated monocytes to a certain extent. Overexpression, defined as 1log increase above normal CD56 expression on monocytes is aberrant and associated with chronic myelomonocytic leukaemia. It can be of relevance for the differential diagnosis of MDS and MDS/MPD such as CMML [21, 43]. The combination of CD56 expression with underexpression of a myeloid marker is reported to be unique for CMML monocytes [56]. Monocytosis with two or more immunophenotypic aberrancies with 20% or more BM monocytes showing moderate CD14 expression diagnosed CMML with 67% sensitivity and 100% specificity [56].
Erythroid and Megakaryocytic Lineage The detection of erythroid dysplasia by flow cytometry in MDS is limited due to lack of markers. Erythroid cells can be identified by the absence of CD45 and low
130
C. Alhan et al.
scatter properties. The markers that are mainly investigated in the context of dyserythropoiesis in MDS are CD235a and CD71. CD235a or glycophorin A is expressed early upon differentiation at the erythroblast stage of erythroid development and is maintained throughout terminal red cell differentiation. CD71 is the antibody recognizing the transferrin receptor. The transferrin receptor is needed for uptake of iron. Nucleated erythroid cells express CD71 but non-nucleated erythrocytes lack CD71 expression. Erythroid precursor cells express dim CD117 and upon maturation to terminally differentiated erythroid cells CD117 expression is lost [22, 51]. CD105 (endoglin) is a receptor for members of the transforming growth factor beta superfamily (TGF-β) and is specifically expressed on erythroblasts. In combination with CD36 and CD117 the immature erythropoietic cell compartment can be analyzed. Aberrancies that can be found in MDS are abnormal expression of CD117 and CD34, abnormal levels of CD71, asynchronous expression of CD45 versus CD71, asynchronous expression of CD45 versus CD235a and asynchronous expression of CD71 versus CD235a on nucleated red cell precursors. The most frequently observed immunophenotypic aberrancy in the erythroid lineage was persistent or low levels of CD71 expression on glycophorin A-positive erythroid precursors compared with pathologic and healthy BM controls, Fig.€8.5 [27, 42]. A high proportion of immature erythroid cells is also a common finding in MDS patients [27]. Both aberrant CD71 expression and increased immature cells are associated with morphologic features of dyspoiesis. Other markers that are associated with erythroid dysplasia in MDS are the intracellular ferritin subunits, H-ferritin and L-ferritin and mitochondrial ferritin (MtF). b
CD235a
a
CD71
Fig. 8.5↜渀 Erythroid differentiation in MDS. Erythroid progenitors lose CD117 and gain CD235a expression upon differentiation. The most mature erythroid cells lose CD71 expression and remain CD235a positive. In healthy individuals there is a ‘gap’ between CD71 positive and negative cells. Panel a shows erythroid differentiation in the BM of an healthy individual. Erythroid progenitors are indicated in dark blue and can be identified by CD117 expression. Panel b shows an MDS patient with aberrant erythroid differentiation. As can be seen from the plot, erythroid progenitors are absent and the ‘gap’ is filled with erythroid cells that have CD71dim expression
8â•… Flow Cytometry in Myelodysplastic Syndromes
131
In MDS with ring sideroblasts (RS), erythroid precursor cells express increased iron receptors at the cell surface compared with patients without RS, which is associated with iron storage in the mitochondria. Flow cytometric analyses of proteins of iron metabolism in MDS patients are an indirect way of analyzing erythroid dysplasia. Patients with RS had higher levels of MtF and CD105 than patients without RS. Furthermore, MtF expression is related to presence of RS in BM by morphology [10, 45]. Analysis of dyspoiesis in the megakaryocytic lineage by flow cytometry is limited due to technical aspects. The number of megakaryocytes is relatively too low compared with the other cell lineages in the BM to be analyzed by flow cytometry without extensive enrichment. Furthermore, binding of platelets to non-megakaryocytic cells may result in false positivity for platelet-associated antigens, such as CD36. In a multiparameter setting, CD41a and CD61 have been used to analyze aberrancies in the megakaryocytic lineage [42]. However, characterization of abnormalities in megakaryocytes by flow cytometry was less sensitive than morphology [42].
Pitfalls in Flow Cytometry in MDS Recommendations for sample handling and processing are described in a report from the ELNet working conference for the standardization of flow cytometry in MDS [23]. Basic requirements such as adequate standardization of flow cytometric instruments and procedures should be fulfilled. In MDS sample handling procedures, such as the choice of anti-coagulant, temperature, delays in sample handling can cause considerable changes in antigen expression patterns. It is recommended that BM is collected in heparin-coated tubes, stored at room temperature and analyzed within 24€h after drawing. Delayed processing of samples that are drawn in EDTA-coated tubes may influence antigen expression of antigens such as CD11b [11, 40, 50]. Table€8.3 gives an overview of the pitfalls in flow cytometric analysis of MDS. Although the degree of dysplasia and quantification of cells by flow cytometry correlates with morphology, there are discrepancies between flow cytometric findings and morphologic findings in the BM. When analyzing myeloid progenitors with flow cytometry, it should be kept in mind that the definition of a myeloid blast by morphology can be different than by flow cytometry. Progenitor B cells can also resemble myeloid progenitors. Granular blasts may be excluded from myeloid progenitor analyses and can give an underestimation of myeloid progenitor count by flow cytometry. It is of importance to use a combination of antibodies that defines the myeloid progenitor compartment by flow cytometry and that recognizes contamination with plasmacytoid dendritic cells, basophils and hypogranular neutrophils. The percentage of immature erythroid cells may be underestimated caused by impaired lysing of non-nucleated erythroid cells and loss of a variable amount of nucleated erythroid cells. Therefore, the myeloid to erythroid ratio might be higher in flow cytometry than by morphology. Flow cytometric analysis on BM
132
C. Alhan et al.
Table 8.3↜渀 Pitfalls in the analysis of BM in MDS by flow cytometry General • Lack of knowledge on normal hematopoiesis and changes in antigen expression that are not specific for MDS • Lack of age-matched (pathologic) controls • Awareness of the presence of a PNH clone Pitfalls in analysis of • Definition by flow cytometry versus definition by morphology myeloid progenitors • Contamination with plasmacytoid dendritic cells, basophils and/or hypogranular neutrophils • Hemodilution • Apoptosis Pitfalls in analysis of maturing myelo• CD33 polymorphism monocytic cells • Hypogranularity • Contamination with eosinophils in the neutrophil gate • Aberrant expression of HLA-DR on mature neutrophils • Aberrant lack of CD10 on mature neutrophils Pitfalls in analysis of • Loss of variable amount of (non)-nucleated erythroid cells durerythroid cells ing the lysing procedure Technical issues • Lack of standardization of flow cytometric instruments and procedures • Inadequate sample handling procedures: choice of anti-coagulant, temperature, delay in sample handling General, patient and (pathologic) control group related points of attention are listed. Pitfalls per subpopulation of hematopoietic cells are described next to basic technical requirements that need to be fulfilled
should preferably be performed on the BM sample from one of the first draws. A discrepancy in blasts count by flow cytometry and morphology may also be caused by hemodilution. The sample that is drawn for morphology smears contains more BM spicules than samples from subsequent draws. Therefore, the BM sample that is analyzed for flow cytometry may be (more) hemodiluted. The degree of PB contamination can be estimated by using the Holdrinet method, which is based on the red blood cell count and leukocyte count in BM and PB [5, 17]. Hemodilution can be corrected by using CD16 expression on mature neutrophils. The percentage of CD16 positive mature neutrophils from disaggregated BM trephine biopsies was determined by flow cytometry and used for normalization of blast counts in BM aspirates [24]. However, the power of flow cytometry is the detection of qualitative aberrancies in the (im)mature myelo-monocytic and erythroid lineage rather than quantification of cells in the BM. Furthermore, in MDS dyspoiesis may cause difficulties in analysis of subpopulations of cells by flow cytometry. Neutrophils in MDS can be hypogranular, resulting in a low SSC in MDS and interfere in monocytes analysis. Eosinophils, defined as CD45 positive and high SSC, can cause a high total neutrophil SSC and can interfere with the differentiation pattern of neutrophils. Therefore, eosinophils should be excluded from neutrophil analysis. Distinction of myelo-monocytic subpopulations in the BM might be hampered due to aberrant expression of HLA-DR or lack of CD10 expression on neutrophils. Next to that, apoptosis can cause loss of antigen expression and can be mistaken for aberrant expression. Knowledge of normal vari-
8â•… Flow Cytometry in Myelodysplastic Syndromes
133
ation in expression of antigens at each stage of differentiation of hematopoiesis and polymorphisms such as CD33 is relevant. Moreover, by using an appropriate agematched (pathologic) control group, alterations in antigen expression patterns that are not caused by MDS such as following growth factor treatment and with cell activation can be recognized. An aberrant immunophenotype should be distinguished from variations related to a relative increase of a proportion of BM hematopoietic cells such as a (non-clonal) increase in immature cells, maturation arrest and hemodilution [8]. Furthermore, the presence of a paroxysmal nocturnal hemoglobinuria (PNH) or PNH type cells in the BM of MDS patients is common and might be the cause of aberrant patterns of myelo-monocytic cells [32]. Knowledge of what may cause changes in antigen expression relationships in hematopoiesis that are not attributable to dyspoiesis in MDS and the application of multiparameter analysis can help to overcome some of these pitfalls.
Role in Diagnosis The diagnostic utility of multi-parameter flow cytometry of the myeloid, erythroid and megakaryocytic lineage in the BM for MDS was first described by Stetler-Stevenson et€al. [42]. In a series of 65 patients, a diagnosis of MDS was established by morphology in 45 patients. In these patients, the rate of detection of abnormalities in two or more lineages was 35/40 (88%) by flow cytometry and 37/40 (93%) by morphology. Interestingly, flow cytometry was informative in 15/20 (75%) patients with initial indecisive BM morphology by showing bi- and/or tri-lineage immunophenotypic aberrancies. For the megakaryocytic lineage there were only quantitative findings that were similar with the control group. Therefore, it was concluded that morphology was more sensitive for the detection of megakaryocytic dysplasia. This study showed that flow cytometry could be instrumental in the detection of immunophenotypic aberrancies in cytopenic patients with non-diagnostic BM morphology and cytogenetics. Several studies show that flow cytometric analyses correlate with established diagnostic classification systems, such as French-American-British (FAB) and World Health Organization (WHO) [3, 18, 31, 49, 54]. Table€8.4 gives an overview of the flow cytometric studies that have been performed until now. One of these studies analyzed aberrancies in the immature myeloid and mature myelo-monocytic compartment in a group of 207 MDS patients by flow cytometry [31]. The data analysis was performed by using hierarchal clustering of fluorescent intensities of the antibody expressions. By using the most discriminating markers CD16, CD34, CD36, CD38, CD71 and HLA-DR, the immunophenotypic clusters for myeloid progenitors identified subgroups of patients with RAEB/RAEB-T, CMML and RA(RS). For the neutrophil compartment patients with RA(RS) and CMML, RAEB and RAEB-T clustered together by using CD11b, CD13, CD33, CD36, CD38, CD71 and HLA-DR. Aberrancies in the monocytic compartment did not form discriminatory clusters of MDS patients, which might be caused by an inadequate combina-
134 Table 8.4↜渀 Overview of studies on flow cytometry in MDS Study Most relevant (com- Most common aberbination of) MoAbs rancies in MDS
C. Alhan et al.
Most important conclusion for the diagnosis and prognosis of MDS Neutrophil Stetler-Steven- Myeloid: 35/40 (88%) MDS patients hypogranularity son et€al. CD11 b/CD16/CD13 were identified by flow Decreased CD71 Erythroid: cytometry [42] expression on CD71/CD235a 15/20 (75%) with inconclusive CD235a+ erythroid Megakaryocytic: morphology were identified CD41a/CD61 as MDS by flow precursors After repeated BM biopsies Immunophenotypic clusters Maynadié et€al. Mature myeloid: [31] CD11b, CD13, based on the most discriminating combination CD33, CD36, of markers correlated with CD38, CD71, FAB classification HLA-DR Myeloid progenitors: CD16, CD34, CD36, CD38, CD71, HLA-DR (Im)mature myelo- Antigen homogeneity FCSS correlates with WHO Wells et€al. 2001 classification Presence of lineage [54] monocytic: infidelity markers Severe pre-transplantation CD13/CD16, FCSS was associated with CD11b/HLA-DR Decreased CD45 post-transplantation relapse expression CD5, CD7, CD19 90% of MDS patients had a CD14, CD33, CD34 positive FCSS Kussick et€al. Myeloid progenitors: Aberrant antigen Flow identified MDS with [20] a sensitivity of 89% and expression in the CD13, CD33, CD38 specificity of 88% myeloid progeniCD117, HLA-DR tor compartment Flow correlated with morphology and cytogenetics A single aberrancy was not able Myeloid progenitors: Increased percentMalcovati to differentiate MDS from age of myeloid CD33, CD34 et€al. [27] non-MDS cases progenitors Myeloid cells: A discriminant analysis identiCD10, CD16, CD33, Presence of CD10fied 87% of MDS patients neutrophils, CD56 expression of Erythroid cells: immature markers CD71/CD235a Increased proportion of erythroid progenitors Lorand-Metze Myeloid progenitors: Myeloid progenitors: A set of parameters, including SSC of CD34 positive cells, SSC CD34 et€al. [25] promyelocytes and metamyMyeloid cells: Myelo-monocytic elocytes was able to classify Number of neutrocells; 87% of MDS patients phils, promyeloCD10, CD11b, cyte SSC CD13, CD16, Monocytes: CD64 Number of Erythroid cells: monocytes CD71/CD235a
8╅ Flow Cytometry in Myelodysplastic Syndromes Table 8.4╇ (continued) Study Most relevant (com- Most common aberbination of) MoAbs rancies in MDS
135
Most important conclusion for the diagnosis and prognosis of MDS Stachurski Myeloid progenitors: Myeloid progenitors: Lineage infidelity marker expression on myeloid Increased CD117 et€al. [40] CD117 progenitors was exclusively expression Prospectively CD2, CD5, CD7, seen in MDS Mature myeloid: CD56 validated Sensitivity to diagnose MDS Hypogranularity, by Truong Myeloid cells: was 98% and specificity aberrant CD11b/CD16/CD13 et€al. [47] 78% CD11b/CD13/CD16 Monocytes: CD56 on monocytes was assopattern CD13 and CD56 ciated with MDS/MPD Monocytes: Aberrant CD13 expression 60% of MDS patients with van de Loos(Im)mature myelo- Presence of lineage transfusion dependency drecht et€al. infidelity marker monocytic: or progressive disease had expression CD13/CD16, [49] myeloid progenitors with CD11b/HLA-DR Decreased percentaberrant CD7 or CD56 age of B cell CD5, CD7, CD19 expression progenitors CD14, CD33, CD34 Neutrophil hypogran- 92% patients with unilineage erythroid dysplasia by ularity, aberrant morphology had multiCD11 b/CD13/ lineage dysplasia by flow CD16 pattern cytometry Increased or decreased number of monocytes The number of patients identiDecrease in relative Ogata et€al. Lymphoid and fied by flow for Japan was number of B cell [35] myeloid 30.8% and for Italy 67.3% progenitors progenitors: Decreased SSC of CD34, CD45 neutrophils Myeloid cells: SSC, CD10 Decreased CD38 expression Goardon et€al. Myeloid progenitors: CD38 expression is identified MDS patients CD34/CD38 decreased in MDS [13] with 95% sensitivity and patients 92% specificity Aberrant immunophenotype of Westers et€al. Myeloid progenitors: Aberrant myeloid myeloid progenitors was a progenitors in CD13, CD33, CD34, [55] biomarker for the prediction 23/46 (50%) of CD45, CD117 of response to growth factor cases CD5, CD7, CD56 treatment in low and int-1 risk MDS patients
C. Alhan et al.
136 Table 8.4╇ (continued) Study Most relevant (com- Most common aberbination of) MoAbs rancies in MDS Matarraz et€al. [30]
Myeloid progenitors: CD34, CD117 Myeloid cells: CD11b/CD13/CD16, CD15, CD33, CD65, MPO Monocytes: CD14, CD36, CD64 CD2, CD56 Erythroid cells: CD36, CD71/ CD235a
Increased number of CD34 positive cells Presence of aberrant CD34 negative myeloid progenitors Decreased number of mature neutrophils CD34 negative erythroid precursors Increased number of CD36 negative/ dim erythroid precursors
Most important conclusion for the diagnosis and prognosis of MDS The number and degree of severity of flow cytometric aberrancies discriminated between MDS and (pathologic) controls High immunophenotypic scores were associated with adverse prognostic factors The immunophenotypic score was an independent prognostic factor for overall survival
The subpopulations of hematopoietic cells in the BM that were analyzed by flow cytometry for each study are given. The most common found aberrancies and the most relevant conclusions for the diagnosis and prognosis of MDS are described in the table for each study. The antibody combinations CD11b/CD16/CD13 and CD71/CD235a were analyzed in combination in order to analyze differentiation of neutrophils and erythrocytes, respectively MPO myeloperoxidase
tion of antibodies or inaccurate gating strategy that was applied in this study to analyze monocytes by flow cytometry. The immunophenotypic clusters correlated with the established FAB classification for the diagnosis of MDS. To make a more simple, numerical display of flow cytometric data, a flow cytometric scoring system (FCSS) was developed [54]. This FCSS showed a good correlation with WHO 2001 classification for MDS [49]. However, flow scores were heterogeneous within WHO subgroups. This indicates that flow cytometry might identify subgroups within existing classification systems and offer a more refined classification with potential prognostic impact. Del Canizo et€al. investigated the immunophenotypic differences between MDS patients and healthy individuals by flow cytometry. The BM of 101 patients MDS patients was analyzed and compared with the BM of 12 healthy volunteers. Four types of aberrant immunophenotypes were identified; CD15 positive, HLA-DR negative, CD34 positive myeloid progenitors, abnormally low CD45 expression on monocytes, CD33 overexpression and/or HLA-DR expression on neutrophils. The presence of three or more aberrancies was more frequent in MDS RAEB patients as compared to lower risk MDS patients [9]. Kussick et€al. validated an antibody panel to analyze the immature myeloid and myelo-monocytic compartment to diagnose MDS in a group of 124 patients with unexplained cytopenias or monocytosis. Five major types of abnormalities were identified: deviations in myeloid antigen intensity, abnormal homogenous antigen expression, asynchronous expression of two myeloid-associated antigens, aber-
8â•… Flow Cytometry in Myelodysplastic Syndromes
137
rant expression of non-myeloid antigens on myeloid cells and decreased neutrophil SSC. Subsequently, patients were classified as flow-normal, flow-intermediate and flow-abnormal depending on flow cytometric findings. Antigens that were aberrant in at least 50% or more patients in at least one of the defined flow subgroups were HLA-DR, CD13, CD33, CD38 and CD117 and mainly in the immature myeloid compartment [20]. In a study by Stachurski et€al. a comparable approach was applied in a group of 180 MDS patients. MDS or MDS/MPD patients were correctly classified when flow was positive with a sensitivity of 84% and specificity of 97% [40]. In a later prospective study, 102 cytopenic patients with inconclusive BM morphology and cytogenetics were analyzed using the same flow cytometric approach [47]. Twelve cytopenic patients developed MDS during follow-up and 9 (75%) were identified by flow cytometry. Sixty-one patients had a non-MDS related cytopenia, flow was positive in only 4 (7%) patients. Therefore, the positive predictive power of flow cytometry was 69% and negative predictive value was 95%. Malcovati et€al. used a learning cohort of 103 MDS patients and 46 pathologic and healthy controls and a cohort of 69 MDS patients and 46 pathologic controls to validate a flow cytometric approach for the diagnosis of MDS [27]. A single aberrancy was not able to differentiate MDS from non-MDS cases. Therefore, the erythroid and (im)mature myeloid flow cytometric aberrancies were integrated in a discriminant analysis. In the validation cohort of 69 patients, erythroid and myeloid discriminant analysis correctly diagnosed 60 (87%) MDS patients. In this cohort, conclusive BM morphology was obtained in 44 (64%) MDS patients. Interestingly, the discriminant function analysis identified MDS RA(RS) patients that already had multi-lineage involvement according to flow cytometry but with only erythroid dysplasia by morphology. Previously, multilineage dysplasia as determined by morphology was associated with adverse clinical outcome [28]. A study by van de Loosdrecht et€al. also showed that aberrancies in the myelo-monocytic lineage could be detected in the majority of MDS patients with unilineage erythroid dysplasia (92%, 12/13) according to morphology and WHO classification [49]. To widely apply flow cytometry in laboratories it is necessary to make a diagnostic test that is simple and reproducible, with a high sensitivity and specificity. In a collaborative study between Japan and Italy, a flow cytometric test to diagnose low risk MDS patients was designed based on four cardinal parameters [35]. Bone marrow samples of 134 low-risk MDS patients were analyzed for the percentage of myeloid progenitors, B cell progenitors, CD45 expression of myeloid progenitors and neutrophil SSC. The number of MDS patients that could be identified by flow cytometry was 30.8% for Japan and 67.3% for Italy. The percentages increased to 65.4% and 89.4% for Japan and Italy, respectively, when adjunctive parameters CD11b, CD15 and CD56 expression on myeloid progenitors were added. Until now, most studies focussed on multi-parameter flow cytometry for the diagnosis of MDS. Interestingly, it was reported that CD38 expression on CD34 positive cells might be of value as a single flow cytometric parameter for the diagnosis of MDS [13]. CD38 expression in MDS patients with less than 5% blasts is significantly decreased compared with pathologic controls and even more decreased in MDS patients with more than 5% blasts.
138
C. Alhan et al.
The majority of flow cytometric studies focussed on the enumeration of phenotypic abnormalities which might provide a measurement for the degree of dysregulation of hematopoiesis or distance from normal. However, some phenotypic aberrancies might be of more significance than others in detecting dysregulation of hematopoiesis. Weighing immunophenotypic aberrancies for their severity may be required for the diagnosis of MDS [23]. Furthermore, developments in flow cytometric analysis software might be helpful in quantification of the distance from normal and discrimination of MDS cases from normal or non-clonal hematopoietic disorders. Flow cytometric analyses of BM of cytopenic patients patients needs to be further developed and validated, also in new disease entities such as idiopathic cytopenia of unknown significance. In conclusion, the current established diagnostic approach for patients with cytopenia and a suspicion of MDS should include morphological examination of BM and PB, BM biopsy and cytogenetic investigations [48]. As can be concluded from flow cytometric studies, immunophenotyping of BM of cytopenic patients might provide complementary diagnostic information.
Role in Prognosis The subgroups in the FAB and WHO 2001 classification system provide prognostic information. MDS patients in FAB RAEB/RAEB-T, WHO RAEB-1 and RAEB-2 have higher risk of progression to an AML and shorter overall survival compared with MDS FAB RA(RS) and WHO 2001 RA(RS)/RCMD(RS). As described above flow cytometric evaluation of BM of MDS patients correlates with the established classification systems FAB and WHO 2001. Within the low risk categories, multi lineage dysplasia is of prognostic relevance. The IPSS and WPSS provide a prognostic scoring system integrating not only morphologic information but also karyotyping and transfusion need, respectively. Several studies show that flow cytometric aberrancies in BM of MDS patients correlate with the prognostic scoring systems IPSS and WPSS (Table€8.4) [25, 27, 31, 36, 49, 54]. In studies that quantified the number of flow cytometric aberrancies in BM of MDS patients, high numbers of aberrancies were associated with (high risk) MDS categories and an adverse clinical outcome [9, 49, 54]. In a series of 77 newly diagnosed MDS patients, immunophenotypic studies were carried out by flow cytometry analyzing the combinations: CD34/CD33/CD38, CD15/CD34/HLADR and HLADR/CD13/CD45 in BM. Overall 90% of patients had immunophenotypic aberrations and 60% showed two or more aberrations. In univariate analysis, the finding of more than three immunophenotypic aberrations had a significant negative influence on survival. In patients lacking cytogenetic information or in which the karyotype was normal, flow cytometry added significant prognostic information in multivariate analysis [2]. Wells et€al. designed a flow cytometric scoring system (FCSS) based on aberrancies in the (im)mature myelo-monocytic compartment. The FCSS comprised the categories normal-mild (0–1 points), moderate (2–3 points) and severe (4 points or more) degrees of dysplasia. In a group of 111 MDS patients that were treated with allogeneic
8â•… Flow Cytometry in Myelodysplastic Syndromes
139
hematopoietic stem cell transplantation, flow scores correlated with posttransplantation outcome independent of the IPSS score. The probability of posttransplantation relapse in a MDS patient with a severe pretransplantation FCSS score was 33% (Pâ•›<â•›0.01) with a bad overall survival (36%, Pâ•›<â•›0.01) compared to the normal-mild and moderate FCSS categories. The FCSS was validated in a group of 152 MDS patients. The hazard ratio of MDS patients for relapse after stem cell transplantation in the severe FCSS category was 2.8 (Pâ•›=â•›0.02) compared with MDS patients in the normal-mild category [39]. Interestingly, in the FCSS extra points are given to patients with an increased percentage of myeloid progenitors or aberrant myeloid progenitors when the percentage of myeloid progenitors is not increased in the BM. Myeloid progenitors were abnormal if there was homogenous expression of antigens such as CD34 or CD117 (29% of patients), expression of lymphoid antigens such as CD5, CD7, CD19 or CD56 (23% of patients) and an abnormal decrease in CD45 expression (16% of patients) [54]. There are indications that aberrancies in the (myeloid) progenitor compartment might be of more relevance for prognostication of MDS patients than aberrancies in the mature myelo-monocytic compartment [30, 49, 55]. Low risk MDS patients with less than 5% blasts can already have abnormal blasts by flow cytometry [20, 39, 49, 54, 55]. More importantly, these low risk MDS patients have an adverse clinical outcome with a higher risk for transfusion dependency and/or progressive disease, independent of existing and validated prognostic classification systems [49]. In the group of transfusion dependent patients and those with progressive disease, 60% had myeloid progenitors with CD7 or CD56 expression compared with 9% of the non-transfusion dependent patients. There are indications that myeloblasts with CD7 expression have more aggressive characteristics than myeloblasts without CD7 expression, such as a high proliferative capacity and less apoptosis in vitro [37]. The expression of lymphoid antigens by a significant proportion of myeloid or monocytic cells might carry more weight than altered expression of myeloid or monocytic antigens [8]. Quantification of CD34 positive cells in the PB of MDS patients by flow cytometry might be a relevant tool for the prognostication of MDS patients [6]. Low risk MDS patients with circulating blasts have a comparable prognosis as MDS RAEB1 patients [19]. According to the WHO 2008 classification, a percentage of 2–4% circulating blasts, but less than 5% blasts in the BM defines a patient already as a MDS RAEB-1 [44]. Flow cytometric quantification of circulating CD34 positive cells might be a more sensitive tool than counting by automated differential [1, 6]. At this stage further prospective studies are warranted to validate the prognostic relevance of flow cytometric findings in MDS patients.
Prediction of Response to Therapy by Flow Cytometry An appropriate and active approach to the treatment of MDS patients is important, not only for improvement of the quality of life, but also to increase overall survival [16]. The first line of treatment in IPSS low and intermediate-1 risk MDS patients is
140
C. Alhan et al.
supportive therapy consisting of transfusions and growth factors such as erythropoietin (Epo) and human recombinant granulocyte-CSF (G-CSF). Response to treatment can be predicted by a model that includes pre-treatment endogenous serum Epo levels and transfusion need [14]. This validated score system distinguishes three patient groups: MDS patients that are likely to respond to growth factor treatment (74%), with intermediate probability (23%) and poor response to treatment (7%) [15]. In a group of 46 IPSS low and intermediate-1 risk MDS patients who were treated with Epo and G-CSF and evaluated by flow cytometry, the presence of immunophenotypically aberrant myeloid progenitors was instrumental in predicting response to growth factor treatment [55]. Aberrancies in the myeloid progenitor compartment included lineage infidelity marker expression (CD5, CD7 or CD56), loss of CD45 expression and loss of CD33 expression. A new predictive model based on flow cytometry and endogenous serum Epo levels was proposed and identified three subgroups of MDS patients. Patients with low serum Epo and normal myeloid progenitors by flow cytometry have a high probability to respond to growth factor treatment (94%) compared with patients with high serum Epo levels and aberrant myeloid progenitors with a low probability to respond to treatment (11%). Concluding from these findings, flow cytometry might add significantly to validated predictive models in the selection of patients that are eligible for Epo/G-CSF treatment. Furthermore, new treatment strategies for high risk MDS patients with the potential to change the natural course of the disease are emerging. These developments require standardized criteria to assess response to treatment. Flow cytometry might be instrumental in predicting and monitoring treatment of MDS patients.
Conclusion Recent developments show that the detection of aberrancies in hematopoietic cells by flow cytometry in MDS might be of diagnostic and prognostic relevance. Furthermore, the detection of aberrant myeloid progenitors might be instrumental in treatment decisions and monitoring. Prospective studies are necessary to validate the previously studied flow cytometric approaches next to validated diagnostic and prognostic classification systems. It is anticipated that flow cytometry will be part of the diagnostic and prognostic work-up of MDS patients next to morphology and cytogenetics in the near future.
References 1. Alhan C et€ al (2009) Do peripheral blasts count in myelodysplastic syndromes? Leuk Res 33:209–211 2. Arroyo JL et€al (2004) Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J 5:227–233
8â•… Flow Cytometry in Myelodysplastic Syndromes
141
╇ 3. Bennett JM et€al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199 ╇ 4. Bowen KL, Davis BH (1997) Abnormal patterns of expression of CD16 (Flow cytometryRIII) and CD11b (CRIII) antigens by developing neutrophils in the bone marrow of patients with myelodysplastic syndrome. Lab Hematol 3:292–298 ╇ 5. Brooimans RA et€ al (2008) Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination 1. Cytometry B Clin Cytom 76B:18–26 ╇ 6. Cesana C et€al (2008) Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res 32:1715–1723 ╇ 7. Cherian S et€al (2005) Flow-cytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol 79:243–245 ╇ 8. Craig FE, Foon KA (2008) Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:3941–3967 ╇ 9. Del Canizo MC et€ al (2003) Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 88:402–407 10. Della Porta MG et€ al (2006) Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 20:549–555 11. Elghetany MT, Davis BH (2005) Impact of preanalytical variables on granulocytic surface antigen expression: a review. Cytometry B Clin Cytom 65:1–5 12. Feller N et€al (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18:1380–1390 13. Goardon N et€al (2009) Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica 94:1160–1163 14. Hellström-Lindberg E et€al (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodyplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351 15. Hellström-Lindberg E et€al (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietinâ•›+â•›granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037–1046 16. Hellström-Lindberg E, Malcovati L (2008) Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 45:14–22 17. Holdrinet RS et€al (1980) A method for quantification of peripheral blood admixture in bone marrow aspirates. Exp Hematol 8:103–107 18. Jaffe ES et€ al (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon 19. Knipp S et€al (2008) Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res 32:33–37 20. Kussick SJ et€al (2005) Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 124:170–181 21. Lacronique-Gazaille C et€al (2007) A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 92:859–860 22. Loken MR et€al (1987) Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 69:255–263 23. Loken MR et€al (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 32:5–17 24. Loken MR et€al (2008) Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom 76B:27–36 25. Lorand-Metze et€al (2007) Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with nonclonal disorders. Leuk Res 31:147–155
142
C. Alhan et al.
26. Lorand-Metze et€al (2008) The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leuk Res 32:211–213 27. Malcovati L et€al (2005) Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 19:776–783 28. Malcovati L et€ al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594–7603 29. Matarraz S et€al (2008) The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 22:1175–1183 30. Matarraz S et€al (2010) Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom 78:154–168 31. Maynadié M et€ al (2002) Immunophenotypic clustering of myelodysplastic syndromes. Blood 100:2349–2356 32. Nakao S et€ al (2006) Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure. Int J Hematol 84: 118–122 33. Ogata K et€al (2002) Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100:3887–3896 34. Ogata K et€al (2006) Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108:1037–1044 35. Ogata K et€al (2009) Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica 94:1066–1074 36. Pirruccello SJ et€ al (2006) Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 125:884–894 37. Satoh C et€ al (2008) Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 32:699–707 38. Satoh C et€al (2009) Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. Leuk Res 33:326–331 39. Scott BL et€ al (2008) Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112:2681–2686 40. Stachurski D et€ al (2008) Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 32:215–224 41. Sternberg A et€al (2005) Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 106:2982–2991 42. Stetler-Stevenson M et€al (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98:979–987 43. Subirá D et€al (2008) Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or myeloproliferative disorders? Trans Res 151:240–245 44. Swerdlow SH (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press, Switzerland 45. Tehranchi R et€ al (2005) Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 106:247–253 46. Terstappen LW et€al (1992) Flow cytometric characterization of acute myeloid leukemia. Part II: phenotypic heterogeneity at diagnosis. Leukemia 6:70–80 47. Truong F et€al (2009) The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 33:1039–1046
8â•… Flow Cytometry in Myelodysplastic Syndromes
143
48. Valent P et€al (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuke Res 31:727–736 49. van de Loosdrecht AA et€al (2008) Identification of distinct prognostic subgroups in low and intermediate-1 risk myelodysplastic syndromes by flow cytometry. Blood 111:1067–1077 50. van de Loosdrecht AA et€ al (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 94:1124–1134 51. van Lochem EG et€al (2004) Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related and disease-induced shifts. Cytometry B Clin Cytom 60:1–13 52. Wood BL (2007) Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukaemia. Clin Lab Med 27:551–575 53. Wells DA et€al (1998) Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 110:84–94 54. Wells DA et€al (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102:394–403 55. Westers TM et€al (2010) Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 115:1779–1784 56. Xu Y et€al (2005) Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukaemia from reactive monocytosis. Am J Clin Pathol 124:799–806
Chapter 9
MDS as an Autoimmune Process W. Ingram, Y. Kordasti and G. J. Mufti
Introduction The Myelodysplastic Syndromes (MDS) represent a markedly heterogeneous group of haematopoietic stem cell disorders, with a wide diversity in outcome. Whilst some cases of MDS carry an indolent course with prolonged survival, others may progress rapidly to acute myeloid leukaemia (AML) and death. The pathophysiology of MDS remains poorly understood, in part due to the heterogeneity of the disease. Several clonal karyotypic and genetic mutations are reported in MDS and likely to play a key role in its pathogenesis. Moreover, defects in immune responses, both innate and adaptive, together with, or in the absence of, altered cytokine/chemokine profiles are integral to the disease process. It is hypothesised that a combination of environmental factors, genetic background and autoimmune responses play role in the pathogenesis of MDS (Fig.€9.1). This chapter will focus on the immunological aspects of MDS and provide the clinical evidence to support MDS as an autoimmune disorder.
Autoimmune Phenomena in MDS The association between autoimmunity and MDS is well described in the literature with up to 10% of MDS patients reported to have a concomitant autoimmune disorder [1–4]. The first review of which was reported by Hamblin et€al. in 1996 [1]. Several groups have since confirmed the association of MDS with a number of autoimmune disorders such as; vasculitis, arthritis, peripheral neuropathy, pulmonary infiltrates, inflammatory bowel disease, connective tissue disorders, glomeruloneW. Ingram () Department of Haematology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK Tel.: +44-29-2074-2654 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_9, ©Â€Springer Science+Business Media B.V. 2011
145
146
W. Ingram et al.
•Environmental factors •External Agent
•Genetic Background •Age
CD34+ Fate
NK cells
Immune response
Th17
γδ Τ
Th1
Foxp3+ Tregs
l
na clo igo 8 Ol CD
Mo
no
cells
cy
tes
Fig. 9.1↜渀 Interaction of environmental factors, genetic background and immune response in the pathogenesis of bone marrow failure in MDS. The pathophysiology of MDS is multi-factorial; involving genetic, environmental and immunological factors. Genetic factors predispose progenitor cells to an increased susceptibility to environmental triggers, a consequence of which is aberrant expression of cell surface molecules e.g. WT1. The initial immune attack may be directed against these aberrantly expressed proteins on CD34+ progenitor cells which lead to cell death and consequent exposure of self proteins. The self proteins are processed by antigen presenting cells with resulting immune attack against normal CD34+ cells. Several immune subsets then play a role in the immune mediated bone marrow failure in low risk MDS as indicated in the figure
phritis, thyroid abnormalities, sweets syndrome and autoimmune cytopenias [3–7]. The specificity of such autoimmunity is unclear and it remains to be discovered whether there is a relationship between the pathophysiology of autoimmune disorders and the immune mediated bone marrow failure observed in some cases of MDS. Moreover, a high incidence of asymptomatic immunological abnormalities are reported in MDS [8]. One such report describes the presence of autoantibodies, both organ and non-organ specific in 22% of MDS patients [8]. In addition, monoclonal gammopathies were observed in 12% and polyclonal hypergammaglobulinaemia or hypogammaglobulinaemia reported in a further 50% of cases [8]. In keeping with these findings, a further study has shown immunological abnormalities in up to 63% of MDS cases [5]. A summary of the autoimmune manifestations described in MDS patients is shown in Table€9.1. The question as to whether the presence of concurrent immunological disorders adversely affect outcome in MDS has been the subject of investigation by
9╅ MDS as an Autoimmune Process Table 9.1↜渀 Autoimmune manifestations reported in MDS patients
147
Autoimmune cytopenias •╇ Haemolytic anaemia •╇ Thrombocytopenia Connective tissue disorders •╇ Systemic lupus erythematosis •╇ Raynaud’s phenomena •╇ Sjogren’s syndrome •╇ Polymyalgia rheumatica •╇ Relapsing poychondritis Acute systemic vasculitis Chronic autoimmune manifestations •╇ Peripheral neuropathy •╇ Skin vasculitis •╇ Polyarthritis •╇ Glomerulonephritis •╇ Vitiligo •╇ Chronic inflammatory demyelinating polyneuropathy •╇ Pyoderma gangrenosum •╇ Ulcerative colitis •╇ Hashimoto’s thyroiditis Asymptomatic serological findings •╇ Hypogammaglobulinaemia •╇ Polyclonal hypergammaglobulinaemia •╇ Monoclonal hypergammaglobulinaemia •╇ Rheumatoid factor positive •╇ Cryoglobulinaemia •╇ Anti-neutrophil antibody positive •╇ Lupus anticoagulant •╇ Coombs test positive
wseveral groups [2, 4, 5]. Although a poorer survival is described in MDS patients with associated autoimmunity, the majority of studies did not take into account the international prognostic scoring system (IPSS). As such, the poorer outcome may just reflect the advanced nature of the underlying disease, rather than a result of the concomitant autoimmune disorder.
Autoimmune Pathogenesis of MDS T cell Clonality and Antigen Specificity Increased CD8+ cytotoxic T lymphocytes (CTLs) displaying an effector phenotype are a feature of MDS [9–11]. A pattern of oligoclonality of such lymphocytes in MDS patients was first demonstrated by X-chromosome inactivation patterns [12]. Spectratyping, a method by which the TCRVβ repertoire is analysed, has confirmed early findings and shown the CD8+ T cells to consist of limited T cell receptors
148
W. Ingram et al.
(TCRs), termed oligoclonal T cells [9, 10, 13, 14]. Oligoclonal T cells are a feature of several haematological disorders including; MDS, aplastic anaemia, T cell large granulocytic leukaemia and paroxysmal nocturnal haemoglobinuria (PNH) [15–17]. Of interest, in one study of MDS patients a correlation between a positive response to immunosuppressive therapy and a loss of clonal T cells was demonstrated [15]. Clonal expansion of T cells in MDS may indeed represent an autoreactive phenomenon as shown in other disorders such as, rheumatoid arthritis and multiple sclerosis [18, 19]. Although in contrast to the above studies in which the target antigen is well defined, the specificity of immune response in MDS remains unclear. Several hypotheses describing the mechanism by which oligoclonal T cells arise have been proposed. The prevalence of CMV infection increases with age, as such, some researchers speculate that the expansion of CD8+ CTLs could simply be a reflection of CMV infection rather than a genuine autoimmune response. However, other groups report a higher incidence of oligoclonal T cells in MDS patients compared to healthy age matched controls [20]. An alternate hypothesis proposes that effector T cells may be triggered as a result of increased apoptotic cytokines and aberrant expression of oncogenes or fusion genes in haematopoietic stem cells [13]. Whilst another group speculate a viral aetiology, in which chronically infected bone marrow stromal cells or immune cell subsets may lead to changes to the cytokine milieu in the BM microenvironment, which consequently result in a growth advantage for clonal haematopoietic stem cells [21]. In order to provide support for the theory of an antigen driven expansion of T cells in MDS, a search for common antigenic determinants in MDS patients has been performed. The clonotypes have been used as signatures of individual CTL clones, providing a surrogate marker for potential target antigens [16]. In one study, the variable region of the TCR α and β regions in MDS patients and erythroid hypoplasia was examined [14]. Although a limited repertoire of TCRVα regions was reported, with unique sequences in a high proportion of the complementaritydetermining region 3 (CDR3) of the TCR α and β chains of the expanded T-cells, the sequences within the CDR3 were heterogeneous between patients [14]. Similarly, a more recent study demonstrated CTL expansion in over 90% of MDS patients. However, despite the presence of immunodominant CDR3 clonotypes no unique clonotype was identified [15]. Although the studies indirectly support the theory that the CTL expansion in MDS is antigen driven, the specificity of antigen response remains poorly defined. Furthermore, to date, there is no clear evidence to support a unique and universal antigen trigger to the CTL response.
CD4+ T cells and MDS A less clear aspect of the immune biology of MDS is the potential role of CD4+ T cells. There are two important roles for the different subsets/lineages of CD4+ T cells in humans. (1) An indirect induction of the immune response and mainte-
9â•… MDS as an Autoimmune Process
149
nance of the necessary inflammatory environment. (2) Regulation of immune response and peripheral tolerance [22]. Based on these two distinctive roles, CD4+ T cells may be grouped into T-helper cells or regulatory T cells (Tregs) respectively. Among different subsets of CD4+ T cells, Tregs and Th17 cells have been shown to have a significant correlation with MDS stage and risk of disease progression [23]. As such, these two subsets of CD4+ T cells are briefly reviewed here.
Regulatory T cells (Tregs) Tregs have been shown to play an important role in the maintenance of self tolerance. Initial studies in the early 1970s demonstrated that T cells were capable of exerting a suppressive function [24, 25]. Interest in the field was subsequently revived following work by Sakaguchi et€al. in the mid 1990s. Sakaguchi reported a population of CD4+ T cells with high expression of CD25, which were able to maintain self tolerance by down-regulating immune responses to self and non-self antigens, in an antigen non-specific manner [26]. Several subsets of T cells with suppressor function have since been identified and include; (1) naturally occurring Tregs; (2) antigen-induced Tr1 and Th3 cells; (3) adaptive Tregs; (4) CD8+ Tregs; (5) certain subsets of NKT cells [27]. Although the development, cytokine profiles and mode of action of the various subsets of regulatory T cells differs considerably, a function central to all is in the suppression of effector T cells [28]. The most widely studied subset being the CD4+CD25+Foxp3+ naturally occurring Tregs. Tregs play an important role in the tumour microenvironment by suppressing anti-tumour immune responses. Increased numbers of CD4+CD25+ Tregs are reported in several haematological and non-haematological malignancies. As previously described, the myelodysplastic syndromes encompass a heterogenous group ranging from cases with low risk disease and minimal blast cell numbers to others who present with advanced disease and rapid disease progression to AML. The pathophysiology of such disease subsets is likely to be quite disparate. Indeed an increased number of CD4+CD25highFoxp3+ Tregs is reported in high risk MDS, whilst no difference was observed on comparison of low risk MDS patients with healthy age matched controls [29]. In this study, high risk MDS was defined as >5% bone marrow blasts or high IPSS. In a further study, the function and trafficking of Tregs in MDS was analysed [30]. Dysfunctional Tregs with impaired bone marrow homing through the CXCL12/CXCR4 axis, as a result of down-regulation of CXCR4 was observed in patients with early stage MDS. In contrast, an increased number of Tregs with normal function and bone marrow homing were reported in cases with advanced MDS [30]. A fall in the number of Tregs was also noted in patients responding to treatment for MDS [30]. These studies support the hypothesis that in early stage disease the lower number of Tregs may facilitate the emergence of autoimmunity, whereas in keeping with other malignancies, the increased number of Tregs in high risk MDS may permit the expansion of leukaemic clones.
150
W. Ingram et al.
Th17 Cells CD4+ IL-17 producing T cells, which are now widely known as Th17 cells, were recently proposed as the third lineage of T-helper cells in addition to Th1 and Th2 cells [31]. Th17 cells have been shown to play an important role in the immune response to pathogens and in autoimmunity [32–38]. Importantly, CD4+ T-helper cells can be induced to differentiate towards Th1, Th2, Th17 or Tregs depending on the local cytokine environment [39]. Although differences are noted between human and murine studies, IL-17 producing cells which co-express IFN-γ are reported in human studies of autoimmune disease [40, 41]. In light of the knowledge that low risk MDS is associated with a pro-inflammatory environment, the role of IL-17 producing T cells in MDS was examined. Indeed, a significantly higher number of IL-17 producing CD4+ T cells was reported in low risk MDS in comparison with high risk disease [23]. As expected, an inverse relationship between Th17 cells and Tregs was confirmed, with a higher ratio of Th17 cells to Tregs in low risk MDS and a lower ratio in high risk disease. In keeping with the notion that low risk MDS is associated with a pro-inflammatory environment, increased serum levels of IL-17, IL-12, RANTES and IFN-γ are reported in low risk disease. In contrast, an increase in the inhibitory factors IL-10 and soluble IL-2 receptor were observed in high risk MDS patients [23]. Although bone marrow apoptosis was notably higher in low risk disease and correlated with higher numbers of IL-17 producing cells, the mechanism by which IL-17 cells induce apoptosis remains unknown. Together these findings provide evidence to favour the hypothesis that bone marrow failure in low risk MDS may occur as a consequence of increased apoptosis induced by the inflammatory environment, which is created and maintained by Th17 cells, oligoclonal CD8+ T cells and proinflammatory cytokines.
Innate Immune Response Natural killer (NK) cells belong to the innate immune system and are important in the first line of defence against intracellular pathogens and tumour cells. The delicate balance of NK cell activation and inhibitory receptors together with their respective target cell ligands are responsible for regulating NK cell function. The role of NK cells in the pathophysiology of MDS has been explored in a small number of studies. Although a normal number of NK cells is reported in MDS, NK cell function has been shown to be impaired [42, 43]. In particular, NK cell cytotoxicity is significantly impaired in high risk MDS and may be as a result of down-regulation of NK cell activating receptors such as NKG2D [43]. Conversely, NK cell expression of granzyme B is reported to be higher in low and intermediate risk MDS patients with an increase in non-MHC directed killing of autologous haematopoietic precursor cells [44]. These results provide support for a potential role of the innate
9â•… MDS as an Autoimmune Process
151
immune response in the pathogenesis of low risk MDS, whereas impaired NK cell function in high risk MDS may facilitate disease progression. Monocytes may also play a role in the immune dysregulation of MDS through the activation of T-helper cells. In a study of low risk MDS the effect of activated monocytes on the activation of T-helper cells through CD40-CD40 ligand (CD154) interactions was examined. Both a higher CD40 expression on monocytes and CD40 ligand expression on T-helper cells was observed [45]. Stimulation of CD40 on monocytes resulted in higher levels of TNF-α in MDS patients. Moreover, coculture of bone marrow mononuclear cells in the presence of CD40 blocking antibody, led to increased colony-forming units, supporting the hypothesis that the CD40-CD40 ligand may play a role in the immune mediated bone marrow failure in MDS [45]. Lastly the role of γδ T cells in the pathophysiology of MDS has recently been explored. γδ T cells play an important role in the rapid response against tumour and non tumour cells and are an important component of lymphoid stress-surveillance response [46–49]. γδ T cells bearing the Vγ9Vδ2 rearrangement constitute a small proportion (up to 10%) of circulating peripheral blood T cells. A lower number of γδ T cells is reported in MDS patients [50]. The results were most profound in MDS patients with associated autoimmune disorders. In a subset of MDS patients the γδ T cells failed to expand in response to bromohalohydrin pyrophosphate and demonstrated limited proliferative potential in response to IL-2, however, the cytolytic function was preserved in those where expansion was observed [50]. Although the importance of such findings to the pathophysiology of MDS remains unclear, the data provides further insight into the complexity of the immune dysregulation in MDS.
Bone Marrow Apoptosis Increased bone marrow apoptosis is a feature of MDS and is thought to contribute towards the ineffective haematopoiesis and consequent peripheral blood cytopenias [51, 52]. The majority of studies demonstrate that increased apoptosis is most prominent during the early stages of disease [53, 54]. Moreover, one study has shown an inverse correlation between the level of apoptosis of CD34+ cells and prognostic stage [55]. Although there remains some controversy over the precise phenotype of the cells which undergo apoptosis, the majority of studies favour involvement of early haematopoietic progenitor cells [53–56]. Disturbances within the bone marrow microenvironment such as the balance of stimulatory and inhibitory cytokines have been shown to play a key role in triggering increased cell death. Increased levels of TNFα and high expression of Fas on CD34+ cells appear to be a consistent finding [57–60]. Increased Fas expression can lead to activation of caspases, in particular caspase 3, which subsequently trigger apoptosis. Several other cytokines which have been studied include; IL-1β, IL-6, IL-8, GM-CSF, TGFβ and stem cell factor but have shown inconsistent results
152
W. Ingram et al.
[61–63]. Bone marrow stromal cells may also play a role in triggering apoptosis. Studies have shown that stromal cells from MDS patients are able to induce apoptosis of normal CD34+ cells [64]. Furthermore, these stromal cells show decreased or absent growth in long term cultures [64]. Although the precise mechanism by which apoptosis is initiated in MDS is unclear, there is a general consensus that increased apoptosis is central to the pathophysiology of at least the early stages of MDS. Additional studies are nevertheless required to address the contribution of any potential molecular defects in triggering apoptosis and to further examine the role of the bone marrow microenvironment in its ability to support ongoing apoptosis. Importantly, the interplay between haematopoietic stem cells, the bone marrow microenvironment, stromal cells and trafficking of autoreactive T cells requires further study.
Immunosuppressive Therapy The treatment of MDS and the role of haematopoietic stem cell transplantation are described elsewhere within this book. As such, this chapter will focus on providing an overview of the use of immunosuppressive agents in MDS and the evidence generated forthwith to support MDS as an autoimmune disorder. Improvement in peripheral blood cytopenias is reported in just a minority of MDS patients following treatment with steroids [2, 65, 66]. Poor responses together with an increased risk of infection have led to steroids being an unattractive therapeutic option in MDS. Prednisolone and methylprednisolone have nonetheless been used to treat the autoimmune manifestations associated with MDS with variable success [2, 67]. Favourable responses to alternative agents such as cyclophosphamide or azathioprine are also described in a small proportion of MDS patients with associated autoimmune diseases [2]. Antithymocyte globulin (ATG) in combination with cyclosporine A has led to significant haematological responses in MDS [68–74] (Table€ 9.2). Younger age (<60 years), the presence of HLA-DR15 allele and less heavily transfusion dependent patients have been shown to predict response to ATG treatment [75, 76]. A recent study reported an overall response rate of 24% in patients treated with ATG alone, 8% with cyclosporine A and 48% following combination with ATG and cyclosporine A [77]. Transfusion independence and complete haematological response was observed in 31% of all responding patients [77]. Interestingly, age <60 years was the strongest predictor of outcome [77]. In a further study, low IPSS and bone marrow hypocellularity correlated with a favourable response to ATG therapy [78]. Importantly, the removal of CD3+ or CD8+ T cells from bone marrow progenitor cell cultures led to a significant increase in granulocyte-macrophage colony-forming units (CFU-GMs) in patients who responded to ATG, but no difference in nonresponders [79]. Furthermore, in-vitro suppression of CFU-GMs was observed after adding back peripheral blood lymphocytes from patients who responded to ATG. Of particular interest was the finding that the TCRVβ repertoire changed from clonal to
9â•… MDS as an Autoimmune Process
153
Table 9.2↜渀 A summary of response rates and predictors of favourable outcome following ATG therapy in MDS Number of patients Response rate Predictors of favourable response median age years Molldrem et€al. [68]
25
Killick et€al. [69]
30 54.5 years (31–73 years) 31 59 years (28–79 years) 61
Yazji et€al. [72] Molldrem et€al. [74]
44% ORR 84% OS at 3 years 50% ORR
NA
16% ORR
NA
34% transfusion independence 47% platelet count increased 29% transfusion independence
Younger age (?what) Lower platelet count (?what)
Saunthararajah et€al. [75, 76]
69
Sloand et€al. [77]
74 ATG alone 42 ATG plus cyclosporine A
24% ORR 48% ORR
Lim et€al. [78]
96 54 years (19–75 years)
42% ORR
NA
HLA-DR15 Younger age Shorter duration red cell dependance PNH clone Younger age HLA-DR 15 IPSS low or intermediate IPSS low Bone marrow hypocellularity
ORR Overall response rate, NA Not available
polyclonal in one responding patient following ATG treatment [79]. A further study confirmed these early findings. Analysis of the TCRVβ spectratype was performed in patients before and after ATG therapy [20]. A loss or diminution in clonal T cell populations was observed in patients responding to ATG treatment. These results provide additional evidence for the role of autoreactive T cells in the pathophysiology of bone marrow suppression in MDS. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) offers the potential for long term survival and even cure, in a subset of MDS patients. The role and outcome of transplantation in MDS is detailed elsewhere within this book. Nonetheless, it is prudent to recall that the benefit of allo-HSCT, in particular with respect to reduced intensity conditioned regimens, is based upon its ability to stimulate an immune mediated rejection of tumour cells. The important role of T cells in this process is highlighted by the reported increased relapse rates and a lower incidence of graft versus host disease (GvHD) following the use of T cell depletion [80, 81]. Moreover, the ability to restore a state of complete remission following administration of donor leukocyte infusions, provides further evidence for the central role of T cells and other potential immune subsets such as NK cells, in the graft versus leukaemia/tumour effect following allo-HSCT [82, 83].
154
W. Ingram et al.
Concluding Remarks Although there remains no robust evidence to support an autoimmune basis for bone marrow failure in MDS, the observations described within this chapter, in particular skewed T cell subsets, altered cytokine profile, increased apoptosis and the high incidence of concomitant autoimmune disorders, support an immune mediated basis for the pathogenesis of early stage MDS. Moreover, the marked haematological responses following ATG treatment with consequent diminution in T cell clonality provide further evidence to support a key role of T cells in the pathogenesis. Further studies are required to define the potential antigens which stimulate the CTL response and to gain a better understanding of the interplay between the immune subsets and the cytokine/chemokine milieu in the bone marrow microenvironment.
References ╇ 1. Hamblin TJ (1996) Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33(2):150–162 ╇ 2. Enright H et€al (1995) Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 91(2):403–408 ╇ 3. Castro M et€al (1991) Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 18(5):721–727 ╇ 4. Billstrom R et€al (1995) Immune-mediated complications in patients with myelodysplastic syndromes—clinical and cytogenetic features. Eur J Haematol 55(1):42–48 ╇ 5. Okamoto T et€al (1997) Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 66(3):345–351 ╇ 6. O’Donnell BF, Williams HC, Carr R (1995) Myelodysplastic syndrome presenting as cutaneous vasculitis. Clin Exp Dermatol 20(5):439–442 ╇ 7. Saif MW, Hopkins JL, Gore SD (2002) Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 43(11):2083– 2092 ╇ 8. Mufti GJ et€al (1986) Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 63(1):143–147 ╇ 9. Kook H et€al (2001) Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 29(11):1270–1277 10. Melenhorst JJ et€al (2002) Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 119(1):97– 105 11. Epling-Burnette PK et€al (2007) Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 21(4):659–667 12. Culligan DJ et€al (1992) Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 81(3):346–352 13. Epperson DE et€al (2001) Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25(12):1075–1083 14. Matsutani T et€al (2003) Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 27(4):305–312 15. Wlodarski MW et€ al (2006) Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 108(8):2632–2641
9â•… MDS as an Autoimmune Process
155
16. Risitano AM et€al (2002) Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood 100(1):178–183 17. O’Keefe CL et€al (2004) Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol 172(3):1960–1969 18. Hong J et€ al (1999) A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol 163(6):3530–3538 19. Mima T et€al (1999) Dominant and shared T cell receptor beta chain variable regions of T cells inducing synovial hyperplasia in rheumatoid arthritis. Biochem Biophys Res Commun 263(1):172–180 20. Kochenderfer JN et€al (2002) Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100(10):3639–3645 21. Raza A (1998) Hypothesis: myelodysplastic syndromes may have a viral etiology. Int J Hematol 68(3):245–256 22. Abbas AK (2007) Cellular and molecular immunology, 6th€edn. Saunders, Philadelphia 23. Kordasti SY et€al (2009) IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 145(1):64–72 24. Gershon RK, Kondo K (1971) Infectious immunological tolerance. Immunology 21(6):903– 914 25. Berendt MJ, North RJ (1980) T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151(1):69–80 26. Sakaguchi S et€al (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151–1164 27. Kennedy R, Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222:129–144 28. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8(7):523–532 29. Kordasti SY et€al (2007) CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 110(3):847–850 30. Kotsianidis I et€ al (2009) Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 23(3):510–518 31. Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8(5):337–348 32. Chen Z, O’Shea JJ (2008) Th17 cells: a new fate for differentiating helper T cells. Immunol Res 41(2):87–102 33. Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13(2):139–145 34. Yen D et€al (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116(5):1310–1316 35. Cho ML et€al (2006) STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176(9):5652–5661 36. Nakae S et€al (2003) IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 100(10):5986–5990 37. Komiyama Y et€al (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177(1):566–573 38. Nakae S et€al (2003) Suppression of immune induction of collagen-induced arthritis in IL-17deficient mice. J Immunol 171(11):6173–6177 39. Afzali B et€al (2007) The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148(1):32–46
156
W. Ingram et al.
40. Annunziato F et€al (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204(8):1849–1861 41. van Beelen AJ et€al (2007) Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27(4):660–669 42. Kiladjian JJ et€al (2006) Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 20(3):463–470 43. Epling-Burnette PK et€al (2007) Reduced natural killer (NK) function associated with highrisk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 109(11):4816–4824 44. Chamuleau ME et€al (2009) Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 94(4):496–506 45. Meers S et€al (2007) Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells. Leukemia 21(12):2411–2419 46. Hayday AC (2009) Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31(2):184–196 47. Band H et€al (1990) Recognition of mycobacterial antigens by gamma delta T cells. Res Immunol 141(7):645–651 48. Kunzmann V et€al (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392 49. Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46(5):671–680 50. Kiladjian JJ et€al (2008) Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 93(3):381– 389 51. Yoshida Y (1993) Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 7(1):144–146 52. Raza A et€al (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86(1):268–276 53. Bouscary D et€al (1997) Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11(6):839–845 54. Rajapaksa R et€al (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88(11):4275–4287 55. Parker JE, Mufti GJ (1998) Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 101(2):220–230 56. Mundle S et€al (1999) The relative extent and propensity of CD34+ vs. CD34− cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 69(3):152–159 57. Lepelley P et€al (1998) Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma 30(3–4):307–312 58. Mundle SD et€al (1999) Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 140(1–2):201–207 59. Kitagawa M et€al (1998) Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 12(4):486–492 60. Sawanobori M et€al (2003) Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 27(7):583–591 61. Maurer AB et€al (1993) Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 7(11):1728–1733 62. Bowen D et€al (1993) Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 85(1):63–66 63. Fontenay-Roupie M et€al (1999) Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 106(2):464–473
9â•… MDS as an Autoimmune Process
157
64. Aizawa S et€al (1999) Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 23(3):239–246 65. Bagby GC Jr, Gabourel JD, Linman JW (1980) Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Intern Med 92(1):55–58 66. Motoji T et€al (1990) Successful treatment of refractory anemia with high-dose methylprednisolone. Am J Hematol 33(1):8–12. 67. George SW, Newman ED (1992) Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum 21(6):345–354 68. Molldrem JJ et€ al (1997) Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99(3):699–705 69. Killick SB et€al (2003) A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol 120(4):679–684 70. Tichelli A et€al (1988) Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68(1):139–140 71. Steensma DP et€al (2003) Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101(6):2156–2158 72. Yazji S et€al (2003) Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17(11):2101–2106 73. Aivado M et€al (2002) Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68(4):210–216 74. Molldrem JJ et€al (2002) Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137(3):156–163 75. Saunthararajah Y et€al (2003) A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102(8):3025–3027 76. Saunthararajah Y et€al (2002) HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100(5):1570–1574 77. Sloand EM et€al (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26(15):2505–2511 78. Lim ZY et€al (2007) Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21(7):1436–1441 79. Molldrem JJ et€ al (1998) Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102(5):1314– 1322 80. Remberger M et€ al (2002) Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 29(5):391–397 81. Kottaridis PD et€al (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96(7):2419–2425 82. Kolb HJ et€al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86(5):2041–2050 83. Depil S et€al (2004) Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33(5):531–534
Chapter 10
The Myelodysplastic Overlap Syndromes W. Ingram and G. J. Mufti
Introduction The myelodysplastic overlap syndromes encompass a group of clonal neoplastic bone marrow disorders, which, at the time of presentation, demonstrate clinical, morphological or laboratory findings in keeping with both the myelodysplastic syndromes (MDS) and the myeloproliferative neoplasms (MPN) [1]. Cases present along a continuum, ranging from those with a predominant dysplastic phenotype to others with predominant features of myeloproliferation such as a high white blood cell count (WBC) and/or hepatosplenomegaly. One such disorder is chronic myelomonocytic leukaemia (CMML). The classification of CMML has caused much controversy. Historically, the French-American-British (FAB) classification placed CMML in the MDS subgroup as it did not contain a separate category for such overlap syndromes [2, 3]. However, while some cases of CMML present with a low WBC and overt dysplasia, others present with a marked increase in the WBC count and organomegaly, more in keeping with the MPN. As a result, the 3rd edition of the WHO classification of Tumours of Haematopoietic and Lymphoid Tissues recognised the need to create a separate entity for such disorders. A subgroup termed the myelodysplastic/myeloproliferative neoplasms (MDS/MPN) was created and encompasses disorders with both dysplastic and proliferative features [1, 4]. According to the WHO classification, the MDS/MPN subgroup includes Chronic Myelomonocytic Leukaemia (CMML), atypical Chronic Myeloid Leukaemia (aCML), Juvenille Myelomonocytic Leukaemia (JMML) and the Myelodysplastic/Myeloproliferative neoplasms, unclassifiable (MDS/MPD, U) [1]. Whilst the aetiology of such disorders is unknown, a common finding is the high incidence of RAS/MAPK signalling pathway aberrancies. NRAS/KRAS mutations are detected in approximately a third of cases with CMML and aCML [5, 6]. Mutations of NRAS, KRAS, NF1 or PTPN11 are observed in up to 80% of cases of JMML [7]. W. Ingram () Department of Haematology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK Tel.: +44-29-2074-2654 e-mail:
[email protected] J. Várkonyi (ed.), The Myelodysplastic Syndromes, DOI 10.1007/978-94-007-0440-4_10, ©Â€Springer Science+Business Media B.V. 2011
159
160
W. Ingram and G. J. Mufti
In contrast to the classical BCR-ABL1 negative MPN in which a high incidence of the JAK2 V617F mutation is observed, only a small proportion of CMML and aCML cases carry the mutation. Somatic mutations in TET2 are reported in up to 40% of CMML patients, approximately a third of cases with aCML and a smaller number of unselected cases of MDS or MPN [8–12]. TET2 (Ten-Eleven Translocation-2) is located at chromosome 4q24 and has been thought of as a putative tumour suppressor gene, the function of which is unknown [10]. Within the same family, TET1 encodes an enzyme responsible for the conversion of 5-methylcytosine to 5-hydroxymethylcytosine and thus may have a role in epigenetic regulation [13]. A growing insight into the molecular basis of the MDS and the MPN has highlighted several less well defined disorders such as, refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) and MDS 5q- with JAK2 V617F mutation. These disorders have the potential to be considered within the same category of overlap syndromes as they display features of both the MDS and the MPN. Such disorders are discussed further within this chapter. An overview of the clinical, laboratory and genetic features of the MDS/MPN overlap syndromes will be provided. JMML is a disorder of childhood and is described in detail elsewhere within this book and therefore will not be discussed further within this chapter.
Chronic Myelomonocytic Leukaemia (CMML) Definition and Presenting Features CMML is characterised by a peripheral blood monocytosis >1â•›×â•›109/l, the morphological features of which are summarised in Table€10.1. The clinical and laboratory features of CMML are highly variable and as such CMML has in the past been divided into myelodysplastic and myeloproliferative subtypes based upon a white blood cell (WBC) count of < or >13â•›×â•›109/l respectively. This classification bears no prognostic significance with the only factor shown to predict survival in CMML being the percentage of peripheral blood (PB) or bone marrow (BM) blasts [1, 14, 15]. The WHO classification therefore divides CMML into two subgroups according to the PB or BM blast count, the blast count including promonocytes. CMML-1 is defined as <5% PB or <10% BM blasts and CMML-2 as 5–19% PB or 10–19% BM blasts, or in the presence of auer rods when the blast count is <20%. A finding of >20% blasts indicates acute myeloid leukaemia (AML). Whilst the majority of patients with CMML present with a high WBC count, a smaller number of patients present with a low WBC count and neutropenia. Constitutional symptoms consisting of general lethargy, weight loss, fevers and night sweats are common. Infections may be increased and bleeding diathesis secondary to thrombocytopenia is frequently observed. Splenomegaly is more commonly observed in patients with leukocytosis, but may be a feature of any subtype of CMML [16]. The enlarged spleen is usually a result of infiltration of the red pulp by leukaemia cells.
10â•… The Myelodysplastic Overlap Syndromes
161
Table 10.1↜渀 Summary of the peripheral blood and bone marrow features observed in the myelodysplastic/myeloproliferative neoplasms Blood Bone marrow Hypercellular BM CMML Persistent monocytosisâ•›>1â•›×â•›109/l Granulocytic proliferation with >10% monocytes Dysplasia ≥1 lineage CMML-1 <5% blasts <10% blasts CMML-2 5–19% blasts 10–19% blasts or presence of auer rods when <20% blasts Atypical CML Hypercellular BM Persistent WBCâ•›>â•›13â•›×â•›109/l Increase in granulocytic precursors Increased neutrophil precursors Prominent dysgranulopoiesis Prominent dysgranulopoiesis Monocytes <10% MDS/MPN, Variable degree of dysplasia and Hypercellular BM unclassifiable myeloproliferation Variable degree of dysplasia and Blastsâ•›<20% myeloproliferation Blastsâ•›<20% Does not fit into any other category of MDS/MPN disorders RARS-Ta Hypercellular BM Variable degree of dysplasia Dysplasia ≥1 lineage Sustained platelet count Ring sideroblasts >15% >450â•›×â•›109/l <5% blasts Large atypical megakaryocytes, sometimes hypolobated MDS with deletion 5q Not as yet defined Hypercellular BM and JAK2 positiveb Usually high platelet count Granulocytic proliferation Megakaryocytes increased, mostly >450â•›×â•›109/l hypolobated or non-lobated Mild leukocytosis present a b
Provisional entity recognised by the WHO classification Currently not recognised as a separate entity by the WHO classification
Epidemiology The median age of CMML at diagnosis is 65–75 years with a slight male predominance. CMML has been poorly defined in epidemiological studies and as such, the true incidence is unknown. It has been estimated at three cases per 100,000 persons over the age of 60 years [3].
Laboratory Features The monocyte count in CMML is by definition >1â•›×â•›109/l, the monocytes usually constituting >10% of peripheral blood leukocytes [1]. The monocytes may show an abnormal chromatin pattern or nuclear lobation, but more often are of normal appearance. Blasts and promonocytes must constitute <20% of total nucleated cells.
162
W. Ingram and G. J. Mufti
Peripheral blood findings are heterogeneous with both neutrophilia and neutropenia observed. The degree of dysgranulopoiesis can be highly variable with less dysplasia noted in cases presenting with a high WBC count. A marked eosinophilia may be present with a mild anaemia (usually normocytic) and moderate thrombocytopenia frequent findings. The bone marrow is typically hypercellular, although a normocellular or even hypocellular marrow may occur. Granulocytic hyperplasia is often the predominant finding. The degree of dysgranulopoiesis, dyserythropoiesis and dysmegakaryopoiesis is highly variable. In certain cases it may be difficult to distinguish abnormal monocytes from dysplastic granulocytes. In such cases cytochemical stains using a non-specific esterase such as α-naphthyl acetate esterase, may be useful to aid identification of the monocytic lineage. Plasmacytoid dendritic cells can be detected in bone marrow nodules in up to 20% of cases of CMML [1]. With respect to immunophenotyping, the myelomonocytic antigens CD13 and CD33 are usually positive. Expression of the monocytic antigens, CD14, CD64 and CD68 are more variably expressed and therefore less useful in isolation in identification of the monocytic component. Aberrant expression of two or more antigens may be observed. Over expression of CD56, decreased expression of CD14, HLADR, CD13, CD15, CD64 or CD36 and aberrant expression of CD2 may be observed [17–19]. An increase in CD34+ cells may indicate transformation to AML.
Genetics Cytogenetic abnormalities are reported in up to 40% of cases of CMML [16, 20– 22]. Trisomy 8, monosomy 7/del 7q and 12p anomalies are frequently observed [1]. The abnormalities are not specific to CMML and are commonly seen in other myeloid malignancies. The presence of isochromosome 17q may be associated with features suggestive of CMML however the current WHO classification places such cases within the MDS/MPD, U subgroup [1]. RAS mutations are a common finding in the MDS/MPN subgroup with a frequency of approximately 30% in CMML [5, 6]. In contrast to the classical BCRABL1 negative myeloproliferative disorders, the JAK2 V617F mutation is reported in a small proportion (up to 10%) of CMML patients [23–25]. Of interest, a recent study reports an association between the proliferative form of CMML with the JAK2 V617F mutation [26]. Up to 40% of patients with CMML carry mutations in the TET2 gene [8–12, 27]. In addition to CMML, an association between TET2 mutations and monocytosis has been described in patients with systemic mastocytosis, suggesting a role for TET2 in monocyte differentiation [28]. Runt-related transcription factor 1 (RUNX1) plays an important role in normal haematopoiesis and is thought of as a tumour suppressor gene. Mutations of RUNX1 are well described in the literature and known to predispose to leukaemia [29–31]. Mutations in the RUNX1 gene are reported in nearly 40% of patients with CMML [29, 30]. Both the myelodysplastic and my-
10â•… The Myelodysplastic Overlap Syndromes
163
eloproliferative forms of CMML may be affected, unlike RAS mutations which are predominantly observed in patients with myeloproliferative subtypes of CMML [29]. Although the presence of RUNX1 mutations has shown no impact on overall survival, a higher risk of transformation to AML is reported in cases with mutations in the C-terminal region of the gene [30]. In a recent study, 43% of CMML patients exhibited acquired mutations in the ASXL1 gene [32]. Although the function of this gene is unknown, it is thought that the ASXL1 protein may play a role in DNA and or histone modifying complexes [33–35]. Utilisation of single nucleotide polymorphism (SNP) microarrays has revealed the presence of uniparental disomy in 48% of CMML and 38% of patients with MDS/MPN-unclassifiable [36]. The technology has facilitated the search for novel mutations within overlapping regions of UPD, such as CBL mutations within the 11q UPD of patients with MDS/MPNs [36–38]. CBL regulates tyrosine kinase signalling, mutations of which are reported in up to 10% of patients with CMML [36– 38]. A summary of the genetic mutations identified in CMML and the other MDS/ MPN are summarised in Table€10.2.
Table 10.2↜渀 Acquired somatic genetic mutations of the myelodysplastic/myeloproliferative neoplasms Cytogenetic abnormalities Genetic mutations CMMLa RAS mutations 30% Abnormality detected in up to 40% JAK2 V617F mutations 10% cases TET2 mutations 40% Trisomy 8 RUNX1 mutations 40% Monosomy 7/del 7q CBL mutations10% 12p aberrancies ASXL1 mutations 43% RAS mutations 30% Atypical CML Abnormality detected in up to 80% JAK2 V617F mutation rare cases TET2 mutations 30% Trisomy 8 CBL mutations 10% Deletion 20q Absence of BCR-ABL 1 Abnormalities chromosome 12, 13, fusion gene 14, 17 and 19 Absence of Philadelphia chromosome Absence of BCR-ABL 1 MDS/MPN, Isochromosome 17q fusion gene unclassifiable Absence of Philadelphia Absence of PDGFRA, PDGchromosome FRB and FGFR1 Absence of del(5q), t(3; 3)(q21; q26) or inv(3)(q21q26) RARS-T Nil specific JAK2 V617F mutation 60% MPL gene mutations less common TET2 mutations 26% MDS with deletion 5q Deletion 5q JAK2 V617F mutation comand JAK2 positive mon finding CMML with eosinophilia associated with the t(5; 12)(q31-33; p12), ETV6-PDGFRB fusion gene classified as a separate entity by the WHO classification [1]
a
164
W. Ingram and G. J. Mufti
A small number of cases of CMML may be associated with a marked eosinophilia. In such cases, examination for gene rearrangements of the PDGFRA and PDGFRB genes should be carried out. The t(5; 12)(q31-33; p12) associated with the ETV6-PDGFRB fusion gene is reported in cases of CMML with eosinophilia and in cases previously described as chronic eosinophilic leukaemia (CEL) [39]. As a result of the potential sensitivity of these disorders to the tyrosine kinase inhibitors such as Imatinib, all myeloid and lymphoid disorders associated with abnormalities of the PDGFRA, PDGFRB and FGFR1 gene are classified as a separate entity within the WHO classification [1]. In a small number of cases CMML may present with an eosinophilia >1.5â•›×â•›109/l in the absence of a PDGFR rearrangement. Such cases may still be referred to as CMML with eosinophilia and should be classified as CMML-1 or CMML-2 as described previously [1]. All cases in which the p190 BCR-ABL1 fusion protein is detected should be classified as chronic myeloid leukaemia (CML) [40, 41].
Prognosis and Management The median survival of patients with CMML is reported between 20–40 months with poorer outcome in patients presenting with advanced stage disease [15, 16, 20, 42]. The management of CMML is generally targeted towards ameliorating symptoms related to the underlying disease such as fever, weight loss and splenomegaly. Treatment may be aimed at suppression of the high WBC count in proliferative subtypes of CMML or at improving cytopenias resulting from bone marrow failure or hypersplenism. Therapeutic options include cytoreductive therapy with agents such as hydroxyurea or busulphan, conventional chemotherapy e.g. cytarabine, topotecan, or splenectomy for cases with predominant hypersplenism and consequent cytopenias [43–45]. AML type chemotherapy with or without allogeneic haematopoietic stem cell transplantation (allo-HSCT) may be considered in the small proportion of patients who are fit for such intensive treatment options. The results of allo-HSCT are discussed elsewhere in this book and as such will not be described in detail within this chapter. In summary, the majority of studies which report outcome of CMML patients following allo-HSCT include small numbers of CMML patients thereby making it difficult to accurately predict response rates [46–48]. One of the largest studies conducted by the EBMT, report the outcome of 50 CMML patients using a variety of conditioning regimens [48]. The 5 year overall survival (OS) was reported at 21% with a 5 year disease free survival (DFS) of just 18%. A smaller recent report describes the outcome of 18 CMML patients following RIC allo-HSCT [47]. The 3 year OS was 31%, with a relapse incidence of 47%. Importantly the results show that none of the patients with intermediate or poor risk cytogenetics survived beyond 2 years and a poorer outcome was observed in patients with >5% bone marrow blasts at the time of transplantation. Patient selection is therefore critical in order to identify those who may benefit most from allogeneic HSCT.
10â•… The Myelodysplastic Overlap Syndromes
165
In view of the knowledge that the majority of patients will not be suitable for such intensive treatment options, the role of novel agents such as the hypomethylating agents, 5-azacytidine and decitabine have been explored in MDS and CMML. 5-azacytidine and decitabine are both approved in the US for the treatment of int-2/ high risk MDS. Two pivotal studies report an improved overall survival following treatment with 5-azacytidine when compared with best supportive care in high risk MDS patients [49, 50]. Silverman et€al. report an overall response rate of 60% for patients randomised to 5-azacytidine compared with 5% for best supportive care [49]. Importantly, response was independent of MDS subgroup with comparable responses observed in patients with a diagnosis of RAEB, RAEB-T and CMML when compared with the RA and RARS subgroups. Although encouraging results are reported in CMML following treatment with 5-azacytidine, studies to date have analysed just small numbers of CMML patients and as such, further studies are ongoing to evaluate its role. Reports of the use of decitabine in CMML are also described and show similarly encouraging results [51, 52]. An overall response rate of 69% with 58% complete response is reported in one such study of 19 CMML patients [52]. Ongoing studies to evaluate the role of hypomethylating agents in combination with other novel agents such as the HDAC inhibitors in MDS and CMML are being conducted, the results of which are eagerly awaited.
Atypical Chronic Myeloid Leukaemia (aCML) Definition and Presenting Features Atypical CML is characterised by a leukocytosis >13â•›×â•›109/l consisting of a neutrophilia, in the absence of the Philadelphia chromosome or BCR-ABL 1 fusion gene. An increased number of neutrophil precursors are seen in association with prominent dysgranulopoiesis. The degree of dysgranulopoiesis is often severe which is the main feature distinguishing it from BCR-ABL1 positive CML [1, 4]. The blood and bone marrow features are summarised in Table€10.1. Patients typically present with features similar to that of BCR-ABL1 positive CML, i.e. symptoms of anaemia, occasionally thrombocytopenia or as a result of splenomegaly [1]. In a smaller number of cases a minimal elevation in the WBC >13â•›×â•›109/l more in keeping with that seen in CMML may be the only presenting feature [53].
Epidemiology Atypical CML is a rare disorder, reported at 1–2 cases for every 100 cases of BCRABL 1 positive CML [4, 54]. It typically occurs in the elderly with a median age re-
166
W. Ingram and G. J. Mufti
ported in the 7th or 8th decade of life however reports of aCML in younger patients are described. The disease is thought to have a slight male predominance [1, 4].
Laboratory Features The WBC count is always >13â•›×â•›109/l but may present at any level with WBC counts of >300â•›×â•›109/l reported [1, 54, 55]. An increase in granulocytic precursors including promyelocytes, myelocytes and metamyelocytes are seen in the PB and may comprise up to 20% of total WBCs. Dysgranulopoiesis is prominent with features such as acquired Pelger-Huet changes, abnormal chromatin clumping or neutrophil hypogranulation. In contrast to CMML, the percentage of monocytes is usually <10% of the total leukocyte count despite an absolute increase in the monocyte count frequently observed. A modest increase in the basophil count may be present but is not a prominent feature, unlike BCR-ABL1 positive CML [1, 4]. The bone marrow is hypercellular with a predominant increase in the granulocytic lineage. The blast count is always less than 20%. Features of dysgranulopoiesis are noted as seen in the blood. The myeloid to erythroid ratio is usually in excess of 10:1 with dysplastic changes in the erythroid lineage. Megakaryocyte number and the degree of dysmegakaryopoiesis are highly variable. Dysplastic changes are generally similar to those seen in MDS. An increase in bone marrow reticulin may be observed at the time of presentation [1, 53]. Atypical CML does not display any specific immunophenotypic characteristics. CD34 staining of bone marrow biopsies may facilitate identification of blast cells and CD14 or CD68R may be useful on immunohistochemical stains to aid identification of monocytes [1].
Genetics Up to 80% of patients with aCML carry a clonal cytogenetic abnormality, the most common being trisomy 8 and deletion (20q) [54, 55]. Other abnormalities of chromosomes 12, 13, 14, 17 and 19 are also reported [4, 54, 55]. Although rare cases with features suggestive of aCML may carry the isochromosome 17q, they are more likely to fit the criteria for CMML or MDS/MPN, unclassifiable as previously discussed. The BCR-ABL1 fusion gene must be absent in order to support the diagnosis of aCML. Rearrangement of the PDGFRA or PDGFRB gene indicates an alternate diagnosis [1]. As observed in CMML, NRAS or KRAS mutations are detected in approximately a third of cases of aCML [56, 57] and CBL mutations in approximately 10% of patients with aCML [36–38]. The JAK2 V617F mutation is rare in aCML, whilst TET2 mutations are reported in up to a third of patients [8–12, 25, 58]. The genetic abnormalities identified in aCML are summarised in Table€10.2.
10â•… The Myelodysplastic Overlap Syndromes
167
Prognosis and Management Patients with aCML generally display an aggressive disease course with a median survival reported between 11–25 months and transformation to AML in up to 40% of cases [4, 54]. The optimal treatment of aCML is unclear. Agents such as hydroxyurea and α-interferon have been used with limited success [59].
MDS/MPN, Unclassifiable Definition and Presenting Features The MDS/MPN, unclassifiable subgroup, enables one to assign a category to a patient who presents with features of both the MDS and the MPN but who does not fit into any of the categories described previously (CMML, aCML, JMML). Such cases may present with any of the symptoms related to MDS or MPN. Patients with a known history of MPN who develop dysplastic features over time should not be included within this category [1]. The blood and bone marrow features are summarised in Table€10.1.
Epidemiology The precise incidence of the MDS/MPN, unclassifiable subgroup is unknown. Reports suggest an incidence of 2% of previously classified MDS cases [4].
Laboratory Features The morphological features of the blood and BM are in keeping with that seen in the MDS and MPN subgroups [56, 60]. The degree of dysplasia is highly variable and proliferation of one or more lineage may be observed with a resultant thrombocytosis >450â•›×â•›109/l or leukocytosis >13â•›×â•›109/l [1]. Blasts always account for <20% of total nucleated cells in the BM or PB. Immunophenotypic, cytochemical and immunohistochemical findings are similar to that described for other MDS/MPNs.
Genetics There are no specific cytogenetic or molecular abnormalities for the MDS/MPN, U subgroup. In order to assign a patient to this category, the Philadelphia chromosome
168
W. Ingram and G. J. Mufti
and BCR-ABL1 fusion gene must be absent. Cases presenting with gene rearrangements of PDGFRA, PDGFRB or FGFR1 should be classified as a separate entity [1]. Moreover, the presence of isolated deletion (5q), t(3; 3)(q21; q26) or inv(3) (q21q26) generally excludes them from the MDS/MPN, U subgroup, however, emerging data suggests that some cases with del(5q) and JAK2 V617F mutation present with features of both MDS and MPN and may be categorised as an overlap syndrome as discussed later [1, 61].
Prognosis and Management The prognosis of the MDS/MPN, U subgroup is unknown as the group represents a mixed cohort of patients. Improved classification of such disorders will inevitably enhance our understanding of their natural history and provide the ability to explore treatment options further.
efractory Anaemia with Ring Sideroblasts and R Thrombocytosis (RARS-T) RARS-T is currently acknowledged as a provisional entity within the MDS/MPN category of the WHO classification [1]. Little is known about its epidemiology. The Dusseldorf group report a frequency of 0.7% of all MDS cases [53]. RARS-T differs from RARS in that it is associated with a high platelet count, together with large atypical megakaryocytes, similar to those seen in essential thrombocythaemia (ET) [62–64]. A recently proposed reduction in the defining platelet count from >600â•›×â•›109/l to >450â•›×â•›109/l is in line with the revised criteria for ET [1]. However the lower platelet threshold has led to difficulty in distinguishing some cases of RARS-T from RARS which may also present with a modest elevation in platelet count. With the finding, that up to 60% of RARS-T cases carry the JAK2 V617F mutation, its classification has caused much controversy [65–67]. Some individuals propose that in view of the high frequency of JAK2 mutation, RARS-T should belong to the MPN category, the ring sideroblasts representing an acquired feature in a preexisting MPN. In keeping with this notion, a small number of RARS-T cases demonstrate somatic mutations within the MPL gene (W515L) [65]. Mutations within the juxtamembrane region of the thrombopoietin receptor MPL are reported in the classical MPNs [68–70]. In contrast, a recent study detailing the gene expression profile of RARS and RARS-T highlights similarities between the diseases [65, 71, 72]. Upregulation of ALAS2, a mitochondrial related gene responsible for encoding heme synthesis and
10â•… The Myelodysplastic Overlap Syndromes
169
downregulation of ABCB7, a gene which encodes a protein that is responsible for enabling transport of iron to the cytoplasm were similarly identified in RARS and RARS-T. An additional study demonstrates a high frequency of haemochromatosis associated gene mutations in both RARS and RARS-T [73]. Moreover, the lack of endogenous growth and poor colony formation demonstrated in RARS-T is more in keeping with that observed in MDS rather than the MPN [74]. On the contrary, a recent study reports TET2 mutations in 26% of cases of RARS-T patients, more in keeping with the MPN [75]. Together, these findings support the hypothesis that RARS-T carries features of both the MDS and MPN subgroups, hence the proposal to consider the disorder as an overlap syndrome. Against this proposal is the favourable prognosis of JAK2 positive RARS-T patients when compared with other cases within the MDS/MPN subgroup [53, 76]. Further studies are therefore required to accurately assess the impact of JAK2 V617F mutation on overall survival.
MDS with Deletion 5q and JAK2 Positive The recent finding of JAK2 V617F mutation in cases of MDS with del(5q-) has prompted the notion that these cases may indeed represent a separate entity when compared with those which lack the JAK2 mutation. Such cases generally present with a higher platelet count and in some cases a higher WBC count [61]. One report demonstrates a proliferative bone marrow and granulocytic hyperplasia in patients with MDS del(5q) and the JAK2 V617F mutation [61]. Dysmegakaryopoiesis is observed, with the characteristic hypolobated and mononuclear megakaryocytes as seen in the classical 5q- syndrome. The precise incidence and long term prognosis of such cases is currently unknown. Further studies are required to evaluate the prognostic significance of JAK2 mutation in patients with del(5q) MDS and to assess the role of lenalidomide in such patients.
Concluding Remarks Hitherto, accurate data on the epidemiology and prognosis of patients within the MDS/MPN subgroup has been limited, mainly as a result of such patients frequently being grouped together with other MDS or MPNs and not treated as separate entities. Emerging data on the natural history and prognostic significance of the MDS/MPD overlap syndromes will inevitably lead to further refinement of their classification in the future and is likely to identify further subgroups of patients which belong to this category. An improved understanding of the genetic and epigenetic aberrations in such disorders will facilitate this process and enable the study of novel treatment options including targeted therapies in the future.
170
W. Ingram and G. J. Mufti
References ╇ 1. Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) World health organization classification of tumours of haematopoietic and lymphoid tissues, 4th€edn. IARC Press (International Agency for Research on Cancer), Lyon ╇ 2. Bennett JM et€ al (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87(4):746–754 ╇ 3. Bennett JM et€al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189–199 ╇ 4. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. SLH Kleihues P (ed) IARC Press: Lyon ╇ 5. Padua RA et€al (1988) RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 2(8):503–510 ╇ 6. Hirsch-Ginsberg C et€al (1990) RAS mutations are rare events in Philadelphia chromosomenegative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76(6):1214–1219 ╇ 7. Koike K, Matsuda K (2008) Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 141(5):567–575 ╇ 8. Delhommeau F et€ al (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360(22):2289–2301 ╇ 9. Langemeijer SM et€al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41(7):838–842 10. Tefferi A et€al (2009) Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23(7):1343–1345 11. Jankowska AM et€al (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113(25):6403–6410 12. Abdel-Wahab O et€al (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114(1):144–147 13. Tahiliani M et€ al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929):930–935 14. Germing U et€ al (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24(12): 983–992 15. Germing U et€al (2007) Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 92(7):974–977 16. Germing U et€al (1998) Problems in the classification of CMML—dysplastic versus proliferative type. Leuk Res 22(10):871–878 17. Lacronique-Gazaille C et€al (2007) A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 92(6):859–860 18. Xu Y et€al (2005) Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 124(5):799–806 19. Woodlock TJ et€al (1994) Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia. Leuk Res 18(3):173–181 20. Fenaux P et€al (1988) Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 6(9):1417–1424 21. Haase D et€al (1995) Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 70(4):171–187 22. Toyama K et€al (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7(4):499–508
10â•… The Myelodysplastic Overlap Syndromes
171
23. Steensma DP et€al (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 106(4):1207–1209 24. Jelinek J et€al (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370–3373 25. Levine RL et€al (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106(10):3377–3379 26. Pich A et€al (2009) JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol 62(9):798–801 27. Kosmider O et€ al (2009) TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 94(12):1676–1681 28. Tefferi A et€al (2009) Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816€V and FIP1L1-PDGFRA correlates. Leukemia 23(5):900–904 29. Gelsi-Boyer V et€al (2008) Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 8:299 30. Kuo MC et€al (2009) RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 23(8):1426–1431 31. Imai Y et€ al (2000) Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 96(9):3154–3160 32. Gelsi-Boyer V et€al (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145(6):788–800 33. Katoh M (2004) Identification and characterization of ASXL3 gene in silico. Int J Oncol 24(6):1617–1622 34. Lee JH, Skalnik DG (2005) CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. J Biol Chem 280(50):41725–41731 35. Cho YS et€al (2006) Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 281(26):17588–17598 36. Dunbar AJ et€al (2008) 250€K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68(24):10349–10357 37. Sanada M et€al (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460(7257):904–908 38. Grand FH et€ al (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113(24):6182–6192 39. Drechsler M et€al (2007) Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Ann Hematol 86(5):353– 354 40. Melo JV et€ al (1994) P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 8(1):208–211 41. Ohsaka A et€al (2002) Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). Intern Med 41(12):1183–1187 42. Storniolo AM et€al (1990) Chronic myelomonocytic leukemia. Leukemia 4(11):766–770 43. Bennett JM (2002) Chronic myelomonocytic leukemia. Curr Treat Options Oncol 3(3):221– 223 44. Beran M et€al (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17(9):2819–2830 45. Beran M et€ al (1996) Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88(7):2473–2479 46. Elliott MA et€al (2006) Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 37(11):1003–1008
172
W. Ingram and G. J. Mufti
47. Krishnamurthy P et€al (2010) Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 45:1502–1507 48. Kroger N et€al (2002) Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 118(1):67–73 49. Silverman LR et€ al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20(10):2429–2440 50. Fenaux P et€al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232 51. Kantarjian H et€al (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52–57 52. Aribi A et€al (2007) Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109(4):713–717 53. Orazi A, Germing U (2008) The myelodysplastic/myeloproliferative neoplasms: